1	 traffic studies by the department show that a majority of the <e1>accidents</e1> are caused by <e2>drivers</e2>."
Cause-Effect(e2,e1)
Comment:

2	 <e1>pain</e1> from <e2>indigestion</e2> feels like an intense burning and is usually accompanied by regurgitation and gas."
Cause-Effect(e2,e1)
Comment:

3	 was intermittently wet and dry, and almost always followed with a whine and often a few <e1>tears</e1> from the terrible <e2>pain</e2>."
Cause-Effect(e2,e1)
Comment:

4	 mite's <e1>burrows</e1>, fecal matter, proteins and eggs cause itching, <e2>rashes</e2> and sensitivity."
Cause-Effect(e1,e2)
Comment:

5	 previous scientific estimates had overstated the <e1>devastation</e1> caused by the <e2>asteroid</e2>, since topographic and ecologic factors contributing to the result had not been taken into account."
Cause-Effect(e2,e1)
Comment:

6	 analysis <e1>device</e1> instigates the <e2>termination</e2> of the connection."
Cause-Effect(e1,e2)
Comment:

7	 we saw our mothers show <e1>fear</e1> from <e2>bugs</e2> /spiders/cockroaches and learned to fear them irrationally."
Cause-Effect(e2,e1)
Comment:

8	 common to get a slight <e1>fever</e1> from <e2>immunizations</e2>, which can make them uncomfortable."
Cause-Effect(e2,e1)
Comment:

9	 are intentionally sewn larger than the pillow to accommodate for <e1>shrinkage</e1> from <e2>washing</e2>."
Cause-Effect(e2,e1)
Comment:

10	 <e1>thunderstorms</e1> caused <e2>cancellation</e2> of races later in the afternoon preventing the Masters Mens fours and Masters Womens and Womens eights from racing."
Cause-Effect(e1,e2)
Comment:

11	 the earthquake is largely from a global company that had interests insured in China, whereas the <e1>snowstorm</e1> <e2>losses</e2> are exclusively from a variety of Chinese companies that we had relationships with for some year."
Cause-Effect(e1,e2)
Comment:

12	 avoiding or limiting contact with trash the chance of contracting <e1>germs</e1> that lead to <e2>sickness</e2> or disease is decreased."
Cause-Effect(e1,e2)
Comment:

13	 the years since the ADM scandal of the 1990s, the <e1>calamities</e1> caused by the <e2>subversion</e2> of the food resources of masses of people to the private profit interests of a few has reached new heights."
Cause-Effect(e2,e1)
Comment:

14	 living <e1>vaccine</e1>, caused a sharp <e2>temperature elevation</e2> on the day following the second injection."
Cause-Effect(e1,e2)
Comment:

15	 a person who already has some neck <e1>tension</e1> from <e2>stress</e2>, such an event can lead to a long-term increase of neck tension."
Cause-Effect(e2,e1)
Comment:

16	 first order of business when a patient complains of palpitations is to check whether the <e1>palpitations</e1> are caused by a <e2>heart rhythm</e2>."
Cause-Effect(e2,e1)
Comment:

17	 <e1>miscarriages</e1> are caused by one time, non-repeating <e2>genetic problems</e2>."
Cause-Effect(e2,e1)
Comment:

18	 found the net aggregate economic benefit to native-born Americans from the enormous <e1>influx</e1> accidentally triggered by the 1965 <e2>immigration</e2> is nugatory-less than $10 billion a year, in an economy of $10 trillion."
Cause-Effect(e2,e1)
Comment:

19	 <e1>talent</e1> stemmed from mother's <e2>teaching</e2>."
Cause-Effect(e2,e1)
Comment:

20	 Beach man pleads in <e1>case</e1> that stemmed from dog <e2>attack</e2> on tot."
Cause-Effect(e2,e1)
Comment:

21	 and tinnitus cause stress or <e2>anxiety</e2>."
Cause-Effect(e1,e2)
Comment:

22	 cool <e1>fog</e1> of the summer morning had inundated the fabric of the blimp's coverings with excess <e2>moisture</e2>, adding additional weight to the aircraft."
Cause-Effect(e1,e2)
Comment:

23	 <e1>perturbations</e1> caused by the substorm related field-aligned <e2>currents</e2> are most notable in the east-west deflections of the geosynchronous magnetic field."
Cause-Effect(e2,e1)
Comment:

24	 works by changing brain <e1>chemicals</e1> that cause stress and <e2>anxiety</e2>."
Cause-Effect(e1,e2)
Comment:

25	 several species of <e1>fungi</e1>, insect, and bacteria cause <e2>mortality</e2> or reduced growth of the tree."
Cause-Effect(e1,e2)
Comment:

26	 author clearly got a great deal of <e1>pleasure</e1> from the <e2>work</e2> and did not allow his vast amount of material to force him into shallow generalizations."
Cause-Effect(e2,e1)
Comment:

27	 information about the <e1>infection</e1> caused by the <e2>bacteria</e2> called Salmonella, when food is eaten raw or undercooked."
Cause-Effect(e2,e1)
Comment:

28	 the <e1>profits</e1> from the <e2>books</e2> listed below are donated to the Norman Historic Preservation Program, Inc. (NHPP) to be used toward the renovation of the old Norman High School as a children's educational center and museum."
Cause-Effect(e2,e1)
Comment:

29	 following the widespread <e1>destruction</e1> caused by the Israeli <e2>invasion</e2>."
Cause-Effect(e2,e1)
Comment:

30	 <e1>hole</e1> has been caused by the <e2>accumulation</e2> of dust into planets like Earth."
Cause-Effect(e2,e1)
Comment:

31	 colon <e1>diverticulitis</e1> is the most common cause of acute <e2>pain</e2> in the left lower abdomen in older adults."
Cause-Effect(e1,e2)
Comment:

32	 relative <e1>calm</e1> produced by the Shia <e2>ceasefire</e2> has coincided with what the CIA is now calling the "near strategic defeat" of al-Qaeda in Iraq."
Cause-Effect(e1,e2)
Comment: calm is stat

33	 are aware that <e1>acne</e1> or pimples are caused by <e2>hormonal imbalance</e2>, improper skin care or bad eating habits."
Cause-Effect(e2,e1)
Comment:

34	 grandmother is beautiful too but she has a lot of <e1>wrinkles</e1> from the <e2>sun</e2>."
Cause-Effect(e2,e1)
Comment:

35	 confrontation between Martyn and Liz earlier ended with a <e1>struggle</e1> that resulted in Martyn's <e2>drowning</e2>."
Cause-Effect(e1,e2)
Comment:

36	 Lancet study already demonstrated that, as of July 2006, the <e1>deaths</e1> caused by the U.S. <e2>invasion</e2> of Iraq rivaled the death toll of the 1994 Rwandan genocide."
Cause-Effect(e2,e1)
Comment:

37	 3-year-old boy sustains a chemical <e1>burn</e1> after the <e2>spilling</e2> of bleach onto his lower extremities."
Cause-Effect(e2,e1)
Comment:

38	 get severe headaches and <e1>dizziness</e1> from colas and <e2>drinks</e2> with nutrasweet (aspartame) and splenda (sucralose)."
Cause-Effect(e2,e1)
Comment:

39	 then, numerous independent feature <e1>directors</e1> have journeyed into <e2>series television</e2>."
Other
Comment: violates b.

40	 a few more years the <e1>surplus</e1> is generated by the <e2>excess</e2> of Social Security tax revenue over benefits paid to today's elderly and disabled."
Cause-Effect(e2,e1)
Comment:

41	 <e1>decline</e1> in populations has been caused by the <e2>influx</e2> of industrial and resident waste water, sludge sedimentation, and land reclamation."
Cause-Effect(e2,e1)
Comment:

42	 <e1>lamp</e1> emiting a strong white <e2>light</e2> is placed on an mobile block makes it possible to the scanner to sweep all the document."
Cause-Effect(e1,e2)
Comment:

43	 head was bowed, though the <e1>heat</e1> was radiating from the young <e2>princess</e2> in waves."
Cause-Effect(e2,e1)
Comment:

44	 many patients, the <e1>disease</e1> caused by the H5N1 <e2>virus</e2> follows an unusually aggressive clinical course, with rapid deterioration and high fatality."
Cause-Effect(e2,e1)
Comment:

45	 <e1>automaton</e1> starts in the initial <e2>state</e2>, reads input character by character and changes state according to the program"
Other
Comment:

46	 has again become a <e1>producer</e1> of renewable domestic <e2>energy</e2> to offset supply disruption and stabilize fuel prices."
Cause-Effect(e1,e2)
Comment:

47	 <e1>lawnmower</e1> cuts a <e2>swath</e2> of grass as it moves across the lawn."
Other
Comment:

48	 centre and right images show progressive <e1>shrinkage</e1> after two and four <e2>years</e2>."
Other
Comment:

49	 Harry noticed it during exercise, the change that was identified was the difference in muscular <e1>discomfort</e1> from the <e2>beginning</e2> of his training program (riding five miles per day) to his current status two months later."
Other
Comment:

50	 <e1>moat</e1> keeps the <e2>enemy</e2> at bay."
Other
Comment:

51	 lung function remained stable after complete <e1>removal</e1> from <e2>exposure</e2> to metalworking fluids."
Other
Comment:

52	 land to new white settlers, non-payment, past broken treaties, plus food shortages and <e1>famine</e1> following crop <e2>failure</e2> led to great discontent among the Dakota people."
Cause-Effect(e2,e1)
Comment:

53	 <e1>patient</e1> is kept in the <e2>hospital</e2> one night for observation."
Other
Comment: Content-Container in e1 --> e2 is excluded because of the restriction that people cannot be contents. An entity-location relation is more appropriate.

54	 people voluntarily get involved with politicisation, while others become victims of <e1>circumstances</e1> created by the <e2>politicisation</e2>."
Cause-Effect(e2,e1)
Comment:

55	 bringing in applications such as catalog management and order <e1>fulfillment</e1> from <e2>vendors</e2>, then laboriously developing and integrating those applications themselves."
Other
Comment:

56	 bears and hippos have joined the ranks of species threatened with <e1>extinction</e1> from <e2>climate change</e2>, unregulated hunting and other dangers created by humans."
Cause-Effect(e2,e1)
Comment:

57	 of the <e1>excitement</e1> came from the <e2>anticipation</e2> of winning a nice prize, all for the sum of one dollar."
Cause-Effect(e2,e1)
Comment:

58	 retreat was disorderly and confused and much like a flight, the Pallantines hanging on their flanks and rear and doing great <e1>damage</e1> from early <e2>dawn</e2> till evening."
Other
Comment:

59	 Hebrew histories tell the story of a people's upward <e1>growth</e1> from <e2>savagery</e2>."
Other
Comment:

60	 comes from constructive <e2>competition</e2>, and churches and religions can benefit greatly from it."
Cause-Effect(e2,e1)
Comment:

61	 concrete <e1>sidewalk</e1> radiated <e2>heat</e2> like a furnace, and there was no relief in the shade of a large crepe myrtle tree as they walked under it."
Cause-Effect(e1,e2)
Comment:

62	 a preliminary investigation, Cheddar <e1>cheese</e1> was made with a lactococcal <e2>starter</e2> overproducing different peptidases."
Other
Comment: It also cannot be Entity-Origin because the lactococcal starter is not the main source material of cheese (milk is), so violation of (b). This cannot be Component-Whole because it violates "(d) X has a clear boundary and could, in principle, be separated from Y" - the case is like 'alcohol-wine'.

63	 <e1>fire</e1> started with an <e2>explosion</e2> in the cargo hold and spread across the ship within 10 minutes."
Cause-Effect(e2,e1)
Comment:

64	 last year, Afghanistan was an <e1>opium</e1> <e2>exporter</e2>, not a major heroin producer."
Other
Comment: Export does not entail production; negation is outside

65	 <e1>logs</e1> sawed smoothly and accurately using either saw <e2>design</e2>."
Other
Comment:

66	 live in constant <e1>terror</e1> of indiscriminate <e2>gunfire</e2> which fills the nights throughout Chechnya."
Cause-Effect(e2,e1)
Comment:

67	 the contents of the <e1>audit</e1> were a closely held <e2>secret</e2>, and attempts to obtain other records were denied repeatedly."
Other
Comment: None of the nine relations seems to hold; "secret" seems to be a state of the audit.

68	 <e1>tenant</e1> has farmed for this <e2>owner</e2> for several years and doesn't want to lose the ground, but also does not want to pay the large increase in rent."
Other
Comment: modality and negation are outsid

69	 was an the <e1>outrage</e1> from the sexism <e2>crusaders</e2>."
Cause-Effect(e2,e1)
Comment:

70	 highly original and topical act reaches from the top of the corporate ladder into blokes' sheds, leaving his audiences <e1>aching</e1> from <e2>laughter</e2>."
Cause-Effect(e2,e1)
Comment:

71	 <e1>toolkits</e1> provide a secure <e2>framework</e2> where sensitive information remains private."
Other
Comment: "Provision" here doesn't mean creation.

72	 a nutshell, <e1>orienteering</e1> combines a physical <e2>skill</e2> with a more cerebral element."
Other
Comment:

73	 <e1>food</e1> is kept in the <e2>kitchen</e2> and guests help themselves as it is a self service."
Other
Comment: food is located in the kitchen.

74	 is a fragile medium subject to damage and <e1>deterioration</e1> from <e2>exposure</e2> to poor environmental conditions and inadequate handling practices."
Cause-Effect(e2,e1)
Comment:

75	 <e1>challenges</e1> are being addressed from a manufacturing <e2>standpoint</e2> rather than ICT solutions that could answer them."
Other
Comment:

76	 of the <e1>steam</e1> comes from a volcano's <e2>magma</e2>."
Cause-Effect(e2,e1)
Comment:

77	 I start the engine the <e1>car</e1> makes a screaching <e2>sound</e2>."
Cause-Effect(e1,e2)
Comment:

78	 sliding <e1>keyboard</e1> offers keyless <e2>typing</e2>."
Other
Comment: Purpose-Tool

79	 enclosed <e1>community</e1> produced the enclosed <e2>personality</e2>, and vice versa."
Cause-Effect(e1,e2)
Comment: Personality is a stat

80	 kept in <e2>good condition</e2> have a 5 to 6 year service life."
Other
Comment: "good condition" is a possible state for batteries.

81	 a clock, the '<e1>tick</e1>' is produced by the <e2>action</e2> of the escapement."
Cause-Effect(e2,e1)
Comment:

82	 <e1>students</e1> benefit from the bursary <e2>scheme</e2>."
Other
Comment:

83	 risks of this procedure include anesthesia complications, post-operative difficulty breathing, and <e1>sore throat</e1> from <e2>intubation</e2>."
Cause-Effect(e2,e1)
Comment:

84	 <e1>bulldozer</e1> is kept in the <e2>area</e2> and is suspected of being used to create makeshift paths across the river."
Other
Comment: "area" cannot be considered a container; this seems an entity-location example.

85	 <e1>marinade</e1> that contains <e2>acid</e2>, alcohol or salt has been used for a short time."
Other
Comment: acid in this case is an ingredient, it stands for an acid ingredient such as lemon or vinegar that do not have clear boundaries (stuff-object relation).

86	 say that <e1>rowing</e1> is just pulling an <e2>oar</e2> is like saying golf is just swinging a club."
Other
Comment: Purpose-Tool

87	 main cell types are fibroblasts, macrophages and adipocytes (the <e1>hypodermis</e1> contains 50% of <e2>body fat</e2>)."
Other
Comment: body fat is part of hypodermis cells but does not have clear boundaries (stuff-object relation).

88	 audio sampled at 8kHz is sufficient for communication, such narrow-band speech does not sound natural, leading to user <e1>frustration</e1> after prolonged <e2>exposure</e2>, and making language learning difficult."
Cause-Effect(e2,e1)
Comment:

89	 these axioms, the <e1>judges</e1> cultivated the <e2>principles</e2> of judgment, and those principles could be used in gauging the restrictions on freedom that were justified or unjustified, in any domain of the law."
Other
Comment:Cultivation is not creation. The principles already existed.

90	 inactivated influenza vaccine contains thimerosal, a <e1>preservative</e1> that contains <e2>mercury</e2>."
Other
Comment: mercury is part of the preservative, and it does not have clear boundaries (stuff-object relation).

91	 during the early 1990's National Mineral Resource Assessment, this project received a major <e1>boost</e1> from <e2>funding</e2> provided through the 'Data-at-Risk' add-on funding received by the USGS through the 2004 fiscal year."
Cause-Effect(e2,e1)
Comment:

92	 pop-up roll cage and active headrests aim to protect occupants during a rollover, and the <e1>floorboard</e1> is made from <e2>bamboo</e2> and aluminum."
Other
Comment:

93	 <e1>energy</e1> of emission produces the <e2>separation field</e2>."
Cause-Effect(e1,e2)
Comment: Neither the energy nor the separation field are concrete objects.

94	 stored in a <e2>discharged state</e2> are susceptible to freezing, sulfation and an increased rate of discharge."
Other
Comment: discharge state is a state of the entity batteries. None of the nine relations holds.

95	 derive tremendous pleasure and <e1>fulfillment</e1> from <e2>teaching</e2>, particularly when I am able to help students understand a previously foreign concept or idea, aid them in seeing a familiar object or event from a new and unusual perspective, guide them with projects they are working on, or encourage the interests they have."
Cause-Effect(e2,e1)
Comment:

96	 the <e1>blockage</e1> comes from <e2>fear</e2>, as for a CEO who hates public speaking but must give frequent speeches."
Cause-Effect(e2,e1)
Comment:

97	 makes the drive more comfortable by intelligently seeking out what the <e1>passengers</e1> inside the <e2>car</e2> prefer in terms of temperature, music, lighting etc."
Other
Comment: Content-Container is excluded because people should not be considered contents. Instead it could be entity-location.

98	 is a family luxury villa with breeze-kissed balconies from which the <e1>sounds</e1> of the sea provide a sensuous nightly <e2>serenade</e2>."
Other
Comment: The sounds are a property of the serenade.

99	 they took the floor against a team favored to win the national championship, the <e1>patriots</e1> radiated carefree <e2>confidence</e2>."
Cause-Effect(e1,e2)
Comment:

100	 discharge <e1>valve</e1> is kept in the <e2>closed position</e2> at all times unless the dike is deliberately being drained."
Other
Comment: closed position describe the state of the valve. None of the nine relations holds.

101	 3 km long <e1>beach</e1> extends from the <e2>mouth</e2> of the Oro River in the west, to the cliffs of Point Caramonal to the southeast."
Other
Comment:

102	 <e1>tests</e1> are generated randomly from a <e2>bank</e2> of questions developed for each module."
Other
Comment:

103	 a <e1>nurse</e1> takes off her familiar loose-fitting <e2>clothes</e2>, and dresses her in clothes, which fit her more closely."
Other
Comment:

104	 outer <e1>shell</e1> is made from anodized <e2>aluminum</e2>."
Other
Comment:

105	 <e1>servant</e1> brought forth <e2>jewels</e2> of silver, and jewels of gold, and clothing, and gave them to Rebekah."
Other
Comment:

106	 almost fat-free salad <e1>dressings</e1> start with fresh <e2>fruit</e2>."
Other
Comment:

107	 1729 the <e1>building</e1> contained only the <e2>grammar school</e2>."
Other
Comment: Buildings shouldn't be considered as containers. Instead the grammar school is located in the building.

108	 <e1>move</e1> makes a <e2>mockery</e2> of China's long-standing opposition to such capabilities in the hands of other powers."
Other
Comment:

109	 went on to examine the <e1>theory</e1> from a risk assessment <e2>perspective</e2>."
Other
Comment:

110	 love watching the stages of <e1>growth</e1> from <e2>caterpillar</e2> to cocoon to butterfly in this easy reliable kit."
Other
Comment:

111	 <e1>mood</e1> inside the <e2>car</e2> was very quiet as the couple continued home and went to bed."
Other
Comment: Here mood stands for the "people in a given/quiet mood" but people shouldn't be contents. None of the nine relations holds.

112	 cooking shows and more advertising have put <e1>wine</e1> in the <e2>limelight</e2>."
Other
Comment: None of the nine relations holds; it cannot be Entity-Destination because of b.1 in E-D's definit

113	 is essential for <e2>growth</e2> and cell division."
Cause-Effect(e1,e2)
Comment:

114	 its non-slip, ambidextrous grip, the <e1>peeler</e1> glides effortlessly through <e2>foods</e2>."
Other
Comment:

115	 backup <e1>vocals</e1> are from a rather talented <e2>female</e2>, Stephanie Eitel."
Cause-Effect(e1,e2)
Comment:

116	 years ago, President George W. Bush ordered the <e1>activation</e1> by the <e2>end</e2> of 2004 of a system capable of defending the United States against a missile attack by a terrorist group or an unfriendly rogue state such as North Korea."
Other
Comment:

117	 soft brown and beige <e1>tones</e1> in the decoration provide a tranquil <e2>mood</e2>."
Cause-Effect(e1,e2)
Comment:

118	 <e1>tram</e1> makes the <e2>trip</e2> from the main university campus in less than 5 minutes, while driving can take 15 minutes or longer."
Other
Comment: Trip is an event.

119	 <e1>lodge</e1> combines a <e2>colonial atmosphere</e2> with the rustic beauty and history of Africa."
Other
Comment:

120	 proved that a <e1>gas</e1> takes up <e2>space</e2>."
Other
Comment:

121	 <e1>success</e1> comes from their <e2>ability</e2> to quickly answer a growing surge of mid-size customer demands -- demands that *always* focus around ease of implementation and ease of administration/use."
Cause-Effect(e2,e1)
Comment:

122	 <e1>filament</e1> emits a yellowish-white <e2>light</e2>, and the walls have a strong yellow tint."
Cause-Effect(e1,e2)
Comment:

123	 program is an effective step to mitigate <e1>damage</e1> from <e2>hurricanes</e2>, but let us not forget this is a retroactive measure."
Cause-Effect(e2,e1)
Comment: modality and negation are outside

124	 not unlike an archeological dig through an attic, <e1>choking</e1> from <e2>laughter</e2> rather than dust, as familiar and forgotten memories are refreshed and taken for a satirical synaptic spin by a master humorist."
Cause-Effect(e2,e1)
Comment:

125	 are memorable words written on a piece of <e1>paper</e1> kept in a <e2>museum</e2>."
Other
Comment: Location.

126	 forged pinking <e1>scissors</e1> cut with exceptional <e2>ease</e2> and efficiency."
Other
Comment:

127	 glowing disks await <e1>activation</e1> by the <e2>footsteps</e2> of desert wanderers."
Cause-Effect(e2,e1)
Comment:

128	 reductions of these levels produce pastries with poor lift in the oven and with unacceptable <e1>shrinkage</e1> after <e2>cooling</e2>."
Cause-Effect(e2,e1)
Comment:

129	 <e1>transmitter</e1> generates the electromagnetic <e2>wave</e2>, some of which will be incident on the receiver."
Cause-Effect(e1,e2)
Comment: the modality is outsid

130	 is set in the most beautiful surroundings and the <e1>land</e1> has been biodynamically farmed for many <e2>years</e2>."
Other
Comment: E2 is a temporal expression.

131	 plants and animals are facing <e1>extinction</e1> from Alberta's <e2>lakes</e2>, rivers, mountains and prairies."
Other
Comment:

132	 <e1>progress</e1> comes from <e2>science</e2>, debate, inference, logic and reasoning."
Cause-Effect(e2,e1)
Comment:

133	 experiments seemed to support this idea in that the <e1>quenches</e1> produced the predicted high <e2>vortex-densities</e2>."
Cause-Effect(e1,e2)
Comment: Wikipedia - A quench refers to a rapid cooling, i.e. an event. The relation is outside the scope of the hedge "seemed".

134	 tear or a crease changes the character of the surface more drastically than a mere <e1>deformation</e1> from <e2>roundness</e2>."
Cause-Effect(e2,e1)
Comment:

135	 <e1>improvement</e1> starts with <e2>measuring</e2> process performance, and instigating a robust process for reviewing further changes logically and quickly."
Cause-Effect(e2,e1)
Comment:

136	 period of tumor <e1>shrinkage</e1> after radiation <e2>therapy</e2> is often long and varied (mean 29 months)."
Cause-Effect(e2,e1)
Comment:

137	 and Franz are thieves, or they're trying to be thieves, and somehow learn that Odile lives in a <e1>house</e1> that contains a large sum of <e2>money</e2>."
Other
Comment: The money seems not to be stored in the house, it is simply located there.

138	 the <e1>sound</e1> radiated from a <e2>surface</e2> simulating a two-dimensional monopole is calculated using an unstructured mesh."
Cause-Effect(e2,e1)
Comment:

139	 have always drawn <e1>satisfaction</e1> from <e2>exertion</e2>, straining my muscles to their limits."
Cause-Effect(e2,e1)
Comment:

140	 happens when the <e1>media</e1> makes a <e2>mistake</e2>."
Cause-Effect(e1,e2)
Comment:

141	 <e1>death</e1> from <e2>inhalation</e2> of petroleum distillates is well recognised in misuses of volatile substances."
Cause-Effect(e2,e1)
Comment:

142	 <e1>architect</e1> carefully designed the 15 <e2>rowhouses</e2>, reflecting the suburban ideal of the late 1800s."
Other
Comment:: The architect is not really the one bringing the house into existence.

143	 piglet's incisor <e1>teeth</e1> are cut off with <e2>pliers</e2>."
Other
Comment:

144	 Inc., a market leader in precision motion technology, today announced that Hydro, a leading offshore <e1>producer</e1> of <e2>oil</e2> and gas, has installed its tenth InterSense IS-900 Precision Motion Tracking System as part of Hydro's large scale immersive visualization rooms."
Other
Comment: An oil producer doesn't actually create oil. The oil already exists in the ground, the producer just exports it.

145	 <e1>move</e1> from binary <e2>access</e2> (yes or no) to fine-grained authorization betrays a shift in mindset: from a defensible perimeter to a qualifier that identifies who can access what room."
Other
Comment:

146	 the courtyard there is a <e1>room</e1> that contains a <e2>billiard table</e2>, a big cinema screen with a Sony DVC/CD Player with over 300 titles and several sofas."
Other
Comment: We prefer considering the room as a location and the billiard table is located in the room.

147	 opened a fridge in the side of the door and got out a <e1>blueberry</e1> <e2>vodka</e2>."
Other
Comment:

148	 <e1>kitchen</e1> holds little <e2>clues</e2> about how we tried to reinvent the past."
Other
Comment: None of the nine relations seems to hold. It could be a property of the abstract concept "cuisine".

149	 continue to see progress toward a world free of the daily <e1>terror</e1> of antipersonnel <e2>landmines</e2>."
Cause-Effect(e2,e1)
Comment:

150	 <e1>micropump</e1> is fabricated by the <e2>anisotropic etching</e2>, the boron diffusion and the metal evaporation."
Other
Comment: The etching is an event or process, restriction (f) applies, events cannot be Producers.

151	 Aimee Rose, a member of the <e1>team</e1> who made the <e2>discovery</e2>, predicts it will save many lives, both military and civilian."
Other
Comment: The word discovery has two senses "the act of discovering" and "what was discovered" and in this sentence both senses are evenly probable. In this context we cannot determine with the discovery is an abstract or physical object. the modality is outside

152	 <e1>control</e1> over agricultural <e2>research</e2>, production, distribution and practice is shifting from public institutions to private corporations, which are profit driven and are not motivated by humanitarian concerns."
Other
Comment:

153	 a conventional, steam turbine-only power plant, the <e1>heat</e1> required to produce the steam comes from a <e2>boiler</e2>."
Cause-Effect(e2,e1)
Comment:

154	 converting a tree into thick planks, the <e1>saw</e1> causes a <e2>waste</e2> of a very small fractional part."
Other
Comment:

155	 recently patient record was represented by <e1>documents</e1> in paper kept in a variety of <e2>formats</e2>, different contents, and places."
Other
Comment: The format is a sort of surface property for paper document.

156	 <e1>display table</e1> contained <e2>books</e2> and posters for visitors to browse."
Other
Comment: Location (books are not enclosed).

157	 several years of self-observation, Alexander began to teach his method of conscious <e1>inhibition</e1> through manual facilitated <e2>movement</e2>."
Cause-Effect(e2,e1)
Comment:

158	 the molten metal cools, it hardens and assumes the <e1>shape</e1> created by the mold's <e2>cavity</e2>."
Cause-Effect(e2,e1)
Comment: Assume that shape is a state. How agentive is the cavity in the shaping process? Borderline.

159	 particular, we work on devices that take the <e1>signal</e1> that is carried in a <e2>beam</e2> of light going through an optical fiber and transfer that signal to another beam of light going through the same fiber."
Other
Comment: Signal-beam is like information-wave (064).

160	 knitting needle or <e1>knitting pin</e1> is a long stick or rod used as a tool in the <e2>manufacture</e2> of hand knitted fabric."
Other
Comment: Purpose-Tool

161	 with sleep <e2>deprivation</e2> has similar effects as driving under the influence."
Other
Comment:

162	 planetary citizens have a unique capacity for <e1>ecstasy</e1> from <e2>repetition</e2> - especially when it comes from drumming."
Cause-Effect(e2,e1)
Comment:

163	 many as 18 products in your home come from this <e1>guy</e1>'s <e2>company</e2>."
Other
Comment: The guy owns the company.

164	 <e1>scintillator material</e1> produces <e2>visible light</e2> when transversed by the particle's radiated energy."
Cause-Effect(e1,e2)
Comment:

165	 acoustic test is where we put the <e1>spacecraft</e1> in a <e2>sound chamber</e2> and blast it with over 140 decibels of noise for at least a full minute to simulate what it is going to experience during the launch."
Other
Comment: e1 --> e2 is entity-location.

166	 <e1>evacuation</e1> after the Chernobyl <e2>accident</e2> was poorly planned and chaotic."
Cause-Effect(e2,e1)
Comment:

167	 typical flu <e1>infection</e1> starts with <e2>fever</e2>, muscular pains, headache and general fatigue."
Other
Comment:

168	 had told this <e1>headhunter</e1>'s <e2>company</e2> repeatedly that I was only interested in working in the Philadelphia area."
Other
Comment:

169	 single <e1>blow</e1> made with the <e2>chisel</e2> angled incorrectly cracks a block or break a delicate protrusion."
Other
Comment:

170	 second aspect of the invention provides apparatuses for indicating the position of an <e1>oar</e1> during <e2>rowing</e2>."
Other
Comment: Purpose-Tool

171	 airships are essentially motorized free balloons and the <e1>engines</e1> are carried in a <e2>car</e2> attached to the lower side or bottom of the bag."
Other
Comment: The car here is a means of transportation.

172	 chemical <e1>activation</e1> by <e2>light</e2> (halogen, plasma, lasers, etc.) enhances their efficiency by reducing exposure time and number of appointments."
Cause-Effect(e2,e1)
Comment:

173	 moisturizers' primary function is to keep skin moist, minimize <e1>wrinkles</e1> from <e2>dryness</e2>, smoothe and soften skin, and to deliver other ingredients, like sunscreen, that benefit the skin."
Cause-Effect(e2,e1)
Comment:

174	 <e1>ancients</e1> cultivated the <e2>species</e2> Heracleum Sphondylium which is the parsnip a similar plant to carrots."
Other
Comment: Cultivation is not creation. The species already existed.

175	 lamp causes serious skin burn and eye <e1>inflammation</e1> from shortwave ultraviolet <e2>radiation</e2> when outer envelope of the lamp is broken or punctured."
Cause-Effect(e2,e1)
Comment:

176	 contrast, clay-textured soils are more difficult to prepare a <e1>canola</e1> <e2>seedbed</e2> because the clods can be too large when worked wet, and they tend to crust once worked to a fine seedbed."
Other
Comment:

177	 recommend rinsing your <e1>grater</e1> in warm <e2>water</e2> immediately after each use."
Other
Comment:

178	 <e1>joy</e1> comes from profound spiritual <e2>awareness</e2> on life and an absolute clarity of direction, living for a purpose."
Cause-Effect(e2,e1)
Comment:

179	 <e1>detainee</e1> is kept in the <e2>cell</e2> 23.5 hours a day."
Other
Comment: People should not be considered contents. Might be entity-location.

180	 shows that 30% to 40% of law students experience <e1>depression</e1> after their first <e2>semester</e2> and this depression persists throughout law school."
Other
Comment:

181	 findings clearly show a high level of <e1>satisfaction</e1> from <e2>customers</e2> using new cutting-edge retail technology that has led to higher sales."
Other
Comment:

182	 <e1>experimenters</e1> designed the <e2>shape</e2> and size of the enlarged fiber ends so they don't experience the stresses that usually snap fibers and limit a short-fiber composite's performance."
Other
Comment: A shape is not a physical object but a state or property of a physical object.

183	 <e1>light</e1> in the background is from the <e2>sunrise</e2>."
Cause-Effect(e2,e1)
Comment:

184	 milled powder is then heated converting it into a <e1>vapour</e1> which is then carried in a <e2>stream</e2> of argon to be deposited on the wafer."
Other
Comment: A stream is not clearly delineated in space. Content-Container is excluded. See 064, 067.

185	 winter has been mild in much of the country, <e1>oil</e1> <e2>prices</e2> have been low for the past few months."
Other
Comment:

186	 <e1>introduction</e1> of the gas stove, the electric mixer and the food processor made the <e2>process</e2> easier, faster and more reliable."
Other
Comment: The introduction does not cause the process.

187	 powered <e1>scissors</e1> effortlessly cut <e2>fabrics</e2>, gift wrap, vinyl and much more."
Other
Comment:

188	 volunteers enjoy a sense of satisfaction and personal <e1>fulfillment</e1> from <e2>helping</e2> others, and recent findings suggest that this feeling may well be a major reason why many people choose to volunteer."
Cause-Effect(e2,e1)
Comment: modality is outsid

189	 simulation <e1>study</e1> produces voluminous <e2>results</e2>, since there are two types of models, each with four different specifications and with two sample sizes involved."
Other
Comment: The study is an event, "result" is used here in the sense of information rather than event.

190	 is best to use bold flavors in <e1>herb</e1> <e2>butter</e2>."
Other
Comment:

191	 also known as catalytic RNA and molecular scissors, break down <e1>nucleic acid</e1> inside a <e2>cell</e2>, cut out bad genetic information and splice in good material."
Other
Comment: nucleic acid is part of the cell, but it does not have clear boundaries (stuff-object relation).

192	 prescription drug alleviates <e1>panic</e1> from <e2>claustrophobia</e2> and is also very handy for airplane rides and in case of broken-down subway cars or elevators."
Cause-Effect(e2,e1)
Comment:

193	 do know this <e1>telecommunications</e1> <e2>company</e2>."
Other
Comment: telecommunications is not a concrete object nor is it an mental activity.

194	 my Vancouver home there is small portion of our <e1>kitchen</e1> that contains my <e2>desk</e2>."
Other
Comment: The desk is located in the kitchen, it is not stored or carried inside it.

195	 public <e1>drinking</e1> <e2>regulations</e2> varied, some form of the beer parlour became the norm across the country."
Other
Comment:

196	 decedent was a licensed commercial truck driver and had been employed by this <e1>trucking</e1> <e2>company</e2> for five years."
Other
Comment:

197	 has helped to revive a city whose primary natural resource -- its charm -- is constantly threatened with <e1>extinction</e1> from <e2>overdevelopment</e2>."
Cause-Effect(e2,e1)
Comment:

198	 remarkably comprehensive 32-page 2004 Memorandum of Understanding prohibited the <e1>candidates</e1> from asking each other <e2>questions</e2>, limited rebuttals to a mere 30 seconds, barred direct follow-up questions and entirely prohibited surrebuttals."
Other
Comment:

199	 Hauksbee proves that sound needs air to travel, by experiments with a <e1>clock</e1> inside a <e2>vacuum</e2>."
Other
Comment: location; the purpose is not storing or carrying.

200	 <e1>ghosts</e1> in my <e2>house</e2> are mischievous, like little children."
Other
Comment: As for people, we could not want to consider "ghosts" as contents; entity-location fits better.

201	 drug shows promise for preventing brain <e1>injury</e1> from radiation <e2>therapy</e2>."
Cause-Effect(e2,e1)
Comment:

202	 date for final payment is shown on the <e1>confirmation</e1> <e2>invoice</e2>."
Other
Comment:

203	 also includes an automatic purge valve for quick <e1>equalization</e1> after <e2>changes</e2> in atmospheric pressure."
Other
Comment:

204	 <e1>driver</e1> spotted stolen <e2>car</e2> shortly after police sent out an alert."
Other
Comment:

205	 gear drive <e1>keyboard</e1> prevents typing <e2>errors</e2>."
Other
Comment:

206	 prolific suspense novelist Johansen's energetic new Eve Duncan thriller (Countdown, 2005, etc.), the forensics <e1>sculptor</e1> makes a dangerous <e2>deal</e2> with a Colombian weapons dealer."
Other
Comment:

207	 <e1>view</e1> from the inside is from the <e2>bridge</e2> that spans Atherton Street."
Other
Comment:

208	 most of the annual showers the <e1>antihelion radiant</e1> is produced by <e2>debris</e2> from unknown sources orbiting in a direct motion like the earth."
Other
Comment: The antihelion radiant is an area of the sky from which sporadic meteors can originate. Debris are concrete.

209	 <e1>kitchen</e1> holds many <e2>opportunities</e2> for teaching kids as well as having fun."
Other
Comment: Pure metaphor.

210	 you think two wrongs can make a right, but that doesn't help the starving people of Zimbabwe, who were previously not starving due to the <e1>land</e1> being farmed for <e2>profit</e2> instead of used as political gifts."
Other
Comment: The modality and negation are outside of the relation.

211	 White House <e1>usher</e1> prepares the blue <e2>room</e2> for a luncheon for the European Commission."
Other
Comment: The usher did not create the blue room.

212	 Wal-Mart Supercenter plans to employ as many as 455 associates, including 180 planned new <e1>jobs</e1> created by the <e2>relocation</e2>."
Other
Comment: Relocation is an event, jobs are organisational entities.

213	 the case of aerodynamic lift, the <e1>aircraft</e1> is kept in the <e2>air</e2> by wings or rotors (see aerodynamics)."
Other
Comment: It is a sort of located in relation. None of the nine relations holds. (Weakly possible: location.)

214	 <e1>rain</e1> begets the <e2>food</e2> we eat."
Other
Comment: Borderline, how active is the contribution of the rain? It can't be Cause-Effect because food is a concrete substance.

215	 local <e1>citizens</e1> farmed for a <e2>living</e2>, raising a variety of crops including peanuts, cotton, hay, sorghum, and a variety of truck crops."
Other
Comment: Living is an abstract object.

216	 <e1>progress</e1> comes from <e2>breakthroughs</e2> and breakthroughs by their very nature are unpredictable and surprising in their impact."
Cause-Effect(e2,e1)
Comment:

217	 the <e1>fissure</e1> created by the meteor's <e2>impact</e2>, Sephiroth merged with all the energy of the planet, granting him god-like power over it."
Other
Comment: Impact is an event, a fissure is a concrete entity.

218	 good friar was insistent on both celibacy and <e1>abstinence</e1> from <e2>laughter</e2>."
Other
Comment:

219	 the other hand, the <e1>information</e1> being carried in a high frequency quasi-sinusoidal <e2>wave</e2> invites comparisons with the auditory system of vertebrates."
Other
Comment: not Component-Whole, not Content-Container.

220	 <e1>midwife</e1> assists the <e2>birth</e2>, and women usually rely on their mothers or other women for support during labour."
Other
Comment: (e) People are not usually classified as Instruments, unless they are clearly non-agentive in the situation.

221	 <e1>afterglow</e1> is produced by <e2>shock waves</e2> in the jets of tenuous gas that shoot from the blast at almost the speed of light."
Cause-Effect(e2,e1)
Comment:

222	 normal 'Simon' games, it starts with a one digit sequence, and then increases indefinitely until the <e1>caller</e1> makes a <e2>mistake</e2>."
Cause-Effect(e1,e2)
Comment:

223	 from <e2>sale</e2> of investments is tax-free for general insurers."
Cause-Effect(e2,e1)
Comment:

224	 conference center has at least one dedicated main conference <e1>room</e1> that contains a minimum of 1,000 <e2>square feet</e2>."
Other
Comment: Measure.

225	 design of the shape of the can ends moreover has a marked effect on their ability to resist <e1>deformation</e1> from internal <e2>pressure</e2>."
Cause-Effect(e2,e1)
Comment:

226	 white fatty <e1>substance</e1> obtained from the head of the sperm whale was used in <e2>pharmaceuticals</e2> and candles."
Other
Comment: The fatty substance is an ingredient of the pharmaceuticals.

227	 <e1>dose</e1> makes the <e2>poison</e2>."
Other
Comment: Dose is a measurement.

228	 margarine is <e1>imitation</e1> <e2>butter</e2> was without the superior flavor and pleasant mouthfeel."
Other
Comment:

229	 <e1>tools</e1> made the <e2>job</e2> easy when it could have been a nightmare."
Other
Comment: The tools help to produce something, the job refers to the process not the product.

230	 face big <e1>risk</e1> from <e2>loss</e2> of key employees."
Cause-Effect(e2,e1)
Comment:

231	 story put <e1>wine</e1> in a <e2>positive health light</e2> and pointed out that it was superior to other foods in that particular regard."
Other
Comment: None of the nine relations seems to hold; it cannot be Entity-Destination because of b.1 in E-D's definition

232	 oil is similar to <e1>diesel</e1> <e2>oil</e2>, and the process of refining it is very similar."
Other
Comment:

233	 because nostalgia serves a useful defensive and reparative function; it took the <e1>sting</e1> from a <e2>painful episode</e2> in his life by shading the script."
Other
Comment: an idiom, none of the nine relations holds. (In a highly metaphorical sense, this might be Component-Whole.)

234	 <e1>plane</e1> makes a parabolic <e2>maneuver</e2>, much like a roller coaster with steep climbs and descents, that simulates zero gravity conditions."
Other
Comment:

235	 people experience <e1>tremors</e1> after <e2>drinking</e2> coffee and tea."
Cause-Effect(e2,e1)
Comment:

236	 running a <e1>charity</e1> that helps the poorest school <e2>libraries</e2> in the U.S."
Other
Comment:

237	 out of <e2>anger</e2> is absolutely wrong."
Cause-Effect(e2,e1)
Comment:

238	 characteristics are inconsistent with <e1>observations</e1> from <e2>earthquakes</e2> of comparable distance and magnitude to those that dominate the hazard at Yucca Mountain."
Other
Comment:

239	 derives great joy and <e1>happiness</e1> from <e2>cycling</e2>."
Cause-Effect(e2,e1)
Comment:

240	 man cannot be too old - in his middle thirties - but his face exhibits more <e1>wrinkles</e1> from <e2>smiling</e2> than I've seen upon the mug of the happiest of grandparents."
Cause-Effect(e2,e1)
Comment:

241	 randomized hypertensive ABCD study demonstrated a decrease in myocardial infarction with ACE inhibitors and a <e1>decrease</e1> in overall mortality with aggressive blood pressure <e2>control</e2>."
Cause-Effect(e2,e1)
Comment:

242	 resulting <e1>shockwaves</e1> produced the metal-forming <e2>conditions</e2> for periods of 100-200 ns."
Cause-Effect(e1,e2)
Comment: Shockwaves and conditions are events.

243	 and Simpson also identify defensive <e1>behaviour</e1> from <e2>learners</e2> like lashing out verbally or physically or threatening the educators or other learners and withdrawing from others emotionally or physically."
Other
Comment:

244	 <e1>drinking</e1> <e2>accident</e2> happened in the Gallup area the other day, which is plagued by drinking and driving accidents."
Cause-Effect(e1,e2)
Comment:

245	 <e1>programmer</e1> made a <e2>mistake</e2> with respect to quoting, but it appeared as over-quoting instead of lurking as a security problem."
Cause-Effect(e1,e2)
Comment:

246	 <e1>temperature</e1> inside the <e2>car</e2> was 79 degrees."
Other
Comment: temperature is a property (or state) of the car's interior.

247	 out of <e2>necessity</e2> is quite common in Europe where 60% of female headed businesses in Northern Europe and 70% in Southern Europe are established for this reason."
Cause-Effect(e2,e1)
Comment:

248	 <e1>actor</e1> played a psychopathic preacher with a restrained <e2>malice</e2>."
Other
Comment:

249	 <e1>nurse</e1> helps the <e2>caregiver</e2>."
Other
Comment: It violates (e) "People are not usually classified as Instruments, unless they are clearly non-agentive in the situation." The nurse "helps", so she is co-operative.

250	 finds inspiration in a beautiful, enigmatic older woman who teaches him to follow his heart and find <e1>happiness</e1> through swing <e2>dancing</e2>."
Cause-Effect(e2,e1)
Comment:

251	 John's wort reduced the severity of <e1>depression</e1> after six <e2>weeks</e2>."
Other
Comment:

252	 <e1>analysis</e1> was made using the PCSM <e2>program</e2>."
Other
Comment: Purpose-Too

253	 <e1>degradation</e1> from within stream <e2>channels</e2>, loss of riparian vegetation, and reductions in water quality degrade and also limit the population."
Other
Comment:

254	 often have a <e1>pump</e1> over the drainage <e2>hole</e2> to draw the waste water towards it."
Other
Comment:

255	 is reserved for treating residual disease six to eight <e1>weeks</e1> after radiation <e2>therapy</e2> or for recurrence."
Other
Comment:

256	 finding the most <e1>joy</e1> comes from Asian <e2>flavours</e2>; beautiful fresh fish; things that have been marinated; roasted vegetables; meats that intensify in flavour during the cooking process; and dishes made from the most brilliant, fresh, in-season food."
Cause-Effect(e2,e1)
Comment:

257	 cancer survivor writes about the relatively rare occurrence of <e1>calcification</e1> of the breast after radiation <e2>therapy</e2>."
Cause-Effect(e2,e1)
Comment:

258	 stored in <e2>contact</e2> with one another generate heat and hydrogen gas."
Other
Comment: "in contact with" describes the way in which batteries are stored. None of the nine relations holds.

259	 the situation in the fifteenth century, Parkes remarks: 'The <e1>mass</e1> of the people cultivated the <e2>land</e2>'."
Other
Comment: The land was not brought into existence by the people, it already existed.

260	 tendency to experience pathological <e1>anxiety</e1> from his early <e2>years</e2> and his tendency to respond to novelty, change, and challenges with an exaggerated anxiety response were noted."
Other
Comment:

261	 entire site was actively farmed during the 2004 growing season and aerial photography indicates the <e1>site</e1> has been farmed for multiple <e2>years</e2>."
Other
Comment: E2 is a temporal expression.

262	 <e1>neutrons</e1> were produced by <e2>bombarding</e2> a tritium target with deuterium."
Cause-Effect(e2,e1)
Comment:

263	 doing for his hair <e1>reduction</e1> by laser <e2>treatment</e2>, he first consulted with a dermatologist."
Cause-Effect(e2,e1)
Comment: modal "should" doesn't affect the relation?

264	 <e1>rings</e1> are preferably made from a <e2>copolymer polypropylene</e2>."
Other
Comment:

265	 pagan traditions used <e1>famine</e1> following <e2>feast</e2> as a way of revealing truth."
Other
Comment:

266	 <e1>students</e1> designed the home's living <e2>areas</e2> with an eye toward making a small house feel spacious."
Other
Comment:

267	 <e1>company</e1> developed the <e2>negatives</e2> and returned the camera with a fresh roll of film."
Other
Comment: Developing negatives doesn't mean making them.

268	 <e1>measurement</e1> was made using a gonio-photometric color measurement <e2>system</e2>."
Other
Comment: Purpose-Tool

269	 <e1>deformation</e1> from the circular <e2>form</e2> have a significant effect on the ability of the hose to sustain internal pressure."
Other
Comment:

270	 check given by Charles V to the advance of the Ottoman power along the African coast made him appear to the world as the liberator of the Christians and the <e1>terror</e1> of the <e2>infidels</e2>, and gave him such prestige that Francis felt obliged to get all the advantage possible out of his alliance."
Other
Comment:

271	 expressed his <e1>frustration</e1> after Monday's <e2>meeting</e2>."
Other
Comment:

272	 supports the personal information and interaction environment thus liberating the <e1>person</e1> from tedious <e2>chores</e2> and enriching their life and interaction with others in social or business contexts it enlarges the personal contribution."
Other
Comment:

273	 <e1>clutter</e1> in my <e2>house</e2> was destroying me."
Other
Comment: A state.

274	 is a motorized spherical mechanism that simulates the <e1>rowing motion</e1> of an <e2>oar</e2>."
Other
Comment:

275	 site was encircled by a high fence and one could see a <e1>crane</e1> lifting some heavy <e2>construction material</e2>."
Other
Comment:

276	 lyrical descriptions of landscape and terse, unpunctuated dialogue, a distinctive <e1>voice</e1> powered a gripping <e2>story</e2>."
Other
Comment: The voice might be interpreted as an Instrument, but Agency is missing. No one of the nine relations applies.

277	 his travel to Russia you managed to buy vodka in a <e1>plastic</e1> <e2>bag</e2>."
Other
Comment:

278	 them, 24% is related to <e1>microarrays</e1> fabricated by the microspotting <e2>approach</e2>."
Other
Comment:

279	 liquor is a kind of <e1>wine</e1> produced by solidified <e2>fermentation</e2> of grain."
Other
Comment: Fermentation is an event, wine is a concrete substance.

280	 <e1>saw</e1> cut a large <e2>hole</e2> in a huge concrete wall at the plant."
Other
Comment: e1 is an Instrument, so Cause-Effect and Product-Producer are ruled out. But e2 is not an Agent.

281	 <e1>raindrop</e1> keeps the same <e2>shape</e2> to a reasonable approximation all the time it is falling."
Other
Comment:

282	 <e1>scientists</e1> made the surprising <e2>observation</e2> that SMN binds efficiently -- and carry out its functions -- when the proteins to which it needs to bind are first "tagged" by specific enzymes."
Other
Comment: Observation is ambiguous, it could be an event or a speech act. The former seems more probable.

283	 side effects are uncommon, but include <e1>headache</e1> from <e2>eyestrain</e2>, nausea, agitation or nervousness."
Cause-Effect(e2,e1)
Comment:

284	 reaction <e1>mixture</e1> is kept in the <e2>dark</e2> at room temperature for 1 1/2 hours."
Other
Comment: "Dark" is a state.

285	 is caused by excessive <e1>growth</e1> from <e2>overfertilizing</e2>, by allowing the grass to get too high before mowing, or by incorrect watering."
Cause-Effect(e2,e1)
Comment:

286	 has since enacted legislation, allowing <e1>death</e1> by lethal <e2>injection</e2> as an alternative choice to death in the electric chair."
Cause-Effect(e2,e1)
Comment:

287	 the officer shone his flashlight on the lock he was working on, he spotted a <e1>marijuana pipe</e1> laying on the floor inside the <e2>car</e2>."
Other
Comment: Vehicles should not be considered containers. The marijuana pipe was located in the car.

288	 <e1>organization</e1> helps educate practitioner <e2>dentists</e2> through clinical meetings."
Other
Comment: This is collaboration rather than use.

289	 newly formed Iraqi battalion is on duty, with 27 scheduled for <e1>activation</e1> by <e2>summer</e2> 2004."
Other
Comment:

290	 <e1>bacon</e1> <e2>manufacture</e2> is the 74th greatest export of Denmark."
Other
Comment: Manufacture is an event.

291	 <e1>trench</e1> was inside the <e2>fenced back yard</e2>."
Other
Comment: The fenced back yard is more a location than a container.

292	 large in scale, this <e1>grater</e1> shaves a perfect <e2>portion</e2> in a single stroke."
Other
Comment:

293	 <e2>oil</e2> is a refined oil made from petroleum, used in furnaces to heat buildings."
Other
Comment:

294	 <e1>sculptures</e1> were carved with a <e2>chainsaw</e2>."
Other
Comment:

295	 very rewarding and I get a great deal of enjoyment and <e1>satisfaction</e1> from <e2>mentoring</e2>."
Cause-Effect(e2,e1)
Comment:

296	 non-native species used in aquaculture are brook trout (Salvelinus fontinalis) and lake trout (Salvelinus namaycush), <e1>fishes</e1> that mainly has been farmed for stocking <e2>purposes</e2>."
Other
Comment:

297	 <e1>bombing</e1> produced the worst <e2>carnage</e2> since a Nov. 23 attack in the Shi'ite slum of Sadr City that killed more than 200 people."
Cause-Effect(e1,e2)
Comment: Bombing and carnage are events.

298	 problem is that the <e1>advertisement</e1> gives the <e2>impression</e2> that women in rural Bangladesh have 6 children."
Cause-Effect(e1,e2)
Comment:

299	 southern <e1>supercell</e1> produced the longest <e2>tornado track</e2> of the outbreak (tornado #4)."
Cause-Effect(e1,e2)
Comment: A super cell storm is an occurrence.

300	 newer lesser-known attraction that the kibbutz offers is a reconstructed <e1>oil</e1> <e2>press</e2> whose beginnings can be traced to the early 20th century in Jaffa."
Other
Comment: This is something like Instrument-Product.

301	 year, summer students at the VLA made the first discovery of radio <e1>emission</e1> from a brown <e2>dwarf</e2>."
Cause-Effect(e2,e1)
Comment:

302	 tongue has taste buds, but a cat's <e1>appetite</e1> comes from the <e2>smell</e2> of the food and doesn't come from the taste of it."
Cause-Effect(e2,e1)
Comment:

303	 understand the <e1>stakes</e1> from a personal <e2>perspective</e2>, as well, since the extremists have tried to assassinate them."
Other
Comment:

304	 <e1>dryer</e1> emits <e2>air</e2> that is regulated close to your body temperature."
Cause-Effect(e2,e1)
Comment:

305	 Anderson is making progress in his <e1>recovery</e1> from <e2>exhaustion</e2> and could return to managing the Detroit Tigers within a week."
Other
Comment:

306	 <e1>disruption</e1> after the <e2>attacks</e2> in the US delayed him there for three days."
Cause-Effect(e2,e1)
Comment:

307	 Parlour shows his <e1>frustration</e1> after Middlesbrough's <e2>defeat</e2>."
Cause-Effect(e2,e1)
Comment:

308	 repair, he used duct tape and caulk to seal <e1>gaps</e1> in the <e2>metal box</e2> and between joints and seams in the duct."
Other
Comment: Here gaps are a status or defect, not a functional part of the box.

309	 of thousands in central China are sleeping outdoors for fear of more <e1>tremors</e1> after Saturday's <e2>earthquake</e2>."
Cause-Effect(e2,e1)
Comment:

310	 <e1>carbohydrase</e1> is produced by a <e2>process</e2> which completely removes the organism Rhizopus oryzae from the carbohydrase product."
Other
Comment: A process cannot be a Producer.

311	 saved the <e1>planet</e1> from the imperialist <e2>threat</e2>."
Other
Comment:

312	 contents of the <e1>satchel</e1> were a <e2>revelation</e2>."
Other
Comment: it seems more a property of the satchel.

313	 Inc., a market leader in precision motion technology, today announced that Hydro, a leading <e1>offshore</e1> <e2>producer</e2> of oil and gas, has installed its tenth InterSense IS-900 Precision Motion Tracking System as part of Hydro's large scale immersive visualization rooms."
Other
Comment:

314	 got rid of the <e1>ants</e1> in the <e2>kitchen</e2> without using dangerous pesticides."
Other
Comment: The kitchen is not a container, ants are located in the kitchen.

315	 <e1>taste</e1> is from the <e2>ginseng</e2>, not alcohol."
Cause-Effect(e2,e1)
Comment:

316	 each <e1>house</e1> lives a <e2>person</e2> with a different nationality."
Other
Comment: People should not be considered content and buildings should not be considered containers.

317	 the most significant difference is that we have changed from <e1>emigration</e1> out of <e2>necessity</e2> to emigration in search of new opportunities."
Cause-Effect(e2,e1)
Comment:

318	 <e1>office</e1> that contains <e2>plants</e2> creates an agreeable environment for yourself and others."
Other
Comment: office is more a location than a container.

319	 daily assault of inflammation in their digestive system, plus the <e1>inflammation</e1> from your <e2>joints</e2> and an overworked immune system and excess weight easily exceed the amount of inflammation your body can effectively handle."
Other
Comment:

320	 Incredible Shrinking Man' follows Matheson's novel and effectively captures the <e1>terror</e1> of the <e2>protagonist</e2> as he shrinks to oblivion."
Other
Comment:

321	 is the sensation of unease and <e1>discomfort</e1> from the <e2>stomach</e2>, with the sufferers feeling that they may vomit."
Other
Comment:

322	 both of my systems, the <e1>reboot</e1> produced the ominous <e2>message</e2> 'Missing operating system'."
Cause-Effect(e1,e2)
Comment:

323	 <e1>person</e1> providing the <e2>alibi</e2> is the culprit and would be providing a fabricated alibi."
Cause-Effect(e1,e2)
Comment: modality is outsid

324	 the <e1>photon</e1> was inside the <e2>cloud</e2>, the control beam was switched off, allowing the photon to come to a halt inside the dense ensemble of atoms."
Other
Comment: A container must be clearly delineated in space. This looks like location.

325	 effect of pain <e1>relief</e1> by <e2>acupuncture</e2> lasts for an extended period of time, sometimes months after the needle was removed."
Cause-Effect(e2,e1)
Comment:

326	 30 ducks were found dead in Klamath County in the past two days, and officials are investigating whether the <e1>deaths</e1> are from a cholera <e2>outbreak</e2>."
Cause-Effect(e2,e1)
Comment:

327	 respond to a <e1>decrease</e1> in uncertainty with more aggressive <e2>strategies</e2>."
Cause-Effect(e1,e2)
Comment:

328	 of the <e1>taste</e1> of strong onions comes from the <e2>smell</e2>."
Cause-Effect(e2,e1)
Comment:

329	 city nightclub has had an ambitious expansion plan blocked over concerns about unruly <e1>behaviour</e1> from drunken <e2>revellers</e2>."
Cause-Effect(e2,e1)
Comment:

330	 studies revealed that skin <e1>irritation</e1> from <e2>soaps</e2>, inaccessibility to supplies or sinks, and insufficient time to wash hands between every patient care contact were the main reasons given by healthcare workers for lack of handwashing compliance."
Cause-Effect(e2,e1)
Comment:

331	 <e1>hardcopy</e1> <e2>book</e2> (at an even higher price) and this one purchase ensures you are up to date with all future releases of the electronic book."
Other
Comment:

332	 not every run of the <e1>experiment</e1> produced the desired <e2>state</e2> - a very large number of failed tries accompanied each successful creation."
Cause-Effect(e1,e2)
Comment:

333	 Mullikin ('00) is working for Willis of Minneapolis as a catastrophe risk analyst for this <e1>reinsurance</e1> <e2>company</e2>."
Other
Comment:

334	 brachioradialis <e1>reflex</e1> is observed by striking the brachioradialis tendon directly with the <e2>hammer</e2> when the patient's arm is resting."
Other
Comment: e2 is an Instrument

335	 <e1>movie</e1> gives the inaccurate <e2>impression</e2> that the Apaches all surrendered."
Cause-Effect(e1,e2)
Comment:

336	 felt a resurgence of the <e1>panic</e1> from this <e2>morning</e2> when he'd regained consciousness in the minefield."
Other
Comment:

337	 to change your vehicle's <e1>engine</e1> <e2>oil</e2> saves you time and money."
Other
Comment:

338	 <e1>soy milk</e1> makes a great coffee <e2>creamer</e2> (and with whatever else you can cook it)."
Other
Comment: "makes" is synonymous with "is" here.

339	 has been bracing itself for a <e1>downturn</e1> in the wake of the <e2>bombs</e2>, especially in the tourist sector."
Cause-Effect(e2,e1)
Comment:

340	 criticism is the study of literature by means of a microscopic knowledge of the language in which a book is written, of its <e1>growth</e1> from various <e2>roots</e2>, of its stages of development and the factors influencing them, of its condition in the period of this particular composition, of the writer's idiosyncrasies of thought and style in his ripening periods, of the general history and literature of his race, and of the special characteristics of his age and of his contemporary writers."
Other
Comment:

341	 <e1>ringtone</e1> makes the <e2>telecommunicator</e2>."
Other
Comment:

342	 <e1>spiciness</e1> comes from small capsaicin <e2>glands</e2> located between the pepper's outside skin and the white ribs inside."
Cause-Effect(e2,e1)
Comment:

343	 one day, the Red Crescent treated more than 50 injuries - mainly broken bones caused by <e1>panic</e1> from <e2>aftershocks</e2>."
Cause-Effect(e2,e1)
Comment:

344	 <e1>sports</e1> are played with the <e2>hands</e2>."
Other
Comment: Hands are parts of the players involved in sports, so they cannot be Instruments.

345	 commuters look at a <e1>clock</e1> inside a Tokyo <e2>train station</e2>."
Other
Comment: Location. A station is not even remotely as container-like as rooms and caves can be.

346	 mounts the photo on a <e1>material</e1> that contains <e2>acid</e2>, so that the paper absorbs the acid which in turn attacks the photo itself."
Other
Comment: The material is made of acid, and acid does not have clear boundaries (stuff-object relation).

347	 the most common form of such an attack, called ischemic stroke, the <e1>blockage</e1> comes from a blood <e2>clot</e2> that develops in one of the brain's blood vessels."
Cause-Effect(e2,e1)
Comment:

348	 report links conditions in some of the worst affected localities and the likelihood that dire poverty - combined with despair and <e1>outrage</e1> over rampant <e2>corruption</e2>, repressive policies, and governments' failure to address local needs - could lead to outbreaks of localised unrest with the potential to spread into a wider regional conflict."
Cause-Effect(e2,e1)
Comment: modality is outsid

349	 in the region experienced the <e1>tremors</e1> after <e2>midnight</e2>."
Other
Comment:

350	 <e1>thermostat</e1> keeps the <e2>water</e2> at the requested temperature."
Other
Comment:

351	 troubled company is still feeling <e1>aftershocks</e1> after its devastating <e2>withdrawal</e2> of the pain medication Vioxx six months ago."
Cause-Effect(e2,e1)
Comment:

352	 <e1>expenditure</e1> through physical <e2>activity</e2> is a key component in the prevention and treatment of overweight and obesity."
Cause-Effect(e2,e1)
Comment:

353	 <e1>artist</e1> who originally made the <e2>song</e2> popular is listed for reference only."
Other
Comment: Making a song popular is not the same as making it.

354	 quartz sample <e1>tube</e1> with polyradical residue was cut with diamond <e2>knife</e2> to the size that fit into the Teflon digestion vessel."
Other
Comment: Again Instrument-Product.

355	 Portis, who missed last week's game against Dallas because of a shoulder <e1>injury</e1> from the <e2>preseason</e2>, rushed for 86 yards on 16 attempts to become the fifth-fastest player to reach the 6,000-yard mark in his career."
Other
Comment:

356	 <e1>cathode</e1> emits <e2>electrons</e2>."
Cause-Effect(e1,e2)
Comment: electrons have no mass.

357	 <e1>product</e1> emits <e2>radiation</e2>."
Cause-Effect(e1,e2)
Comment:

358	 put <e1>wine</e1> in the exact <e2>context</e2> it needs to be kept in - not so bloody serious."
Other
Comment: None of the nine relations hold.

359	 starts with manual <e2>execution</e2> of the binary."
Cause-Effect(e2,e1)
Comment:

360	 <e1>construction</e1> gives a <e2>refinement</e2> of Nori's argument in the case of a self-product of a curve."
Cause-Effect(e1,e2)
Comment:

361	 acid</e1> is kept in an <e2>aqueous solution</e2>, which makes it suitable and safe to handle."
Other
Comment: Picric acid is part of the aqueous solution but does not have clear boundaries (stuff-object relation).

362	 big <e1>savings</e1> is coming from the <e2>hardware side</e2>."
Other
Comment:

363	 include the <e1>exclusion</e1> of certain benefits from funding <e2>standards</e2> and the exclusion of entire plans from certain funding requirements."
Other
Comment:

364	 he was back he noticed that he had locked the <e1>keys</e1> inside the <e2>car</e2>."
Other
Comment: Vehicles should not be considered containers: keys are located, not stored, in the car.

365	 <e1>collaboration</e1> produced the PUMP(Pittsburg urban mathematics program) <e2>curriculum</e2>, which focuses on mathematical analyses of real-world situations, the use of computational tools, and on making algebra accessible to all students."
Other
Comment: The collaboration is an event and cannot be a Producer; the curriculum is a creative work.

366	 only <e1>change</e1> is from the energy company's <e2>end</e2>, where their section of the gas or electricity infrastructure is now supplying an extra home."
Other
Comment:

367	 <e1>potato</e1> <e2>peeler</e2> is a metal blade attached to a metal, plastic or wooden handle that is used for peeling vegetables, usually potatoes."
Other
Comment:

368	 pool with a sand <e1>beach</e1> is located inside the <e2>cave</e2>."
Other
Comment: The cave is more a location than a container and the beach is not stored there (entity-location relation).

369	 third <e1>observation</e1> was made with the Echellette <e2>spectrograph</e2>."
Other
Comment: Purpose-Tool

370	 projects submitted at national level, the <e1>volunteer</e1> is sent by a <e2>organization</e2> legally established in his/her country of residence."
Other
Comment:

371	 zen, there is a strong relationship between <e1>work</e1> and <e2>food</e2>, for the former begets the latter."
Other
Comment: The relation is a causal one, but food is a concrete substance and cannot be an Effect, while work is an event and cannot be a Producer.

372	 were the years of constant fatigue and shortness of breath, the heart attack at age 11, the <e1>collapse</e1> from <e2>exhaustion</e2> on her high school graduation night."
Cause-Effect(e2,e1)
Comment:

373	 commission merely implements the contracts, shielding the major party <e1>candidates</e1> from public <e2>criticism</e2>."
Other
Comment:

374	 because of a last minute <e1>collapse</e1> from <e2>top</e2> to bottom - what would be and should be a perfect season to this point is just another year."
Other
Comment: modality is outside

375	 surrounding <e1>region</e1> is farmed for its <e2>fertility</e2>."
Other
Comment:

376	 worked as a <e1>fertilizer</e1> <e2>salesman</e2> before his arrest."
Other
Comment:

377	 after radiation <e2>chemotherapy</e2> is an effective local treatment, which is able to significantly increase local tumor control compared to radiation chemotherapy only."
Other
Comment:

378	 pipeline had to face the following main concerns from opposition: disturbance of animal migration patterns, environmental <e1>damage</e1> from <e2>spills</e2>, geological concerns and the Alaskan permafrost."
Cause-Effect(e2,e1)
Comment:

379	 <e1>therapist</e1> helps the <e2>patient</e2> to understand himself or herself better."
Other
Comment: (e) People are not usually classified as Instruments, unless they are clearly non-agentive in the situation.

380	 from fluid <e2>loss</e2> is the only major problem the virus causes, most often in the elderly."
Cause-Effect(e2,e1)
Comment:

381	 is fantastic for increased <e2>flexibility</e2>, which is great for cross-training with all the other programs we offer."
Cause-Effect(e1,e2)
Comment:

382	 <e1>electricity</e1> is produced by 440 nuclear <e2>reactors</e2> in 31 countries."
Cause-Effect(e2,e1)
Comment:

383	 <e1>mediator</e1> assists the <e2>parties</e2> in finding their own answers for the problems before them by encouraging constructive communications, keeping the parties focused on settlement alternatives, offering information and suggestions as needed, and building the foundation for improved relations between the parties."
Other
Comment: (e) People are not usually classified as Instruments, unless they are clearly non-agentive in the situation.

384	 year's newest attractions include a dedicated music zone which takes you on a musical journey around the world and gives you a chance to experience musical <e1>ecstasy</e1> from different <e2>cultures</e2>."
Other
Comment:

385	 was a <e1>trouble</e1> <e2>maker</e2> then, a leader in SDS, and a trouble maker he remains."
Cause-Effect(e1,e2)
Comment:

386	 <e1>driver</e1> was trapped inside the <e2>car</e2>, which landed upside down, and died while emergency crews were preparing to transport him to a local hospital."
Other
Comment: We excluded Content-Container because people should not be considered contents and vehicles should not be considered containers.

387	 the <e1>evacuation</e1> was after normal <e2>business hours</e2>, the on-duty Security Officer and maintenance personnel were responsible for the notification and evacuation of occupants of all buildings."
Other
Comment: modality is outsid

388	 controlled environment <e1>facility</e1> is for <e2>growth</e2> of experimental material only."
Other
Comment:

389	 <e1>materials</e1> were produced by <e2>mixing</e2> the constituents and processing them through a press/sinter cycle to produce a consolidated material."
Other
Comment:

390	 hotel is in the style of a <e1>country</e1> <e2>lodge</e2> and only has 18 rooms."
Other
Comment:

391	 summer 2000, an Adventist church in Polotsk, Vitebsk Region, was damaged by a <e1>fire</e1> started with <e2>flammable liquids</e2>."
Cause-Effect(e2,e1)
Comment:

392	 film also features documentary like segments about fishing and about the <e1>evacuation</e1> after the <e2>eruption</e2> of the volcano."
Cause-Effect(e2,e1)
Comment:

393	 voltage swing obtainable across the load is greater than the output voltage <e1>swing</e1> obtainable from the <e2>amplifier</e2> alone, thus the efficiency of the amplifier system and power handling capacity of the system are improved."
Cause-Effect(e2,e1)
Comment:

394	 was the signal for dozens of others to do the same and the <e1>noise</e1> inside the <e2>car</e2> was quite something."
Other
Comment: None of the nine relations seems to hold. The car is not the origin/producer of the noise.

395	 1871, nearly 60 percent of the Italian <e1>population</e1> farmed for a <e2>living</e2>, attempting to eke out an existence from arid land that often was not their own."
Other
Comment: Living is an abstract object.

396	 through physical <e2>activity</e2> promotes important life skills."
Other
Comment:

397	 examined mood <e1>alterations</e1> through physical <e2>activity</e2> and other interventions."
Cause-Effect(e2,e1)
Comment:

398	 addition, scientists maye have a number of potentially useful targets to prevent and treat this lethal tumour because of the findings that NOX5 mediated <e1>overproduction</e1> of hydrogen peroxide is responsible for increased <e2>growth</e2> and decreased death of cancer cells."
Cause-Effect(e1,e2)
Comment:

399	 a little time the numbers increased from forty-five to eighty, and soon after to a greater number; which, with the majority of the clergy, and the whole of the national representatives, put the <e1>malcontents</e1> in a very <e2>diminutive condition</e2>."
Other
Comment: None of the nine relations holds. (Maybe state.); cannot be Entity-Destination since E-D's c.3 does not allow states as destinations

400	 the <e1>novelist</e1> has a <e2>computer</e2> but uses his old Smith Corona manual."
Other
Comment:

401	 was also felt necessary at this time to draw up a similar document, dealing not with the prevention of marine <e1>pollution</e1> by <e2>dumping</e2>, but instead with the prevention of marine pollution by discharges of dangerous substances from land-based sources, watercourses or pipelines."
Cause-Effect(e2,e1)
Comment:

402	 disability and long-term <e1>disability</e1> <e2>benefits</e2> are available at no cost to USTelecom employees."
Cause-Effect(e1,e2)
Comment:

403	 are three set changes and two intervals which help the <e1>recovery</e1> from <e2>laughter</e2>, but the entertainment is maintained despite the well expected ending."
Other
Comment:

404	 proves that the <e1>generator</e1> actually produced the renewable <e2>energy</e2> purchased and acts as the operative instrument of the transaction."
Cause-Effect(e1,e2)
Comment:

405	 it's a strong, lint-free synthetic material with tiny absorbent fibers, <e1>microfiber</e1> allows a <e2>mop</e2> to hold sufficient water without dripping."
Other
Comment: Not Component-Whole because microfiber is a material not a part.

406	 <e1>shroud</e1> is kept in the <e2>cathedral</e2> of St. John the Baptist in Turin, Italy."
Other
Comment: Location

407	 said <e1>whistle</e1> produced the 2600 Hz <e2>tone</e2> necessary to authorize calls."
Cause-Effect(e1,e2)
Comment:

408	 that operation was a success, the <e1>contents</e1> of the satchel were a tiny <e2>loss</e2> for the traffickers."
Other
Comment: None of the nine relation holds between "loss" and "satchel".

409	 exists a widespread <e1>controversy</e1> over stem cell <e2>research</e2> that emanates from the techniques used in the creation and usage of stem cells."
Cause-Effect(e2,e1)
Comment: The controversy is widespread and about the research, moreover the research causes the controversy. According to our guidelines Cause-Effect is however more informative.

410	 the months leading up to trade negotiations, estimates of the economic <e1>gains</e1> from trade <e2>liberalization</e2> suddenly become newsworthy."
Cause-Effect(e2,e1)
Comment:

411	 resulting anti-social <e1>behaviour</e1> from alcohol <e2>consumption</e2> is an on-going matter that the town and the police continue to address, particularly in the summer months."
Cause-Effect(e2,e1)
Comment:

412	 <e1>revolution</e1> brought forth impassioned <e2>pleas</e2> condemning the common law for not respecting the interests of the people and calling for law reform."
Cause-Effect(e2,e1)
Comment:

413	 John was able to talk to some people in the U.S. government and verify that the substantive contents of the <e1>memo</e1> were a reasonably accurate <e2>transcription</e2> of what had transpired."
Other
Comment: Mis-tagged again... It's a form of "equivalence", in that the memo is a transcription (not part of it); modality is outside

414	 combines strawberries and <e1>powder</e1> <e2>sugar</e2> and mixes well."
Other
Comment:

415	 health <e1>benefits</e1> of alcoholic <e2>beverages</e2> are the subject of this investigation."
Cause-Effect(e2,e1)
Comment:

416	 we do recommend excersise, as the <e1>kitchen</e1> holds <e2>culinary temptations</e2> in store for you that are bound to prolong your evening and lift your spirit."
Other
Comment: None of the nine relations seems to hold; modality is outside

417	 struggle for my dream of painless perfection but a <e1>snowdrift</e1> keeps the <e2>door</e2> from opening."
Other
Comment:

418	 conducted a usability test on the enterprise-wide navigation system for this <e1>heathcare</e1> <e2>company</e2>'s proposed intranet redesign."
Other
Comment: Healthcare is not a concrete object nor is it an mental activity.

419	 through synaptic <e2>depression</e2> is unlike the previous forms of inhibition in that it turns on more slowly and thus acts as delayed negative feedback."
Cause-Effect(e2,e1)
Comment:

420	 <e1>joy</e1> comes from Cather's <e2>writing</e2>: precise observation and wording, the lilting cadence of her phrasing, the beautiful and clear pictures she evokes of scenery and characters, and the unfamiliar, old fashioned words and expressions she uses."
Cause-Effect(e2,e1)
Comment:

421	 <e1>robber</e1> was inside the <e2>office</e2> when the manager decided to take action and escape out the side door."
Other
Comment: People should not be contents, instead the robber was located in the office.

422	 following <e2>drought</e2> has hit the West African savannahs, where there have been other bad droughts, notably the great one of 1972-74."
Cause-Effect(e2,e1)
Comment:

423	 for the family that shares the cooking and clean up duties, the <e1>kitchen</e1> holds a special <e2>nuturing role</e2> beyond supplying nutrition for the physical body."
Other
Comment: This might be purpose.

424	 small knife <e1>assemblies</e1> are widely used for cutting various <e2>strips</e2> of flexible materials."
Other
Comment:

425	 harvest the <e2>seeds</e2>, macerate them, and roll them into thick sticks of dry, hardened paste which can then be stored or exported from the region."
Other
Comment: Harvesting is not creation

426	 tend to cause significant <e1>damage</e1> from <e2>autumn</e2> to spring by which time the larvae are becoming fully grown."
Other
Comment:

427	 with <e2>sleep deprivation</e2> who listened to soft classical music at bedtime reported a 35 percent improvement in their quality of sleep."
Other
Comment:

428	 was this moist <e1>ground</e1> that during construction engulfed a <e2>crane</e2> which remains under the stadium today."
Other
Comment:

429	 plans to continue to live the <e1>country</e1> <e2>life</e2> as he grows older."
Other
Comment:

430	 Adelaide the <e1>land</e1> is intensively farmed for <e2>dairying</e2>, fruit, and vegetables."
Other
Comment: Dairying is an event, not an entity.

431	 Metrorail and then pick up a car just <e1>steps</e1> from the <e2>train</e2> to run errands, shop or reach any other business or social event not easily accessible via transit."
Other
Comment:

432	 had sent the old <e1>man</e1> into the world with a <e2>chisel</e2> in his hand."
Other
Comment: The man isn't using the chisel for anything.

433	 of course, everyone wants to prove the truth of their beliefs through experience, but the <e1>belief</e1> begets the <e2>experience</e2>."
Cause-Effect(e1,e2)
Comment: Both elements are occurrences; modality is outside

434	 mesopause separates the <e1>mesosphere</e1> from the <e2>thermosphere</e2>."
Other
Comment:

435	 <e1>man</e1> radiated <e2>jolliness</e2>."
Cause-Effect(e1,e2)
Comment:

436	 relieve the <e1>discomfort</e1> from <e2>traveling</e2> with a cold allergy or sinus condition."
Cause-Effect(e2,e1)
Comment:

437	 is a rise in erratic <e1>behaviour</e1> from substance <e2>abuse</e2> and frustration caused by long waits for hospital treatment."
Cause-Effect(e2,e1)
Comment:

438	 residents and <e1>scientists</e1> learned from the Krakatau <e2>explosion</e2>."
Other
Comment:

439	 is an overview of the viewer from a <e1>developer</e1>'s <e2>perspective</e2>."
Other
Comment:

440	 later, the <e1>birds</e1> composed the <e2>syllables</e2> into complete songs, whether the songs matched natural patterns or not."
Other
Comment: The sentence describes the creation of songs from pre-existing syllables.

441	 spring <e1>molt</e1> produces mottled brown <e2>feathers</e2>, making the female almost invisible as she sits on her nest."
Cause-Effect(e1,e2)
Comment: The molt is the process or the cause, not the producer.

442	 had scarcely uttered these words when the <e1>castle</e1> radiated with <e2>light</e2>."
Cause-Effect(e1,e2)
Comment:

443	 tendons, and ligaments surround the ankle providing the <e1>stability</e1> the <e2>ankle joint</e2> needs for walking and running."
Other
Comment:

444	 durable short sleeve crew neck tee shirt is made of preshrunk cotton to minimize <e1>shrinkage</e1> after <e2>washing</e2>."
Cause-Effect(e2,e1)
Comment:

445	 <e1>institution</e1> provides a <e2>deposit</e2>, as set in the Commission dues and fees schedule, towards the fee when it submits its appeal document."
Other
Comment:

446	 take <e1>multivitamin</e1> that contains <e2>vitamins</e2> D, E, K, and beta-carotene."
Other
Comment: vitamins are part of the multivitamin with no clear boundaries (stuff-object relation).

447	 <e1>students</e1> deviate from the ideal <e2>curricula</e2> presented in a later section of this bulletin."
Other
Comment:

448	 gain moral strength and <e1>happiness</e1> from <e2>giving</e2>."
Cause-Effect(e2,e1)
Comment:

449	 <e1>canola</e1> <e2>production</e2> requires hands-on involvement with the crop."
Other
Comment:

450	 EQ is a powerful sound tuning feature which uses a microphone to monitor and analyse the <e1>acoustics</e1> inside the <e2>car</e2>."
Other
Comment: Acoustics is a property of the interior of the car.

451	 very robust metal hydride discovery <e1>approach</e1> was made with a demonstrated HTS <e2>methodology</e2>."
Other
Comment: Purpose-Tool

452	 Norwalk <e1>juicer</e1> grinds and presses any <e2>fruit</e2> or vegetable."
Other
Comment:

453	 the <e1>conflict</e1> of interest created by the ethics <e2>charges</e2>, Nifong asked the state attorney general's office to take over the lacrosse case."
Cause-Effect(e2,e1)
Comment:

454	 <e1>joy</e1> comes from unexpected <e2>places</e2>."
Other
Comment:

455	 inside the <e1>cave</e1> was an old, broken-down army field <e2>telephone</e2>."
Other
Comment: The "cave" is more a location than a container.

456	 residents in Delaware were awarded $1 million for health problems due to mold <e1>growth</e1> from unrepaired <e2>leaks</e2>."
Cause-Effect(e2,e1)
Comment:

457	 rap star was apprehended at John Wayne Airport late last month and his <e1>truncheon</e1> was confiscated by <e2>police</e2>."
Other
Comment:

458	 severe <e1>famine</e1> following the <e2>good years</e2> required a political and economic reorganization in the country."
Other
Comment:

459	 have done their bit to put <e1>wine</e1> in the <e2>hands</e2> of the masses, to make it more accessible to the wider UK public."
Other
Comment: None of the nine relations holds. It's a metaphorical location, perhaps.

460	 <e1>kitchen</e1> contained primarily <e2>drug paraphernalia</e2>."
Other
Comment: drug paraphernalia were located in the kitchen.

461	 lamp's lumen output expresses the total amount of <e1>light</e1> the <e2>lamp</e2> emits in all directions per unit time."
Cause-Effect(e2,e1)
Comment:

462	 <e1>tutors</e1> provide a consistent, reliable <e2>intervention</e2> that allows students who are falling behind an opportunity to reach proficiency."
Other
Comment:

463	 after <e2>meals</e2> became part of your daily schedule."
Other
Comment:

464	 <e1>bus</e1> <e2>company</e2> has pledged a week-long roadside survey after a group of workers complained about its Bradford to Morley service."
Other
Comment: In this sentence the bus company does not produce the buses but it uses them.

465	 deliberations began, the <e1>crowd</e1> of people jamming the hallways radiated <e2>optimism</e2>."
Cause-Effect(e1,e2)
Comment:

466	 snooker <e1>player</e1> played the game with a <e2>smile</e2> on his face."
Other
Comment: The player isn't using his smile for anything. Could be Cause-Effect?

467	 Hong Kong was able to recover from that and is now experiencing strong economic <e1>growth</e1> from <e2>exports</e2>."
Cause-Effect(e2,e1)
Comment:

468	 <e1>sun</e1> emits <e2>light</e2> or radiation at a large range of energies or frequencies."
Cause-Effect(e1,e2)
Comment:

469	 the fact that the guinea pigs appeared to function in a normal physiological manner indicates that the <e1>diets</e1> contained the necessary <e2>energy density</e2>."
Other
Comment: energy density seems to be a property of the diets.

470	 C notes <e1>worsening</e1> of seizures and cognition with sleep <e2>deprivation</e2> and stress."
Cause-Effect(e2,e1)
Comment:

471	 punk <e1>explosion</e1> cultivated the underground/indie rock <e2>scene</e2> that would one day be called 'alternative music'."
Other
Comment: modality is outsid

472	 <e1>carpet</e1> is made from recycled <e2>materials</e2>."
Other
Comment:

473	 is incorrect, and when a <e1>minicab</e1> <e2>company</e2> uses the word taxi on their livery it can lead to prosecution by the local government body."
Other
Comment: In this sentence the mincab company does not produce the minicabs but it uses them.

474	 <e1>facilitator</e1> keeps the <e2>discussion</e2> focused and limited to the allotted time, while the recorder keeps a written record of the panel's recommendations."
Other
Comment:

475	 creams counteract <e1>dryness</e1> from <e2>exposure</e2> to wind, sun, and detergents."
Cause-Effect(e2,e1)
Comment:

476	 <e1>discomfort</e1> from this <e2>staring effect</e2> is exacerbated by low humidity."
Cause-Effect(e2,e1)
Comment:

477	 <e1>transmitter</e1> emits a constant radio <e2>signal</e2> to crea."
Cause-Effect(e1,e2)
Comment:

478	 also experience <e1>anxiety</e1> from <e2>fear</e2> of the suffering of their child and worry about an uncertain outcome."
Cause-Effect(e2,e1)
Comment:

479	 chemical lasers the <e1>inversion</e1> is produced by a chemical <e2>reaction</e2>."
Cause-Effect(e2,e1)
Comment:

480	 V8 <e1>engine</e1> mated with a manual transmission powers the convertible <e2>concept</e2>."
Other
Comment: The engine is an integral and functional part of the concept (car). Agencies cannot use their parts as Intruments.

481	 the <e1>notice</e1> is sent by <e2>fax</e2>, the notice is not deemed received until 3 days after faxing it."
Other
Comment:

482	 farmers and city officials in the region have tried to get state money to move the <e1>farmers</e1> <e2>market</e2> into a first-class operation and tourist attraction."
Other
Comment:

483	 who manage cachectic patients, particularly those with protracted diarrhoea and/or receiving anti-malarial drugs including <e1>mefloquine</e1>, should be aware of the risk of <e2>severe hypoglycaemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

484	 and triggering factors of <e1>hypoglycaemia</e1> induced by <e2>mefloquine</e2> and some other anti-malarial quinine analogues are discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

485	 -associated <e2>hypoglycaemia</e2> in a cachectic AIDS patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

486	 and its isomer <e1>quinidine</e1> are well-known causes of <e2>iatrogenic hypoglycaemia</e2>, due to excessive insulin secretion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

487	 and its isomer quinidine are well-known causes of <e2>iatrogenic hypoglycaemia</e2>, due to excessive insulin secretion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

488	 report a case of <e1>hypoglycaemia</e1> after <e2>mefloquine</e2> therapy (1,500 mg over two days) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

489	 <e1>sumatriptan</e1> can cause <e2>coronary artery vasospasm</e2>, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of <e1>sumatriptan</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

490	 arrest</e1> following use of <e2>sumatriptan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

491	 report a 35-year-old woman with occult coronary artery disease who experienced <e1>cardiac arrest</e1> within minutes after receiving a first-time dose of subcutaneous <e2>sumatriptan</e2> for migraine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

492	 -induced <e2>bradycardia</e2> reversed by glucagon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

493	 present a case of <e1>sotalol</e1> -induced <e2>bradycardia</e2> reversed by glucagon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

494	 endometrial adenocarcinoma</e1> in a patient on <e2>tamoxifen</e2> for breast cancer: a report of a case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

495	 unusual pattern of <e1>low-grade endometrial carcinoma</e1> adds to the spectrum of uterine neoplasia associated with <e2>tamoxifen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

496	 unusual pattern of low-grade endometrial carcinoma adds to the spectrum of <e1>uterine neoplasia</e1> associated with <e2>tamoxifen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

497	 believe that this is the first report of <e1>secretory carcinoma of the endometrium</e1> associated with <e2>tamoxifen</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

498	 <e1>endometrial adenocarcinoma of the secretory type</e1> (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on <e2>tamoxifen</e2> therapy 5 years after mastectomy for breast carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

499	 candidiasis</e1> following <e2>omeprazole</e2> therapy: a report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-A

500	 candidiasis</e1> was diagnosed at endoscopy in two patients receiving <e2>omeprazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

501	 atrioventricular block</e1> during <e2>dipyridamole</e2> stress testing."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

502	 present a case in which <e1>dipyridamole</e1> induced <e2>high-grade atrioventricular (AV) block</e2> that responded promptly to intravenous aminophylline but not to atropine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

503	 management of <e1>doxorubicin</e1> -induced <e2>cardiomyopathy</e2> associated with 'low' doses of <e1>doxorubicin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

504	 management of <e1>doxorubicin</e1> -induced <e2>cardiomyopathy</e2> associated with 'low' doses of <e1>doxorubicin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

505	 is a dose-effect relationship between <e1>doxorubicin</e1> and the incidence of <e2>symptomatic cardiac failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

506	 endometrioid carcinoma and <e1>endometriosis</e1> developing in a postmenopausal breast cancer patient during <e2>tamoxifen</e2> therapy: a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

507	 endometrioid carcinoma</e1> and endometriosis developing in a postmenopausal breast cancer patient during <e2>tamoxifen</e2> therapy: a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

508	 association with prolonged unopposed estrogen-like stimulation with <e1>tamoxifen</e1> as a possible factor in the development of <e2>ovarian endometrioid carcinoma</e2> is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

509	 present the first case of ovarian endometrioid carcinoma and <e1>endometriosis</e1> in a postmenopausal patient who was treated with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

510	 present the first case of <e1>ovarian endometrioid carcinoma</e1> and endometriosis in a postmenopausal patient who was treated with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

511	 demyelinating disease</e1> developed in a patient during adjuvant therapy with <e2>levamisole</e2> for malignant melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

512	 inflammatory leukoencephalopathy</e1> associated with <e2>levamisole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

513	 in our patient suggest that the <e1>leukoencephalopathy</e1> that developed in previously reported patients who received <e2>5-fluorouracil</e2> and levamisole may have been caused at least partly by levamisole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

514	 in our patient suggest that the <e1>leukoencephalopathy</e1> that developed in previously reported patients who received 5-fluorouracil and <e2>levamisole</e2> may have been caused at least partly by <e2>levamisole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

515	 in our patient suggest that the <e1>leukoencephalopathy</e1> that developed in previously reported patients who received 5-fluorouracil and <e2>levamisole</e2> may have been caused at least partly by <e2>levamisole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

516	 case of <e1>noncardiogenic pulmonary edema</e1> by <e2>ethanolamine oleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

517	 <e1>EO</e1> -induced <e2>noncardiogenic pulmonary edema</e2> has not been reported in human."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

518	 report a case of <e1>noncardiogenic pulmonary edema</e1> developed after therapeutic trial of <e2>EO</e2> as sclerosing agent for esophageal varix."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

519	 patients are described in whom only <e1>gentamicin sulfate</e1> appeared responsible for <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

520	 -associated <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

521	 failure</e1> appeared 8 to 17 days after beginning <e2>gentamicin</e2> therapy and was characterized by creatinine clearances 4 to 10 ml/min, urine to plasma creatinine ratios less than 20, urinary sodium concentrations 16 to 60 mEq/liter, proteinuria, and cylindruria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

522	 15-year follow-up of <e1>phenytoin</e1> -induced <e2>unilateral gingival hyperplasia</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

523	 aim of this case report is to present a 15-year follow-up of a patient with <e1>phenytoin</e1> (PHT) intoxication with <e2>unilateral gingival hyperplasia</e2> (GH)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

524	 aim of this case report is to present a 15-year follow-up of a patient with phenytoin (<e1>PHT</e1>) intoxication with <e2>unilateral gingival hyperplasia</e2> (GH)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

525	 report a case of <e1>generalized cutaneous sclerosis</e1> associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and <e2>aminotriazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

526	 report a case of <e1>generalized cutaneous sclerosis</e1> associated with muscle and oesophageal involvement in a patient exposed to herbicides containing <e2>bromocil</e2>, diuron and aminotriazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

527	 report a case of <e1>generalized cutaneous sclerosis</e1> associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, <e2>diuron</e2> and aminotriazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

528	 -induced hypokalemia and its potential <e2>cardiac toxicity</e2> are discussed briefly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

529	 -induced <e2>hypokalemia</e2> and its potential cardiac toxicity are discussed briefly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

530	 after normal doses of neubulized <e2>albuterol</e2> (salbutamol)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

531	 after normal doses of neubulized albuterol (<e2>salbutamol</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

532	 cases of two asthmatic patients who became <e1>hypokalemic</e1> after inhalation of normal doses of <e2>albuterol</e2> are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

533	 -induced <e2>wide complex dysrhythmia</e2> responsive to sodium bicarbonate therapy has not been previously reported in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

534	 -induced <e2>wide QRS complex dysrhythmia</e2> responsive to sodium bicarbonate--a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

535	 report: <e1>mannitol</e1> <e2>nephrotoxicity syndrome</e2>: role of hemodialysis and postulate of mechanisms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

536	 should be performed for rapid reversal of <e1>mannitol</e1> -induced <e2>ARF</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

537	 intravenous <e1>mannitol</e1> infusion in various clinical settings may result in <e2>acute renal failure</e2> (ARF)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

538	 intravenous <e1>mannitol</e1> infusion in various clinical settings may result in acute renal failure (<e2>ARF</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

539	 -induced <e2>ARF</e2> responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

540	 literature is also reviewed for <e1>ARF</e1> associated with <e2>mannitol</e2> infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of <e2>mannitol</e2> nephrotoxicity are discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

541	 literature is also reviewed for ARF associated with <e1>mannitol</e1> infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of <e1>mannitol</e1> <e2>nephrotoxicity</e2> are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

542	 is a report of a case of <e1>anuric ARF</e1> after high-dose <e2>mannitol</e2> infusion for treatment of narrow-angle glaucoma that readily responded to acute hemodialysis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

543	 patients with <e1>extrapyramidal side effects</e1> after the use of <e2>fluphenazine decanoate</e2> were evaluated by means of IBZM-SPECT."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

544	 reversal of <e1>benzodiazepine</e1> -induced <e2>sedation</e2> for a patient with severe pre-ECT anxiety."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

545	 SUMMARY: A 68-year-old woman developed a dry, <e1>irritating cough</e1> within one month of starting <e2>quinapril</e2> therapy for the treatment of essential hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-

546	 induced by <e2>quinapril</e2> with resolution after changing to fosinopril."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

547	 To report a case of chronic, nonproductive <e1>cough</e1> secondary to the angiotensin-converting enzyme (ACE) inhibitor <e2>quinapril</e2>, with complete resolution after switching to another ACE inhibitor, fosinopril."
DRUG-ADE(e2,e1)
Comment: DRUG-A

548	 <e1>cough</e1> continued for the duration of therapy with <e2>quinapril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

549	 report a case of <e1>cough</e1> following the administration of <e2>quinapril</e2>, with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

550	 of the femoral neck</e1> occurred in one patient during <e2>PSL</e2> therapy, although the relationship between the fracture and <e2>PSL</e2> therapy was uncertain."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

551	 -induced <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

552	 our patient, <e1>DIAN</e1> possibly was related to <e2>cefuroxime</e2>, but the patient did not experience associated allergic symptoms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

553	 diagnosis was supported by the temporal course of <e1>renal deterioration</e1> during exposure to <e2>cefuroxime</e2> and improvement on its discontinuation; the pattern repeated with rechallenge."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

554	 is the first reported case of suspected <e1>DIAN</e1> due to <e2>cefuroxime</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

555	 case of <e1>basilar invagination</e1> which is thought to have arisen from the patient's intrauterine exposure to <e2>phenytoin</e2> is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

556	 invagination</e1> and mid-line skeletal abnormalities due to in utero exposure to <e2>phenytoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

557	 invagination and <e1>mid-line skeletal abnormalities</e1> due to in utero exposure to <e2>phenytoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

558	 symptoms of brain stem compression were alleviated and the role of <e1>phenytoin</e1> in the production of his <e2>craniocervical abnormality</e2> is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

559	 neurologic abnormalities</e1> were observed in one out of 23 patients undergoing chemotherapy with high-dose <e2>methotrexate</e2> (HD-MTX) for osteogenic sarcoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

560	 patient developed sequential symptoms including alternative hemiparesis, dysarthria and <e1>altered consciousness</e1> 5 days after the second course of <e2>HD-MTX</e2> (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

561	 patient developed sequential symptoms including alternative hemiparesis, <e1>dysarthria</e1> and altered consciousness 5 days after the second course of <e2>HD-MTX</e2> (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

562	 patient developed sequential symptoms including alternative <e1>hemiparesis</e1>, dysarthria and altered consciousness 5 days after the second course of <e2>HD-MTX</e2> (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

563	 neurological disturbances</e1> induced by the chemotherapy of high-dose <e2>methotrexate</e2> for osteogenic sarcoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

564	 report a 5-year-old boy with CF who had a <e1>stricture of the hepatic flexure region with associated narrowing</e1> due to submucosal fibrosis of the transverse colon, secondary to <e2>high-lipase pancreatin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

565	 report a 5-year-old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to <e1>submucosal fibrosis of the transverse colon</e1>, secondary to <e2>high-lipase pancreatin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

566	 pancreatitis</e1> associated with <e2>danazol</e2> treatment for endometriosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

567	 <e1>danazol</e1> produces <e2>hepatocellular damage</e2> in approximately 10% of women."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

568	 and anabolic/androgenic side-effects</e1> of <e2>danazol</e2> are well known by the gynaecologist and some of them are present in > 50% of patients being treated for endometriosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

569	 present report describes the first case of <e1>acute pancreatitis</e1> associated with <e2>danazol</e2> treatment of endometriosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

570	 <e2>neurotoxicity</e2>: clinical experience and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

571	 produces <e2>neurologic symptoms</e2> that resemble extension of viral infection into the central nervous system."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

572	 disease, most commonly renal dysfunction, preceded all 30 reported cases of <e1>acyclovir</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

573	 discuss our observations in the cases of two patients with <e1>acyclovir</e1> <e2>neurotoxicity</e2> and review the findings of all previous reports in the English language literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

574	 of a <e1>promethazine</e1> -induced <e2>coma</e2> to flumazenil."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

575	 report the first case of a patient in a <e1>promethazine</e1> -induced <e2>coma</e2> responding to treatment with flumazenil."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

576	 abscess of the spleen</e1> complicated by <e2>metronidazole</e2> -induced neurotoxicity: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

577	 abscess of the spleen complicated by <e1>metronidazole</e1> -induced <e2>neurotoxicity</e2>: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

578	 describe a patient with a liver abscess due to Entamoeba histolytica, in whom <e1>metronidazole</e1> therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and <e2>ataxia</e2> and who relapsed 5 months later with a splenic abscess."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

579	 describe a patient with a <e1>liver abscess</e1> due to Entamoeba histolytica, in whom <e2>metronidazole</e2> therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

580	 describe a patient with a liver abscess due to Entamoeba histolytica, in whom <e1>metronidazole</e1> therapy (total dose, 21 g over 14 days) was complicated by <e2>reversible deafness</e2>, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

581	 describe a patient with a liver abscess due to Entamoeba histolytica, in whom <e1>metronidazole</e1> therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a <e2>splenic abscess</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

582	 describe a patient with a liver abscess due to Entamoeba histolytica, in whom <e1>metronidazole</e1> therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, <e2>tinnitus</e2>, and ataxia and who relapsed 5 months later with a splenic abscess."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

583	 D</e1> associated <e2>hepatic veno-occlusive disease</e2> --a report of 2 cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

584	 are now reports of <e1>liver failure</e1> following treatment of childhood cancers with <e2>AMD</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

585	 -induced <e2>psychosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

586	 report a cae of <e1>paranoid psychosis</e1> following use of a decongestant containing <e2>PPA</e2> and summarize the case report literature of psychiatric adverse effects to <e2>PPA</e2> in which doses were known and stated to be within recommended guidelines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

587	 report a cae of paranoid psychosis following use of a decongestant containing <e1>PPA</e1> and summarize the case report literature of <e2>psychiatric adverse effects</e2> to <e1>PPA</e1> in which doses were known and stated to be within recommended guidelines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

588	 Although <e1>budesonide</e1> may be beneficial because of its anti-inflammatory effects, clinicians should be alert to its potential for causing <e2>contact dermatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

589	 dermatitis</e1> due to <e2>budesonide</e2>: report of five cases and review of the Japanese literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

590	 Five cases of <e1>contact dermatitis</e1> due to <e2>budesonide</e2>, a nonhalogenated steroid, are described."
DRUG-ADE(e2,e1)
Comment: DRUG-A

591	 <e1>Budesonide</e1> use can cause <e2>contact dermatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

592	 other nitrites induce <e1>methemoglobinemia</e1>, exposure to <e2>methyl nitrite</e2> during phenylpropanolamine production appears to be a new cause of occupational <e1>methemoglobinemia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

593	 other nitrites induce <e1>methemoglobinemia</e1>, exposure to <e2>methyl nitrite</e2> during phenylpropanolamine production appears to be a new cause of occupational <e1>methemoglobinemia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

594	 an occupational hazard of <e2>phenylpropanolamine</e2> production."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

595	 and after <e1>IFN</e1> therapy we should consider the possibility of occurrence of <e2>IDDM</e2> as well as other autoimmune diseases and observe the clinical course carefully."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

596	 years after the beginning of <e1>IFN</e1> therapy, he acutely developed <e2>moderate hyperglycemia</e2> and severe ketonuria with positive islet cell antibody, and then 28 units/day of insulin injection was started."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

597	 years after the beginning of <e1>IFN</e1> therapy, he acutely developed moderate hyperglycemia and <e2>severe ketonuria</e2> with positive islet cell antibody, and then 28 units/day of insulin injection was started."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

598	 of <e1>IDDM</e1> during <e2>interferon</e2> therapy for chronic viral hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

599	 report a case of <e1>IDDM</e1> which occurred during <e2>interferon</e2> therapy for chronic hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

600	 patients who manifested symptoms of the antiepileptic drug (AED) <e1>hypersensitivity syndrome</e1> during therapy with <e2>carbamazepine</e2> are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

601	 hypotension</e1> immediately after seizures in <e2>nortriptyline</e2> overdose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

602	 hypotension immediately after <e1>seizures</e1> in <e2>nortriptyline</e2> overdose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

603	 use of <e1>methotrexate</e1> (MTX) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and <e2>accelerate HIV disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

604	 use of methotrexate (<e1>MTX</e1>) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which <e1>MTX</e1> appeared to potentiate opportunistic infections and <e2>accelerate HIV disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

605	 use of methotrexate (<e1>MTX</e1>) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which <e1>MTX</e1> appeared to potentiate opportunistic infections and <e2>accelerate HIV disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

606	 This case describes the clinically significant <e1>increase of INR</e1> in an elderly patient after adding a chemotherapy regimen of levamisole and <e2>5-FU</e2> to a previous regimen of warfarin alone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

607	 This case describes the clinically significant <e1>increase of INR</e1> in an elderly patient after adding a chemotherapy regimen of <e2>levamisole</e2> and 5-FU to a previous regimen of warfarin alone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

608	 This case describes the clinically significant <e1>increase of INR</e1> in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of <e2>warfarin</e2> alone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

609	 prolongation of <e1>5-FU</e1> half-life and an <e2>increase in INR</e2> have been reported with the concurrent use of <e1>5-FU</e1> and warfarin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

610	 prolongation of 5-FU half-life and an <e1>increase in INR</e1> have been reported with the concurrent use of 5-FU and <e2>warfarin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

611	 liver disease</e1> with ductopenia (vanishing bile duct syndrome) after administration of <e2>clindamycin</e2> and trimethoprim-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

612	 liver disease</e1> with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and <e2>trimethoprim-sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

613	 liver disease with <e1>ductopenia</e1> (vanishing bile duct syndrome) after administration of <e2>clindamycin</e2> and trimethoprim-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

614	 liver disease with <e1>ductopenia</e1> (vanishing bile duct syndrome) after administration of clindamycin and <e2>trimethoprim-sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

615	 liver disease with ductopenia (<e1>vanishing bile duct syndrome</e1>) after administration of <e2>clindamycin</e2> and trimethoprim-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

616	 liver disease with ductopenia (<e1>vanishing bile duct syndrome</e1>) after administration of clindamycin and <e2>trimethoprim-sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

617	 patient who received <e1>clindamycin</e1> had liver biopsy findings of marked cholestasis, portal inflammation, <e2>bile duct injury</e2> and bile duct paucity (ductopenia)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

618	 patient who received <e1>clindamycin</e1> had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and <e2>bile duct paucity</e2> (ductopenia)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

619	 patient who received <e1>clindamycin</e1> had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity (<e2>ductopenia</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

620	 patient who received <e1>clindamycin</e1> had liver biopsy findings of <e2>marked cholestasis</e2>, portal inflammation, bile duct injury and bile duct paucity (ductopenia)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

621	 patient who received <e1>clindamycin</e1> had liver biopsy findings of marked cholestasis, <e2>portal inflammation</e2>, bile duct injury and bile duct paucity (ductopenia)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

622	 second patient, who developed <e1>cholestasis</e1> after receiving <e2>trimethoprim-sulfamethoxazole</e2>, had marked duct paucity in the liver biopsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

623	 second patient, who developed cholestasis after receiving <e1>trimethoprim-sulfamethoxazole</e1>, had marked <e2>duct paucity</e2> in the liver biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

624	 is the first description, to our knowledge, of <e1>ductopenia</e1> apparently caused by <e2>clindamycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

625	 years later, treatment with <e1>ampicillin</e1> caused another episode of cholestatic hepatitis with <e2>cholestasis</e2> and duct paucity on rebiopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

626	 years later, treatment with <e1>ampicillin</e1> caused another episode of <e2>cholestatic hepatitis</e2> with cholestasis and duct paucity on rebiopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

627	 years later, treatment with <e1>ampicillin</e1> caused another episode of cholestatic hepatitis with cholestasis and <e2>duct paucity</e2> on rebiopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

628	 A patient who developed dramatic, permanent <e1>vision loss</e1> after a 9-month course of treatment with <e2>ethambutol</e2> and isoniazid for pulmonary tuberculosis is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-A

629	 A patient who developed dramatic, permanent <e1>vision loss</e1> after a 9-month course of treatment with ethambutol and <e2>isoniazid</e2> for pulmonary tuberculosis is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-A

630	 <e1>Ethambutol</e1>, and to a lesser extent isoniazid, are both implicated in the <e2>development of visually related side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

631	 Ethambutol, and to a lesser extent <e1>isoniazid</e1>, are both implicated in the <e2>development of visually related side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

632	 is documentation of <e1>ocular toxicity</e1> with <e2>ethambutol</e2> when administered at dosages generally pronounced as being safe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

633	 optic neuropathy</e1> associated with <e2>ethambutol</e2>: implications for current therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

634	 the use of <e1>zidovudine</e1> is one of the few specific measures available, and as a potentially teratogenic and fetotoxic agent, any decision for its use requires evaluation of the potential for <e2>fetal damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

635	 the use of <e1>zidovudine</e1> is one of the few specific measures available, and as a potentially teratogenic and <e2>fetotoxic</e2> agent, any decision for its use requires evaluation of the potential for fetal damage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

636	 the use of <e1>zidovudine</e1> is one of the few specific measures available, and as a potentially <e2>teratogenic</e2> and fetotoxic agent, any decision for its use requires evaluation of the potential for fetal damage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

637	 a series of 104 cases of intentional or inadvertent use of <e1>zidovudine</e1> at differing gestations in pregnancy, there were eight spontaneous first trimester abortions, eight therapeutic terminations, and eight cases of <e2>fetal abnormality</e2> occurring among a total of 88 cases where the pregnancy progressed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

638	 a series of 104 cases of intentional or inadvertent use of <e1>zidovudine</e1> at differing gestations in pregnancy, there were eight spontaneous <e2>first trimester abortions</e2>, eight therapeutic terminations, and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

639	 use in pregnancy: a report on 104 cases and the occurrence of <e2>birth defects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

640	 <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

641	 subsequent rechallenge with <e1>celiprolol</e1> led to recurrence of the <e2>pneumonitis</e2>, 10 weeks after drug readministration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

642	 report on a patient who developed <e1>hypersensitivity pneumonitis</e1> during treatment with the beta-blocker, <e2>celiprolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

643	 -induced reversible <e2>leukopenia</e2> during treatment for congestive heart failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

644	 leukopenia</e1> was documented in an 81-year-old woman treated with adjunctive <e2>ibopamine</e2> 100 mg t.i.d. for chronic congestive heart failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

645	 apparently adversely affected both the clinical and biochemical parameters of the <e2>acute intermittent porphyria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

646	 clinical improvement of the <e1>porphyria</e1> followed withdrawal of the <e2>diphenylhydantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

647	 53-year-old male, without any prior history of psychosis, developed <e1>schizophrenia</e1> 4 days after starting low-dose <e2>bromocriptine</e2> therapy for a macroprolactinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

648	 -induced <e2>schizophrenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

649	 acute megaloblastic anaemia</e1> and pneumonitis: a severe side-effect of low-dose <e2>methotrexate</e2> therapy during rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

650	 acute megaloblastic anaemia and <e1>pneumonitis</e1>: a severe side-effect of low-dose <e2>methotrexate</e2> therapy during rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

651	 a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose <e1>methotrexate</e1>: an <e2>acute megaloblastic anaemia</e2> and a pneumonitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

652	 a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose <e1>methotrexate</e1>: an acute megaloblastic anaemia and a <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

653	 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (<e1>Levemepromazine</e1>) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from <e2>respiratory distress syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

654	 11-year-old boy who was treated with a relatively high dose of <e1>methotrimeprazine meleate</e1> (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from <e2>respiratory distress syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

655	 association of <e1>phenothiazine</e1> overdose and <e2>respiratory distress syndrome</e2> merits consideration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

656	 two patients, <e1>apomorphine</e1> remained effective in the morning, but increased the intensity of the <e2>dyskinesias</e2> in the afternoon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

657	 report on three observations of parkinsonian patients with <e1>levo-dopa</e1> -induced <e2>diphasic dyskinesias</e2>, who received subcutaneous apomorphine to reduce the duration of abnormal movements."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

658	 hepatitis</e1> with severe lactate acidosis in HIV-infected patients on <e2>didanosine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

659	 hepatitis with <e1>severe lactate acidosis</e1> in HIV-infected patients on <e2>didanosine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

660	 prompted us to suspect that <e1>ddI</e1> might be responsible for <e2>fulminant hepatitis</e2> in all three AIDS patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

661	 report two cases of <e1>fulminant hepatic failure</e1> in HIV-1-infected patients treated with didanosine (<e2>ddI</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

662	 report two cases of <e1>fulminant hepatic failure</e1> in HIV-1-infected patients treated with <e2>didanosine</e2> (ddI)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

663	 argyria</e1> after habitual use of <e2>AgNO3</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

664	 case of <e1>fluoxetine</e1> induced <e2>seizures</e2>, in a person with Down syndrome, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

665	 associated with <e2>fluoxetine</e2> therapy are uncommon."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

666	 associated with <e2>fluoxetine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

667	 <e1>fluoxetine</e1> -induced <e2>headache</e2> occurred in one patient, the other five reported no side effects at the doses used."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

668	 valproate and <e1>carbamazepine</e1>, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce <e2>psoriasiform eruptions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

669	 valproate</e1> and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce <e2>psoriasiform eruptions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

670	 present findings from three patients who experienced a <e1>psoriasiform eruption</e1> apparently due to the antiepileptic agents sodium valproate and <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

671	 present findings from three patients who experienced a <e1>psoriasiform eruption</e1> apparently due to the antiepileptic agents <e2>sodium valproate</e2> and carbamazepine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

672	 diffuse interstitial pneumonitis</e1> induced by carmustine (<e2>BCNU</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

673	 diffuse interstitial pneumonitis</e1> induced by <e2>carmustine</e2> (BCNU)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

674	 report a <e1>fatal case of acute interstitial pneumonitis</e1> in a patient treated with carmustine (<e2>BCNU</e2>) for a brain tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

675	 report a <e1>fatal case of acute interstitial pneumonitis</e1> in a patient treated with <e2>carmustine</e2> (BCNU) for a brain tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

676	 78-year-old man with a transvenous cardioverter defibrillator system developed frequent <e1>shocks</e1> during oral <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

677	 proarrhythmia</e1> with <e2>procainamide</e2>: a new ICD-drug interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-A

678	 failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported <e1>electrophysiologic effect</e1> of, or idiosyncratic response to, <e2>procainamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

679	 on our experience and on previously published data, serum ammonia levels appear to be indicated in all ED patients on <e1>valproic acid</e1> therapy who present with <e2>altered mental status</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

680	 has been described as a complication of <e2>valproic acid</e2> therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

681	 has been described as a complication of <e1>valproic acid</e1> therapy but may often be overlooked as a cause of <e2>lethargy</e2> in the postictal patient who presents to the emergency department."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

682	 secondary to <e2>valproic acid</e2> as a cause of lethargy in a postictal patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

683	 secondary to <e1>valproic acid</e1> as a cause of <e2>lethargy</e2> in a postictal patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

684	 present the case of a postictal patient with lethargy, <e1>hyperammonemia</e1>, otherwise normal liver function tests, and a therapeutic <e2>valproic acid</e2> level."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

685	 present the case of a postictal patient with <e1>lethargy</e1>, hyperammonemia, otherwise normal liver function tests, and a therapeutic <e2>valproic acid</e2> level."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

686	 nervous system toxicity</e1> associated with <e2>meperidine</e2> use in hepatic disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

687	 patients with cirrhosis, the metabolism of <e1>meperidine</e1> is decreased, leading to <e2>accumulation of the parent drug</e2> and possible CNS depressive effects similar to hepatic encephalopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

688	 patients with cirrhosis, the metabolism of <e1>meperidine</e1> is decreased, leading to accumulation of the parent drug and possible <e2>CNS depressive effects</e2> similar to hepatic encephalopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

689	 -associated central nervous system (CNS) excitatory toxicities are believed to be caused by <e2>accumulation of the active metabolite normeperidine</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

690	 -associated <e2>central nervous system (CNS) excitatory toxicities</e2> are believed to be caused by accumulation of the active metabolite normeperidine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

691	 received an accidental 450-mg bolus injection of <e1>morphine</e1> intrathecally and developed <e2>hypertension</e2>, status epilepticus, intracerebral hemorrhage, and respiratory failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

692	 received an accidental 450-mg bolus injection of <e1>morphine</e1> intrathecally and developed hypertension, status epilepticus, <e2>intracerebral hemorrhage</e2>, and respiratory failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

693	 received an accidental 450-mg bolus injection of <e1>morphine</e1> intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and <e2>respiratory failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

694	 received an accidental 450-mg bolus injection of <e1>morphine</e1> intrathecally and developed hypertension, <e2>status epilepticus</e2>, intracerebral hemorrhage, and respiratory failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

695	 C</e1> (MMC) is an alkylating agent that has been recently associated with the <e2>hemolytic-uremic syndrome</e2> (HUS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

696	 C (<e1>MMC</e1>) is an alkylating agent that has been recently associated with the <e2>hemolytic-uremic syndrome</e2> (HUS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

697	 C</e1> (MMC) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome (<e2>HUS</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

698	 C (<e1>MMC</e1>) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome (<e2>HUS</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

699	 hemorrhage as a clinical manifestation of <e1>hemolytic-uremic syndrome</e1> associated with <e2>mitomycin C</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

700	 hemorrhage</e1> as a clinical manifestation of hemolytic-uremic syndrome associated with <e2>mitomycin C</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

701	 hemorrhage is an uncommon feature in the <e1>HUS</e1>, and seems to appear especially in the <e1>HUS</e1> associated with <e2>MMC</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

702	 hemorrhage is an uncommon feature in the <e1>HUS</e1>, and seems to appear especially in the <e1>HUS</e1> associated with <e2>MMC</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

703	 hemorrhage</e1> is an uncommon feature in the HUS, and seems to appear especially in the HUS associated with <e2>MMC</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

704	 describe two women who developed <e1>HUS</e1> after <e2>MMC</e2> therapy and presented massive pulmonary bleeding."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

705	 describe two women who developed HUS after <e1>MMC</e1> therapy and presented <e2>massive pulmonary bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

706	 -induced <e2>bradycardia</e2> in patients with spinal cord injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

707	 mechanisms by which <e1>clonidine</e1> decreases spasticity are described, probable mechanisms of induced <e2>bradycardia</e2> are reviewed, and specific treatment recommendations for the use of <e1>clonidine</e1> in spinal cord injured patients are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

708	 mechanisms by which <e1>clonidine</e1> decreases spasticity are described, probable mechanisms of induced <e2>bradycardia</e2> are reviewed, and specific treatment recommendations for the use of <e1>clonidine</e1> in spinal cord injured patients are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

709	 hypotension, dry mouth, and constipation are well-documented possible adverse effects, the possibility of <e1>clonidine</e1> -induced <e2>bradycardia</e2> is less well recognized and is rare."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

710	 hypotension, dry mouth, and <e1>constipation</e1> are well-documented possible adverse effects, the possibility of <e2>clonidine</e2> -induced bradycardia is less well recognized and is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

711	 hypotension, <e1>dry mouth</e1>, and constipation are well-documented possible adverse effects, the possibility of <e2>clonidine</e2> -induced bradycardia is less well recognized and is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

712	 <e1>hypotension</e1>, dry mouth, and constipation are well-documented possible adverse effects, the possibility of <e2>clonidine</e2> -induced bradycardia is less well recognized and is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

713	 high dose of <e1>cotrimoxazole</e1> induced hyperkalaemia with the <e2>elevation of serum creatinine and blood urea</e2>, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

714	 high dose of <e1>cotrimoxazole</e1> induced <e2>hyperkalaemia</e2> with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

715	 high dose of <e1>cotrimoxazole</e1> induced hyperkalaemia with the elevation of serum creatinine and blood urea, and <e2>increased urinary N-acetyl glucosaminase</e2> after several days of the drug administration in these patients; one patient became unconscious."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

716	 high dose of <e1>cotrimoxazole</e1> induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; <e2>one patient became unconscious</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

717	 with renal tubular dysfunction by oral therapy of sulfamethoxazole-trimethoprim (<e2>co-trimoxazole</e2>) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

718	 with renal tubular dysfunction by oral therapy of <e2>sulfamethoxazole-trimethoprim</e2> (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

719	 with <e1>renal tubular dysfunction</e1> by oral therapy of sulfamethoxazole-trimethoprim (<e2>co-trimoxazole</e2>) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

720	 with <e1>renal tubular dysfunction</e1> by oral therapy of <e2>sulfamethoxazole-trimethoprim</e2> (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

721	 with renal tubular dysfunction by <e2>sulfamethoxazole-trimethoprim</e2> for Pneumocystis carinii pneumonia in patients with lymphoid malignancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

722	 with <e1>renal tubular dysfunction</e1> by <e2>sulfamethoxazole-trimethoprim</e2> for Pneumocystis carinii pneumonia in patients with lymphoid malignancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

723	 cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed <e1>subacute combined degeneration of the spinal cord</e1> following <e2>nitrous oxide</e2> anesthesia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

724	 degeneration</e1> associated with <e2>nitrous oxide</e2> anesthesia in patients with vitamin B12 deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

725	 with vitamin B12 deficiency are exceedingly sensitive to <e1>neurologic deterioration</e1> following <e2>nitrous oxide</e2> anesthesia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

726	 <e1>Fluoxetine</e1>, a highly specific serotonin reuptake inhibitor, has been reported to cause <e2>sexual dysfunction</e2> in a minority of patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

727	 -induced <e2>bone marrow suppression</e2> in two cardiac patients with trisomy 21."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

728	 is an infrequent complication following administration of the angiotensin-converting enzyme (ACE) inhibitor, <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

729	 report two cases of <e1>neutropenia</e1> following <e2>captopril</e2> use in cardiac patients with trisomy 21."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

730	 <e1>magnesium sulfate</e1> therapy impact <e2>lactogenesis</e2>?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

731	 explanation for this delay was found, other than the possibility that <e1>magnesium sulfate</e1> treatment <e2>impeded lactogenesis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

732	 days after the initial injection of 3.6 mg of <e1>goserelin acetate</e1>, severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a <e2>flare-up</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

733	 days after the initial injection of 3.6 mg of <e1>goserelin acetate</e1>, <e2>severe dyspnea</e2> developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

734	 days after the initial injection of 3.6 mg of <e1>goserelin acetate</e1>, severe dyspnea developed due to <e2>worsening pleuritis carcinomatosa</e2>, which was considered as a flare-up."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

735	 intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

736	 intoxication in children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

737	 complications of <e1>L-asparaginase</e1> therapy in children with leukemia: <e2>aphasia</e2> and other neuropsychological deficits."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

738	 complications</e1> of <e2>L-asparaginase</e2> therapy in children with leukemia: aphasia and other neuropsychological deficits."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

739	 complications of <e1>L-asparaginase</e1> therapy in children with leukemia: aphasia and other <e2>neuropsychological deficits</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

740	 with acute lymphoblastic leukemia (ALL), treated with <e1>L-asparaginase</e1> are at risk for <e2>cerebral thrombosis</e2> or hemorrhage because of coagulation protein deficiencies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

741	 with acute lymphoblastic leukemia (ALL), treated with <e1>L-asparaginase</e1> are at risk for cerebral thrombosis or hemorrhage because of <e2>coagulation protein deficiencies</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

742	 with acute lymphoblastic leukemia (ALL), treated with <e1>L-asparaginase</e1> are at risk for cerebral thrombosis or <e2>hemorrhage</e2> because of coagulation protein deficiencies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

743	 and seizures disappeared after discontinuation of <e2>L-dopa</e2> and the introduction of valproate sodium (VPA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

744	 and <e1>seizures</e1> disappeared after discontinuation of <e2>L-dopa</e2> and the introduction of valproate sodium (VPA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

745	 and seizures in a patient with parkinsonism: induction by <e2>levodopa</e2> and its confirmation on SEPs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

746	 and <e1>seizures</e1> in a patient with parkinsonism: induction by <e2>levodopa</e2> and its confirmation on SEPs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

747	 was induced and enhanced by <e1>L-dopa</e1>, developing into <e2>generalized seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

748	 was induced and enhanced by <e2>L-dopa</e2>, developing into generalized seizures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

749	 described the occurrence of <e1>L-dopa</e1> -induced <e2>myoclonus</e2> and seizures in a case of parkinsonism with its SEPs findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

750	 described the occurrence of <e1>L-dopa</e1> -induced myoclonus and <e2>seizures</e2> in a case of parkinsonism with its SEPs findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

751	 exposure to <e1>acyclovir</e1> early in pregnancy, which is not uncommon, may cause <e2>excessive maternal and physician anxiety</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

752	 severe form of <e1>exophthalmos</e1> resulting from <e2>lithium</e2> therapy has not been described in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

753	 therapy was discontinued because of poor compliance to the medication and intolerable <e2>polyuria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

754	 of <e1>thyrotoxic ophthalmopathy</e1> following <e2>lithium</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

755	 case of a bipolar patient who developed thyrotoxicosis with <e1>severe exophthalmos</e1> while on <e2>lithium</e2> therapy is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

756	 case of a bipolar patient who developed <e1>thyrotoxicosis</e1> with severe exophthalmos while on <e2>lithium</e2> therapy is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

757	 <e1>exophthalmos</e1> improved dramatically within 72 hours of the withdrawal of <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

758	 <e1>abdominal pain</e1> in low dosage <e2>clofazimine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

759	 describe a 41 yr old leprosy patient treated for 10 yrs with <e1>clofazimine</e1> who underwent laparotomy for severe <e2>abdominal pain</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

760	 B</e1> overdose in pediatric patients with associated <e2>cardiac arrest</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

761	 <e1>Amphotericin B</e1> overdose can be <e2>fatal</e2> in children and infants."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

762	 may decrease the incidence of mortality associated with <e1>cardiac arrhythmias</e1> in children receiving <e2>amphotericin B</e2> overdoses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

763	 may decrease the incidence of <e1>mortality</e1> associated with cardiac arrhythmias in children receiving <e2>amphotericin B</e2> overdoses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

764	 AND RESULTS: <e1>Cardiac complications</e1> were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of <e2>amphotericin B</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

765	 To report the first five cases of <e1>amphotericin B</e1> overdose with secondary <e2>cardiac complications</e2> in a pediatric population."
DRUG-ADE(e1,e2)
Comment: DRUG-A

766	 develops in most patients after transplantation when immunosuppression is based on <e2>cyclosporine</e2> and prednisone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

767	 develops in most patients after transplantation when immunosuppression is based on cyclosporine and <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

768	 death</e1> in an infant from methemoglobinemia after administration of "<e2>sweet spirits of nitre</e2>"."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

769	 administration of "sweet spirits of nitre" (<e1>4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol</e1>) was followed by <e2>acute methemoglobinemia</e2> and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

770	 administration of "<e1>sweet spirits of nitre</e1>" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by <e2>acute methemoglobinemia</e2> and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

771	 administration of "sweet spirits of nitre" (<e1>4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol</e1>) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin <e2>died</e2> from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

772	 administration of "<e1>sweet spirits of nitre</e1>" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin <e2>died</e2> from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

773	 administration of "sweet spirits of nitre" (<e1>4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol</e1>) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of <e2>hypoxemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

774	 administration of "<e1>sweet spirits of nitre</e1>" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of <e2>hypoxemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

775	 administration of "sweet spirits of nitre" (<e1>4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol</e1>) was followed by acute methemoglobinemia and <e2>severe anoxic metabolic acidosis</e2> in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

776	 administration of "<e1>sweet spirits of nitre</e1>" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and <e2>severe anoxic metabolic acidosis</e2> in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

777	 effects</e1> in a child receiving valproate and <e2>carnitine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

778	 effects</e1> in a child receiving <e2>valproate</e2> and carnitine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

779	 supplementation has been recommended to prevent the <e1>fatal hepatotoxic effects</e1> associated with <e2>valproic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

780	 report on a child with <e1>fatal</e1> <e2>valproate</e2> -related hepatotoxic effects despite this supplementation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

781	 report on a child with fatal <e1>valproate</e1> -related <e2>hepatotoxic effects</e2> despite this supplementation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

782	 case is reported of a 40 year old woman treated with intraventricular <e1>IL-2</e1> for leptomeningeal disease who developed progressive <e2>cognitive dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

783	 <e1>neurotoxicity</e1> of intraventricular <e2>interleukin-2</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

784	 potential for progressive <e1>brain injury</e1> and subsequent disability related to intraventricular <e2>IL-2</e2> therapy is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

785	 potential for progressive brain injury and subsequent <e1>disability</e1> related to intraventricular <e2>IL-2</e2> therapy is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

786	 rare among Western patients, such <e1>lithium</e1> -associated <e2>thyroid dysfunctions</e2> appeared to be more likely to occur in Hong Kong Chinese."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

787	 Chinese female patients who suffered from manic-depressive disorder and underlying autoimmune thyroiditis developed transient episodes of <e1>thyrotoxicosis</e1> during maintenance <e2>lithium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

788	 -associated <e2>transient thyrotoxicosis</e2> in 4 Chinese women with autoimmune thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

789	 seemed to involve multiple aetiological factors, such as autoimmune thyroid disease, the <e1>toxic and immunomodulatory roles</e1> of <e2>lithium</e2> and perhaps genetic and dietary factors."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

790	 <e1>retinoic acid</e1> is well tolerated by the majority of patients with this disease, a potentially <e2>fatal complication</e2> of this kind of treatment has been reported: "the <e1>retinoic acid</e1> syndrome"."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

791	 <e1>retinoic acid</e1> is well tolerated by the majority of patients with this disease, a potentially fatal complication of this kind of treatment has been reported: "the <e1>retinoic acid</e1> syndrome"."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

792	 It is probable that <e1>foscarnet</e1> contributed to the <e2>electrolyte disorders</e2> and symptomatology in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

793	 <e1>Electrolyte disorders</e1> associated with <e2>foscarnet</e2> are reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

794	 -induced severe hypomagnesemia and other <e2>electrolyte disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

795	 -induced <e2>severe hypomagnesemia</e2> and other electrolyte disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

796	 To report a case of possible <e1>foscarnet</e1> -induced severe hypomagnesemia and other <e2>electrolyte disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

797	 To report a case of possible <e1>foscarnet</e1> -induced <e2>severe hypomagnesemia</e2> and other electrolyte disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-A

798	 patient experienced muscle twitches, tremulousness, and <e1>anxiety</e1> on day 17 of <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

799	 patient experienced <e1>muscle twitches</e1>, tremulousness, and anxiety on day 17 of <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

800	 patient experienced muscle twitches, <e1>tremulousness</e1>, and anxiety on day 17 of <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

801	 with the cortisol axis</e1> by the microtubule antagonist, <e2>CPH82</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

802	 results clearly demonstrate that <e1>CPH82</e1> was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical <e2>hypercortisolism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

803	 results clearly demonstrate that <e1>CPH82</e1> was associated with <e2>suppression of the endogeneous production of ACTH and cortisol</e2> with a concomitant paradoxical picture of clinical hypercortisolism."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

804	 variety of <e1>movement disorders</e1> are known to occur in association with <e2>carbamazepine</e2> (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other <e1>movement disorders</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

805	 variety of <e1>movement disorders</e1> are known to occur in association with carbamazepine (<e2>CBZ</e2>) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other <e1>movement disorders</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

806	 variety of movement disorders are known to occur in association with <e1>carbamazepine</e1> (CBZ) therapy in adults and children, but development of <e2>tics</e2> has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

807	 variety of movement disorders are known to occur in association with carbamazepine (<e1>CBZ</e1>) therapy in adults and children, but development of <e2>tics</e2> has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

808	 -induced <e2>tics</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

809	 the third child, the <e1>tics</e1> ceased after <e2>CBZ</e2> discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

810	 cases demonstrate that <e1>CBZ</e1> can induce simple <e2>motor tics</e2> in children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

811	 report 3 children with epilepsy who developed <e1>facial motor tics</e1> after initiation of <e2>CBZ</e2> for complex partial seizures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

812	 -induced <e2>neurotoxicity</e2>: concentration-side effect relationship in acyclovir overdose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

813	 The observation that <e1>neurotoxicity</e1> developed with a delay of 24 to 48 hours after <e2>acyclovir</e2> peak serum concentrations could explain the wide range of <e2>acyclovir</e2> levels reported in similar cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

814	 The observation that <e1>neurotoxicity</e1> developed with a delay of 24 to 48 hours after <e2>acyclovir</e2> peak serum concentrations could explain the wide range of <e2>acyclovir</e2> levels reported in similar cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

815	 Repeated blood samples were drawn in a patient with severe <e1>acyclovir</e1> overdose who developed <e2>coma</e2> and nonoliguric renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-A

816	 Repeated blood samples were drawn in a patient with severe <e1>acyclovir</e1> overdose who developed coma and <e2>nonoliguric renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

817	 To investigate the concentration-side effect relationship in a patient with severe <e1>acyclovir</e1> -induced neurotoxicity and to summarize the information available in the literature about <e2>central nervous system side effects</e2> due to <e1>acyclovir</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

818	 To investigate the concentration-side effect relationship in a patient with severe <e1>acyclovir</e1> -induced <e2>neurotoxicity</e2> and to summarize the information available in the literature about central nervous system side effects due to <e1>acyclovir</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

819	 16-year-old white male with acute biphenotypic leukemia developed evidence of the <e1>eosinophilia myalgia syndrome</e1> associated with total parenteral nutritional support with solutions containing <e2>tryptophan</e2>, which were given during his initial induction chemotherapy and also after autologous marrow transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

820	 eosinophilia myalgia syndrome</e1> in a marrow transplant patient attributed to total parenteral nutrition with a solution containing <e2>tryptophan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

821	 the <e1>eosinophilia myalgia syndrome</e1> can be associated with parenteral <e2>tryptophan</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

822	 patient with acute esophageal variceal bleeding developed <e1>fatal rhabdomyolysis</e1> during treatment with a continuous intravenous infusion of <e2>vasopressin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

823	 factors involving <e1>vasopressin</e1> receptor affinity and distribution, <e1>vasopressin</e1> -associated vasodilation in some vascular beds, and the effect of <e1>vasopressin</e1> on the renin-angiotensin system may further contribute to <e2>impaired tissue perfusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

824	 factors involving <e1>vasopressin</e1> receptor affinity and distribution, <e1>vasopressin</e1> -associated <e2>vasodilation</e2> in some vascular beds, and the effect of <e1>vasopressin</e1> on the renin-angiotensin system may further contribute to impaired tissue perfusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

825	 associated with the use of intravenous <e2>vasopressin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

826	 multiple overlapping factors probably lead to <e1>rhabdomyolysis</e1> in a minority of patients receiving <e2>vasopressin</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

827	 one case, <e1>disulfiram</e1> was the only potential <e2>teratogen</e2> exposed to the fetus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

828	 but <e1>significant abnormalities</e1> have been described in the infants of women treated with <e2>disulfiram</e2> in the first trimester of their pregnancies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

829	 the essential cause of <e1>PV</e1> is unclear, its onset has occasionally been associated with drug therapy, in particular <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

830	 vulgaris</e1> precipitated by <e2>glibenclamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

831	 patient described in this paper was a 78-year-old diabetic man who developed <e1>oral lesions of PV</e1> following institution of <e2>glibenclamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

832	 -induced <e2>pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

833	 <e1>pulmonary toxicity</e1> is probably induced by <e2>piritrexim</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

834	 describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an <e1>abnormal chest x-ray with diffuse interstitial opacities</e1> while on chemotherapy with <e2>piritrexim</e2>, a methotrexate analog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

835	 describe a patient with transitional cell carcinoma of the renal pelvis who developed <e1>respiratory dysfunction</e1> and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with <e2>piritrexim</e2>, a methotrexate analog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

836	 12 year old patient with atrial flutter is presented, in whom intravenous <e1>adenosine</e1> was followed by <e2>acceleration of the heart rate</e2> to a potentially dangerous arrhythmia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

837	 12 year old patient with atrial flutter is presented, in whom intravenous <e1>adenosine</e1> was followed by acceleration of the heart rate to a potentially dangerous <e2>arrhythmia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

838	 of ventricular response</e1> to atrial flutter after intravenous <e2>adenosine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

839	 developing in a patient with rheumatoid arthritis taking <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

840	 mild immunosuppression that occurs with <e1>methotrexate</e1> therapy probably places patients with rheumatoid arthritis at added risk of developing <e2>lymphoproliferative diseases</e2>, but coincidence cannot be excluded."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

841	 report one case of <e1>non-Hodgkin lymphoma</e1> in a patient, with a 30-year history of rheumatoid arthritis, taking low dose <e2>methotrexate</e2> weekly over a 10-month period."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

842	 of <e2>paracetamol</e2> enhanced by ingestion of alcohol: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

843	 biochemistry of <e1>paracetamol</e1> hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the <e2>hepatotoxic effects</e2> of <e1>paracetamol</e1> is remarked upon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

844	 biochemistry of <e1>paracetamol</e1> <e2>hepatotoxicity</e2> is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of <e1>paracetamol</e1> is remarked upon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

845	 <e1>fatal</e1> cases of poisoning by <e2>paracetamol</e2> are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

846	 report a case of drug-induced <e1>Kaposi's sarcoma</e1> (KS) on the sole of the right foot in a 71-year-old man, treated for 6 months with corticosteroid therapy (<e2>prednisolone</e2> 25 mg/day) for pericardial effusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

847	 dystonic reaction</e1> with low-dose <e2>pimozide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

848	 paper reports on a 6.9-year-old autistic male who developed repeated episodes of <e1>acute dystonic reactions</e1> associated with <e2>pimozide</e2> administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following <e2>pimozide</e2> withdrawal, as well as during subsequent thioridazine administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

849	 paper reports on a 6.9-year-old autistic male who developed repeated episodes of <e1>acute dystonic reactions</e1> associated with <e2>pimozide</e2> administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following <e2>pimozide</e2> withdrawal, as well as during subsequent thioridazine administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

850	 paper reports on a 6.9-year-old autistic male who developed repeated episodes of <e1>acute dystonic reactions</e1> associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent <e2>thioridazine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

851	 there is one case report of cholesterol crystal embolization following <e1>t-PA</e1> therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of <e2>atheroembolic acute renal failure</e2> following <e1>t-PA</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

852	 there is one case report of <e1>cholesterol crystal embolization</e1> following <e2>t-PA</e2> therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following <e2>t-PA</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

853	 there is one case report of cholesterol crystal embolization following <e1>t-PA</e1> therapy with only <e2>extrarenal manifestations</e2> (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following <e1>t-PA</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

854	 crystal embolization</e1> -associated renal failure after therapy with recombinant <e2>tissue-type plasminogen activator</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

855	 crystal embolization-associated <e1>renal failure</e1> after therapy with recombinant <e2>tissue-type plasminogen activator</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

856	 report the occurrence of renal failure due to <e1>cholesterol crystal embolization</e1> following thrombolytic therapy with intravenous <e2>recombinant tissue-type plasminogen activator</e2> (t-PA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

857	 report the occurrence of renal failure due to <e1>cholesterol crystal embolization</e1> following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (<e2>t-PA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

858	 report the occurrence of <e1>renal failure</e1> due to cholesterol crystal embolization following thrombolytic therapy with intravenous <e2>recombinant tissue-type plasminogen activator</e2> (t-PA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

859	 report the occurrence of <e1>renal failure</e1> due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (<e2>t-PA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

860	 <e1>haloperidol</e1> is generally well tolerated, but <e2>multiform ventricular tachycardia</e2> has been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

861	 developed <e1>mucocutaneous side effects</e1> within 20 weeks of beginning im <e2>gold</e2> therapy, at a time when RA had improved markedly compared to pretreatment status."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

862	 low can you go? Use of very low dosage of <e1>gold</e1> in patients with <e2>mucocutaneous reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

863	 spinal artery syndrome</e1> --a complication of cervical intrathecal <e2>phenol</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

864	 have seen a case of terminal malignant melanoma in which clinical manifestations, indicative of <e1>anterior spinal artery syndrome</e1>, developed following the injection of 0.3 ml of 10% <e2>phenol-glycerine</e2> into the cervical subarachnoid space at the C4--C5 level for the control of severe right arm pain."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

865	 patient required nursing home placement and a <e1>feeding gastrostomy</e1> as a result of the worsening parkinsonism during <e2>risperidone</e2> treatment, but was able to return home and have the gastrostomy removed after switching from <e2>risperidone</e2> to clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

866	 patient required nursing home placement and a <e1>feeding gastrostomy</e1> as a result of the worsening parkinsonism during <e2>risperidone</e2> treatment, but was able to return home and have the gastrostomy removed after switching from <e2>risperidone</e2> to clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

867	 patient required nursing home placement and a feeding gastrostomy as a result of the <e1>worsening parkinsonism</e1> during <e2>risperidone</e2> treatment, but was able to return home and have the gastrostomy removed after switching from <e2>risperidone</e2> to clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

868	 patient required nursing home placement and a feeding gastrostomy as a result of the <e1>worsening parkinsonism</e1> during <e2>risperidone</e2> treatment, but was able to return home and have the gastrostomy removed after switching from <e2>risperidone</e2> to clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

869	 of the five patients who worsened motorically also developed <e1>encephalopathy</e1> during <e2>risperidone</e2> treatment; the <e1>encephalopathy</e1> resolved when the patients were switched to clozapine treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

870	 of the five patients who <e1>worsened motorically</e1> also developed encephalopathy during <e2>risperidone</e2> treatment; the encephalopathy resolved when the patients were switched to clozapine treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

871	 can cause severe <e2>myelosuppression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

872	 -induced <e2>myelosuppression</e2> due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

873	 <e1>azathioprine</e1> dose was low (1 mg/kg) and <e2>pancytopenia</e2> occurred after 56 days therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

874	 methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound <e1>myelosuppression</e1> after a short course of <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

875	 describe the first documented case of <e1>azathioprine</e1> -induced severe <e2>myelosuppression</e2> due to thiopurine methyltransferase deficiency in autoimmune liver disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

876	 -associated <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

877	 had been taking <e1>nabumetone</e1> for 6 months, but had discontinued the agent 2 weeks before admission due to progressive <e2>edema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

878	 myeloid leukemia</e1> evolving from essential thrombocythemia in two patients treated with <e2>hydroxyurea</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

879	 this report, two cases of ET which evolved into <e1>AL</e1> without prior exposure to radiation or alkylating agents, and which were treated with long-term <e2>hydroxyurea</e2> therapy, are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

880	 used of <e1>hydroxyurea</e1> in patients with ET may lead to therapy-associated <e2>acute leukemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

881	 in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed <e1>cardiac effects</e1> of antimalarial treatment with <e2>halofantrine</e2>, including one sudden death after the treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

882	 in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed cardiac effects of antimalarial treatment with <e1>halofantrine</e1>, including one <e2>sudden death</e2> after the treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

883	 the present paper, we discuss the first Japanese vivax malaria patient whose <e1>QT interval was prolonged</e1> after treatment with <e2>halofantrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

884	 of the QT interval</e1> observed in a Japanese patient with vivax malaria following treatment with <e2>halofantrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

885	 pharmaceutical company producing <e1>Halfan</e1> has reported 8 <e2>cardiac arrests</e2>, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

886	 pharmaceutical company producing Halfan has reported 8 <e1>cardiac arrests</e1>, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with <e2>mefloquine</e2>, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

887	 pharmaceutical company producing <e1>Halfan</e1> has reported 8 cardiac arrests, leading to 6 <e2>deaths</e2>, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

888	 pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 <e1>deaths</e1>, when a higher dose than recommended was used, there was recent or concomitant treatment with <e2>mefloquine</e2>, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

889	 hyperpigmentation</e1> in association with <e2>CHOP</e2> chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

890	 report an unusual pattern of <e1>supravenous hyperpigmentation</e1> occurring after <e2>CHOP</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

891	 toxicity due to concomitant antituberculosis therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

892	 per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on <e1>phenytoin</e1> and 11.6% of these had <e2>blood levels in the toxic range</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

893	 acetylators, who comprise roughly 50% of the South African population, are likely to develop clinical and biochemical features of <e2>phenytoin</e2> toxicity when this drug is given together with antituberculosis therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

894	 wide use of <e1>phenytoin</e1> during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to <e1>phenytoin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

895	 wide use of <e1>phenytoin</e1> during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to <e1>phenytoin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

896	 diabetes insipidus</e1> and renal tubular acidosis secondary to <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

897	 diabetes insipidus and <e1>renal tubular acidosis</e1> secondary to <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

898	 cases of renal acidosis, and only one case of <e1>nephrogenic diabetes insipidus</e1>, has been previously reported as a complication of <e2>foscarnet</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

899	 patient developed both <e1>nephrogenic diabetes insipidus</e1> and renal tubular acidosis with a temporal pattern that demonstrated a link between <e2>foscarnet</e2> therapy and these abnormalities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

900	 patient developed both nephrogenic diabetes insipidus and <e1>renal tubular acidosis</e1> with a temporal pattern that demonstrated a link between <e2>foscarnet</e2> therapy and these abnormalities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

901	 present a patient with human immunodeficiency virus infection under treatment with <e1>foscarnet</e1> for CMV retinitis who complained of thirst and <e2>polyuria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

902	 present a patient with human immunodeficiency virus infection under treatment with <e1>foscarnet</e1> for CMV retinitis who complained of <e2>thirst</e2> and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

903	 hemorrhage</e1> associated with systemic <e2>tissue plasminogen activator</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

904	 The administration of <e1>tissue plasminogen activator</e1> was responsible for the large extent of <e2>hemorrhage</e2> and should be considered in the differential diagnosis of hemorrhagic choroidal detachment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

905	 The administration of <e1>tissue plasminogen activator</e1> was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of <e2>hemorrhagic choroidal detachment</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

906	 To determine the cause of <e1>spontaneous choroidal hemorrhage</e1> in a 67-year-old man after a myocardial infarction and administration of <e2>tissue plasminogen activator</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

907	 nodulosis</e1> during <e2>methotrexate</e2> therapy for juvenile rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

908	 they had only a few <e1>nodules</e1> at diagnosis, the <e1>nodules</e1> increased in number and size 3 to 4 months after the start of <e2>methotrexate</e2> therapy in both patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

909	 they had only a few <e1>nodules</e1> at diagnosis, the <e1>nodules</e1> increased in number and size 3 to 4 months after the start of <e2>methotrexate</e2> therapy in both patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

910	 treating patients with <e1>methotrexate</e1> for juvenile rheumatoid arthritis must be aware of this <e2>extraarticular side effect</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

911	 <e1>nodules</e1> regressed after withdrawal of <e2>methotrexate</e2> therapy in one patient and were arrested with the addition of hydroxychloroquine in the other."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

912	 describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom <e1>accelerated nodulosis</e1> developed during <e2>methotrexate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

913	 <e1>macrophage activation syndrome</e1>, possibly related to <e2>methotrexate</e2> toxicity, developed in a boy with systemic juvenile rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

914	 macrophage activation syndrome, possibly related to <e2>methotrexate</e2> toxicity, developed in a boy with systemic juvenile rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

915	 induced by <e2>streptokinase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

916	 a few reports of overt <e1>jaundice</e1> are associated with <e2>streptokinase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

917	 both patients recovered from the <e1>colitis</e1> after the administration of vancomycin, the first case demonstrated a relapse of the <e1>colitis</e1> after receiving a subsequent course of the same chemotherapy with <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

918	 on our findings, it is thus concluded that <e1>cisplatin</e1> may cause <e2>C. difficile colitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

919	 patients were then treated with a carboplatin alternative to <e1>cisplatin</e1> in the following courses, which resulted in neither a relapse of the <e2>colitis</e2> nor a recurrence of the malignancies up to this time."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

920	 difficile colitis</e1> associated with <e2>cisplatin</e2> -based chemotherapy in ovarian cancer patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

921	 <e1>C. difficile colitis</e1> occurred in 2 patients (6.1%) after receiving <e2>cisplatin</e2> -based combination chemotherapy for ovarian malignancies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

922	 purpose of this study was to examine the incidence and cause of <e1>Clostridium difficile colitis</e1> occurring after <e2>cisplatin</e2> -based combination chemotherapy in ovarian cancer patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

923	 patient with <e1>severe cholestatic jaundice</e1> induced by <e2>captopril</e2> is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

924	 -associated "<e2>pseudocholangitis</e2>'."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

925	 is known to be associated with <e2>dermatologic, hematologic, and pulmonary adverse effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

926	 treated with <e1>captopril</e1> who develop "<e2>atypical cholangitis</e2>" should be suspected of having <e1>captopril</e1> -associated liver damage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

927	 treated with <e1>captopril</e1> who develop "atypical cholangitis" should be suspected of having <e1>captopril</e1> -associated <e2>liver damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

928	 of <e1>nephrotic syndrome</e1> in a patient with acute myeloblastic leukemia after treatment with <e2>macrophage-colony-stimulating factor</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

929	 should be emphasized that the recurrence of <e1>nephrotic syndrome</e1> was observed after the following chemotherapy, including <e2>M-CSF</e2>, whereas the bone marrow still remained completely remitted."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

930	 possibility can be raised that <e1>M-CSF</e1> accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of <e2>nephrotic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

931	 possibility can be raised that <e1>M-CSF</e1> accelerated the underlying <e2>renal disease</e2> in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

932	 evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the <e1>M-CSF</e1> treatment and <e2>macrophage-related glomerular injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

933	 describe a patient with acute myeloblastic leukemia (AML) who developed <e1>nephrotic syndrome</e1> after receiving several courses of chemotherapy, including <e2>macrophage-colony-stimulating factor</e2> (M-CSF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

934	 describe a patient with acute myeloblastic leukemia (AML) who developed <e1>nephrotic syndrome</e1> after receiving several courses of chemotherapy, including macrophage-colony-stimulating factor (<e2>M-CSF</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

935	 the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and <e1>betamethasone</e1>, <e2>edema</e2> developed in both labia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

936	 the fifth day of tocolysis with <e1>magnesium sulfate</e1>, nifedipine, terbutaline and betamethasone, <e2>edema</e2> developed in both labia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

937	 the fifth day of tocolysis with magnesium sulfate, <e1>nifedipine</e1>, terbutaline and betamethasone, <e2>edema</e2> developed in both labia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

938	 the fifth day of tocolysis with magnesium sulfate, nifedipine, <e1>terbutaline</e1> and betamethasone, <e2>edema</e2> developed in both labia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

939	 syndrome</e1> induced by <e2>1,25(OH)2D</e2> in a patient with hypoparathyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

940	 article presents a patient with hypoparathyroidism who was treated with calcium carbonate and <e1>calcitriol</e1> resulting in two admissions to the hospital for <e2>milk-alkali syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

941	 article presents a patient with hypoparathyroidism who was treated with <e1>calcium carbonate</e1> and calcitriol resulting in two admissions to the hospital for <e2>milk-alkali syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

942	 receiving 3 doses of <e1>ifosfamide</e1>/mesna, she was found to be <e2>unresponsive</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

943	 receiving 3 doses of ifosfamide/<e1>mesna</e1>, she was found to be <e2>unresponsive</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

944	 There was a temporal relationship between the onset of <e1>nonconvulsive status epilepticus</e1> and initiation of <e2>ifosfamide</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

945	 <e1>Central nervous system (CNS) toxicity</e1> has been described with <e2>ifosfamide</e2>, with most cases reported in the pediatric population."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

946	 -induced <e2>nonconvulsive status epilepticus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

947	 To describe a patient with <e1>ifosfamide</e1> -induced <e2>nonconvulsive status epilepticus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

948	 represents the first report of <e1>nonconvulsive status epilepticus</e1> induced by <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

949	 -induced <e2>pseudomembranous colitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

950	 a few case reports link <e1>metronidazole</e1> with the development of <e2>pseudomembranous colitis</e2>, albendazole has not been associated with the development of this condition."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

951	 undergoing treatment with <e1>albendazole</e1>, he developed worsening diarrhea with <e2>abdominal pain</e2> and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

952	 undergoing treatment with <e1>albendazole</e1>, he developed worsening diarrhea with abdominal pain and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

953	 undergoing treatment with <e1>albendazole</e1>, he developed <e2>worsening diarrhea</e2> with abdominal pain and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

954	 intoxication, along with other factors, was considered to be the cause of TC development."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

955	 intoxication, along with other factors, was considered to be the cause of <e2>TC</e2> development."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

956	 disturbances</e1> associated with <e2>5-fluorouracil</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

957	 ocular motor disturbances are probably an expression of regional <e1>5-FU</e1> <e2>neurotoxicity</e2> primarily affecting the brain stem."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

958	 <e1>ocular motor disturbances</e1> are probably an expression of regional <e2>5-FU</e2> neurotoxicity primarily affecting the brain stem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

959	 patients treated with <e1>5-fluorouracil</e1> (5-FU) for disseminated adenocarcinoma of the colon developed <e2>cerebellar dysfunction</e2> typical of 5-FU neurotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

960	 patients treated with 5-fluorouracil (<e1>5-FU</e1>) for disseminated adenocarcinoma of the colon developed <e2>cerebellar dysfunction</e2> typical of <e1>5-FU</e1> neurotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

961	 patients treated with 5-fluorouracil (<e1>5-FU</e1>) for disseminated adenocarcinoma of the colon developed <e2>cerebellar dysfunction</e2> typical of <e1>5-FU</e1> neurotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

962	 patients treated with <e1>5-fluorouracil</e1> (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

963	 patients treated with 5-fluorouracil (<e1>5-FU</e1>) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of <e1>5-FU</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

964	 patients treated with 5-fluorouracil (<e1>5-FU</e1>) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of <e1>5-FU</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

965	 of cortisol response was by <e1>insulin</e1> -induced <e2>hypoglycaemia</e2> in three cases, by short tetracosactrin test in two, and by low-dose tetracosactrin and 24-hour urinary cortisol/creatinine ratio in one."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

966	 Six children with growth retardation noted after treatment with high-dose <e1>fluticasone propionate</e1> were found to have <e2>adrenal suppression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

967	 Six children with <e1>growth retardation</e1> noted after treatment with high-dose <e2>fluticasone propionate</e2> were found to have adrenal suppression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

968	 and adrenal suppression</e1> in asthmatic children treated with high-dose <e2>fluticasone propionate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

969	 When high doses of <e1>fluticasone propionate</e1> are used, growth may be retarded and <e2>adrenal suppression</e2> may occur."
DRUG-ADE(e1,e2)
Comment: DRUG-

970	 When high doses of <e1>fluticasone propionate</e1> are used, <e2>growth may be retarded</e2> and adrenal suppression may occur."
DRUG-ADE(e1,e2)
Comment: DRUG-

971	 <e1>Growth retardation</e1> was observed in six severely asthmatic children after introduction of high-dose <e2>fluticasone propionate</e2> treatment (dry powder)."
DRUG-ADE(e2,e1)
Comment: DRUG-A

972	 associated <e2>granulomatous anterior uveitis</e2>: not so uncommon as thought."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

973	 case reports of <e1>bilateral granulomatous anterior uveitis</e1> are described in patients with open angle glaucoma treated with <e2>metripranolol</e2> 0.6% eye drops."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

974	 review of the literature found 11 children and 2 adults in whom intranasal <e1>desmopressin</e1> was associated with hyponatremia, all of whom experienced seizures or <e2>altered mental status</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

975	 review of the literature found 11 children and 2 adults in whom intranasal <e1>desmopressin</e1> was associated with <e2>hyponatremia</e2>, all of whom experienced seizures or altered mental status."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

976	 review of the literature found 11 children and 2 adults in whom intranasal <e1>desmopressin</e1> was associated with hyponatremia, all of whom experienced <e2>seizures</e2> or altered mental status."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

977	 <e1>desmopressin</e1> -induced <e2>hyponatremia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

978	 vague symptoms develop during <e1>desmopressin</e1> therapy, <e2>hyponatremia</e2> must be considered as part of the differential diagnosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

979	 <e1>vague symptoms</e1> develop during <e2>desmopressin</e2> therapy, hyponatremia must be considered as part of the differential diagnosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

980	 24 hours of fluid restriction and cessation of <e1>desmopressin</e1>, her symptoms and <e2>hyponatremia</e2> resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

981	 other causes for the <e1>hyponatremia</e1>, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by <e2>desmopressin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

982	 other causes for the hyponatremia, she was diagnosed with the <e1>syndrome of inappropriate antidiuretic hormone</e1>, presumably caused by <e2>desmopressin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

983	 during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, <e2>clarithromycin</e2> and ethambutol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

984	 during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and <e2>ethambutol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

985	 during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of <e2>rifabutin</e2>, clarithromycin and ethambutol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

986	 <e1>acyclovir</e1> <e2>increase serum lithium levels</e2>?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

987	 days after starting <e1>acyclovir</e1> she exhibited signs of <e2>lithium toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

988	 days after starting acyclovir she exhibited signs of <e2>lithium</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

989	 case suggests that <e1>acyclovir</e1> when given intravenously in doses of 10 mg/kg may result in <e2>increased serum lithium</e2> concentrations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

990	 case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum <e2>lithium</e2> concentrations."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

991	 additional data are available, if intravenous <e1>acyclovir</e1> is administered concurrently with lithium, we recommend closely monitoring patients for signs of <e2>lithium toxicity</e2> and measuring serum lithium levels every second or third day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

992	 additional data are available, if intravenous acyclovir is administered concurrently with <e1>lithium</e1>, we recommend closely monitoring patients for signs of <e1>lithium</e1> toxicity and measuring serum <e1>lithium</e1> levels every second or third day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

993	 measured, the <e1>serum lithium level had increased</e1> 4-fold during <e2>acyclovir</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

994	 measured, the serum <e2>lithium</e2> level had increased 4-fold during acyclovir therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

995	 syndrome in cutaneous lupus erythematosus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

996	 should be aware of the potentially <e1>lethal</e1> side effects of <e2>dapsone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

997	 describe 2 patients with cutaneous lupus erythematosus who developed severe <e2>dapsone</e2> reaction after low dose therapy, with a fatal outcome in one."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

998	 describe 2 patients with cutaneous lupus erythematosus who developed severe <e1>dapsone</e1> reaction after low dose therapy, with a <e2>fatal</e2> outcome in one."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

999	 case is presented which illustrates a probably <e1>fatal interaction</e1> between <e2>minoxidil</e2> and a coagulation disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1000	 diabetes insipidus (<e1>NDI</e1>) is a well-documented complication of <e2>lithium</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1001	 diabetes insipidus</e1> (NDI) is a well-documented complication of <e2>lithium</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1002	 mechanisms regarding the pathophysiology of <e1>lithium</e1> -associated <e2>CDI</e2> are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1003	 association of central diabetes insipidus (<e1>CDI</e1>) with <e2>lithium</e2> use is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1004	 association of <e1>central diabetes insipidus</e1> (CDI) with <e2>lithium</e2> use is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1005	 case emphasizes the importance of the evaluation of <e1>lithium</e1> -associated <e2>polyuria</e2> with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1006	 the best of our knowledge, this is the first case of <e1>lithium</e1> -associated <e2>CDI</e2> and NDI presenting concurrently."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1007	 the best of our knowledge, this is the first case of <e1>lithium</e1> -associated CDI and <e2>NDI</e2> presenting concurrently."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1008	 central diabetes insipidus</e1> in the setting of underlying chronic nephrogenic diabetes insipidus associated with <e2>lithium</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1009	 report a patient receiving chronic <e1>lithium</e1> therapy who presented with a transient <e2>CDI</e2> occurring in the setting of underlying chronic NDI."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1010	 We report a case of a woman with severe <e1>human insulin</e1> -induced <e2>lipoatrophy</e2> who has been treated exclusively with recombinant DNA <e1>human insulin</e1> since the onset of IDDM."
DRUG-ADE(e1,e2)
Comment: DRUG-

1011	 We report a case of a woman with severe human insulin-induced <e1>lipoatrophy</e1> who has been treated exclusively with <e2>recombinant DNA human insulin</e2> since the onset of IDDM."
DRUG-ADE(e2,e1)
Comment: DRUG-

1012	 Jet-injection devices might constitute a helpful method to treat those patients affected by severe <e1>human insulin</e1> -induced <e2>lipoatrophy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1013	 insulin</e1> -induced <e2>lipoatrophy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1014	 To evaluate the efficacy of the administration of insulin by a jet-injector device in stopping and reversing severe <e1>human insulin</e1> -induced <e2>lipoatrophy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1015	 awareness of and further investigation into the <e1>neurotoxic effects</e1> of <e2>ofloxacin</e2> may enhance its safe use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1016	 associated with <e2>ofloxacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1017	 <e1>renal insufficiency</e1> of three patients and the timing of the seizures implicate accumulation of <e2>ofloxacin</e2> as a contributing factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1018	 renal insufficiency of three patients and the timing of the <e1>seizures</e1> implicate accumulation of <e2>ofloxacin</e2> as a contributing factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1019	 describe four patients who had <e1>seizures</e1> while receiving <e2>ofloxacin</e2>; no other causes were evident."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1020	 patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and <e2>abnormal liver function tests</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1021	 patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including fever, <e2>erythroderma</e2>, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1022	 patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including <e2>fever</e2>, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1023	 patient is described with the characteristic features of <e2>phenytoin</e2> hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1024	 patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, <e2>pinhead-sized facial pustules</e2> and abnormal liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1025	 patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including fever, erythroderma, <e2>tibial and facial oedema</e2>, pinhead-sized facial pustules and abnormal liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1026	 corticosteroids in the <e2>phenytoin</e2> hypersensitivity syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1027	 patient is described who developed a poorly differentiated <e1>sarcoma</e1> after <e2>cyclophosphamide</e2> was used to treat his rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1028	 complicating therapy with <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1029	 chronic reaction associated with long-term treatment with <e1>nitrofurantoin</e1> has also been reported and causes irreversible <e2>pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1030	 pulmonary reactions</e1> to <e2>nitrofurantoin</e2> are an uncommon side effect of therapy and can cause minor or life-threatening pulmonary dysfunction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1031	 pulmonary reactions to <e1>nitrofurantoin</e1> are an uncommon side effect of therapy and can cause minor or life-threatening <e2>pulmonary dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1032	 the known <e1>pulmonary side effects</e1> of <e2>nitrofurantoin</e2>, there is no report of this toxicity occurring in pregnant patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1033	 -induced <e2>pulmonary toxicity</e2> during pregnancy: a report of a case and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1034	 present a case of <e1>respiratory failure</e1> occurring in a woman at 16 weeks' gestation who was being treated with <e2>nitrofurantoin</e2> for a urinary tract infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1035	 common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and <e2>agranulocytosis</e2>, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1036	 common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, <e2>an infectious mononucleosis-like syndrome</e2>, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1037	 common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, <e2>cholestatic jaundice</e2>, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1038	 common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, <e2>cutaneous eruptions</e2>, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1039	 common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of <e2>leukopenia</e2> and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1040	 common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and <e2>minor neurological and gastrointestinal complaints</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1041	 common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, <e2>nephrotic syndrome</e2>, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1042	 common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, <e2>peripheral neuropathy</e2>, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1043	 common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, <e2>psychosis</e2>, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1044	 common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, <e2>renal papillary necrosis</e2>, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1045	 common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, <e2>severe hypoalbuminemia without proteinuria</e2>, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1046	 common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, <e2>toxic hepatitis</e2>, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1047	 is another common finding among patients receiving <e2>dapsone</e2> therapy, but rarely does it result in prominent symptoms other than transient pallor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1048	 -accelerated anticonvulsant <e2>osteomalacia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1049	 may have accelerated the development of <e2>osteomalacia</e2> by several mechanisms, including increased renal calcium excretion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1050	 osteomalacia</e1> was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and <e2>acetazolamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1051	 osteomalacia</e1> was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, <e2>phenobarbital</e2>, and acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1052	 osteomalacia</e1> was present in two epileptic patients who were under long-term treatment with congeners of <e2>phenytoin</e2>, phenobarbital, and acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1053	 delayed <e1>encephalopathy</e1> developed 9 and 22 months respectively after the first dose of intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1054	 report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and <e1>hydrocephalus</e1> related to central nervous system prophylaxis by, in the first case intrathecally administered <e2>methotrexate</e2> and, in the second by intrathecally administered <e2>methotrexate</e2> and cranial irradiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1055	 report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and <e1>hydrocephalus</e1> related to central nervous system prophylaxis by, in the first case intrathecally administered <e2>methotrexate</e2> and, in the second by intrathecally administered <e2>methotrexate</e2> and cranial irradiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1056	 report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed <e1>leukoencephalopathy</e1> and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered <e2>methotrexate</e2> and, in the second by intrathecally administered <e2>methotrexate</e2> and cranial irradiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1057	 report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed <e1>leukoencephalopathy</e1> and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered <e2>methotrexate</e2> and, in the second by intrathecally administered <e2>methotrexate</e2> and cranial irradiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1058	 retrospective study was conducted of 40 <e2>loperamide</e2> poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1059	 poisoning in the dog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1060	 67-year-old man with bipolar disorder developed a <e1>Creutzfeldt-Jakob like syndrome</e1> during <e2>lithium carbonate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1061	 -induced <e2>Creutzfeldt-Jakob syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1062	 neurotoxicity should be considered in <e2>Creutzfeldt-Jakob disease</e2> differential diagnosis, serial electroencephalograms being the most valuable."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1063	 neurotoxicity should be considered in Creutzfeldt-Jakob disease differential diagnosis, serial electroencephalograms being the most valuable."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1064	 cases of <e1>lithium</e1> -induced <e2>Creutzfeldt-Jakob syndrome</e2> have been reported to date; all of them were elderly patients and a half had "therapeutic" <e1>lithium</e1> serum levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1065	 cases of <e1>lithium</e1> -induced <e2>Creutzfeldt-Jakob syndrome</e2> have been reported to date; all of them were elderly patients and a half had "therapeutic" <e1>lithium</e1> serum levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1066	 noninvasive method in the differential diagnosis of vecuronium-induced and <e1>magnesium</e1> -induced <e2>protracted neuromuscular block</e2> in a severely preeclamptic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1067	 noninvasive method in the differential diagnosis of <e1>vecuronium</e1> -induced and magnesium-induced <e2>protracted neuromuscular block</e2> in a severely preeclamptic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1068	 occurrence of <e1>neuromuscular blockade</e1> and the resulting potentiation of muscle relaxants during <e2>magnesium sulfate</e2> (MgSO4) administration is well known."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1069	 occurrence of <e1>neuromuscular blockade</e1> and the resulting potentiation of muscle relaxants during magnesium sulfate (<e2>MgSO4</e2>) administration is well known."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1070	 occurrence of neuromuscular blockade and the resulting <e1>potentiation of muscle relaxants</e1> during <e2>magnesium sulfate</e2> (MgSO4) administration is well known."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1071	 occurrence of neuromuscular blockade and the resulting <e1>potentiation of muscle relaxants</e1> during magnesium sulfate (<e2>MgSO4</e2>) administration is well known."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1072	 also describe a new, noninvasive method to assess <e1>magnesium</e1> -induced <e2>neuromuscular block</e2> when curariform muscle relaxant was given simultaneously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1073	 disorders</e1> associated with orally administered <e2>terbinafine</e2> have rarely been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1074	 -induced <e2>cholestatic liver disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1075	 describe a case of prolonged <e1>terbinafine</e1> -induced <e2>cholestatic liver disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1076	 patient with a large hydatid cyst of the left lobe of the liver developed <e1>metabolic acidosis</e1> following rather liberal use of <e2>cetrimide</e2> -chlorhexidine solution as a scolicidal agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1077	 patient with a large hydatid cyst of the left lobe of the liver developed <e1>metabolic acidosis</e1> following rather liberal use of cetrimide-<e2>chlorhexidine</e2> solution as a scolicidal agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1078	 acidosis</e1> induced by <e2>cetrimide</e2> -chlorhexidine solution in hydatid cyst surgery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1079	 acidosis</e1> induced by cetrimide-<e2>chlorhexidine</e2> solution in hydatid cyst surgery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1080	 unusual case of <e2>Ecstasy</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1081	 describe a case of <e1>poisoning</e1> with <e2>3,4-methylenedioxymet-amphetamine Ecstasy</e2> that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1082	 dermatologists should be cautious about a <e1>photosensitivity</e1> reaction induced by <e2>mequitazine</e2> or other phenothiazine-derivative drugs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1083	 addition, an immediate <e1>erythematous macule</e1> was observed on the photopatch test site of <e2>mequitazine</e2> directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1084	 addition, an <e1>immediate erythema</e1>tous macule was observed on the photopatch test site of <e2>mequitazine</e2> directly after UV exposure which was similar to the <e1>immediate erythema</e1> noted in chlorpromazine photoallergy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1085	 case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, <e2>cross-reaction to promethazine</e2>, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1086	 case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, <e2>cross-reaction to promethazine</e2>, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1087	 case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to <e2>promethazine</e2>, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1088	 case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, <e2>decreased MED to both UVA and UVB</e2>, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1089	 case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, <e2>decreased MED to both UVA and UVB</e2>, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1090	 case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to <e1>promethazine</e1>, <e2>decreased MED to both UVA and UVB</e2>, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1091	 case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate <e2>erythema</e2> reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1092	 case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate <e2>erythema</e2> reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1093	 case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate <e1>erythema</e1> reaction, cross-reaction to <e2>promethazine</e2>, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1094	 case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and <e2>persistence of the photosensitivity</e2> over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1095	 case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and <e2>persistence of the photosensitivity</e2> over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1096	 case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to <e1>promethazine</e1>, decreased MED to both UVA and UVB, and <e2>persistence of the photosensitivity</e2> over a 3-year follow-up period after discontinuation of the mequitazine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1097	 seemed to play a part similar to chlorpromazine, and absence of <e1>mequitazine</e1> -induced <e2>photosensitivity</e2> may be due to a relatively low dosage of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1098	 cases of <e1>mequitazine</e1> -induced <e2>photosensitivity reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1099	 experienced 2 cases of <e1>mequitazine</e1> -induced <e2>photosensitivity reaction</e2> in patients who took <e1>mequitazine</e1> for their dermatologic problems."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1100	 experienced 2 cases of <e1>mequitazine</e1> -induced <e2>photosensitivity reaction</e2> in patients who took <e1>mequitazine</e1> for their dermatologic problems."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1101	 in <e2>methamphetamine</e2> abusers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1102	 extensive physiologic effects, inconsistent street purity, and multiple routes of administration offer many possibilities for <e2>injury to the cornea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1103	 causes of methamphetamine-related <e1>keratitis</e1> can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or "cutting" agents such as <e2>lidocaine</e2> and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1104	 causes of <e1>methamphetamine</e1> -related <e2>keratitis</e2> can be divided into four categories resulting from (a) direct pharmacologic and physical effects of <e1>methamphetamine</e1>; (b) the toxic effects of diluting or "cutting" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1105	 causes of methamphetamine-related <e1>keratitis</e1> can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or "cutting" agents such as lidocaine and <e2>quinine</e2>; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1106	 causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the <e1>toxic effects</e1> of diluting or "cutting" agents such as <e2>lidocaine</e2> and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1107	 causes of <e1>methamphetamine</e1> -related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of <e1>methamphetamine</e1>; (b) the <e2>toxic effects</e2> of diluting or "cutting" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1108	 causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the <e1>toxic effects</e1> of diluting or "cutting" agents such as lidocaine and <e2>quinine</e2>; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1109	 increasing prevalence of <e1>methamphetamine</e1> abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of <e1>methamphetamine</e1> -related <e2>keratitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1110	 increasing prevalence of <e1>methamphetamine</e1> abuse and the severity of the associated <e2>ulcers</e2> should alert ophthalmologists to the problem of <e1>methamphetamine</e1> -related keratitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1111	 report four cases of <e1>severe corneal ulceration</e1> in <e2>methamphetamine</e2> abusers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1112	 <e1>Methotrexate</e1> (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or <e2>cirrhosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1113	 Methotrexate (<e1>MTX</e1>) may induce liver damage, which in some psoriatics will lead to fibrosis or <e2>cirrhosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1114	 <e1>Methotrexate</e1> (MTX) may induce liver damage, which in some psoriatics will lead to <e2>fibrosis</e2> or cirrhosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1115	 Methotrexate (<e1>MTX</e1>) may induce liver damage, which in some psoriatics will lead to <e2>fibrosis</e2> or cirrhosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1116	 <e1>Methotrexate</e1> (MTX) may induce <e2>liver damage</e2>, which in some psoriatics will lead to fibrosis or cirrhosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1117	 Methotrexate (<e1>MTX</e1>) may induce <e2>liver damage</e2>, which in some psoriatics will lead to fibrosis or cirrhosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1118	 This study confirmed that in most patients <e1>MTX</e1> -induced <e2>liver cirrhosis</e2> is not aggressive."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1119	 continued low-dose <e1>MTX</e1> led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and <e2>death</e2> in 1 of our patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1120	 continued low-dose <e1>MTX</e1> led, in spite of normal liver tests, 8 years after the last biopsy to <e2>liver failure</e2> and death in 1 of our patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1121	 -induced <e2>liver cirrhosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1122	 performed 10 years ago on 25 patients with <e1>MTX</e1> -induced liver <e2>cirrhosis</e2> indicated that this type of <e2>cirrhosis</e2> was not of an aggressive nature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1123	 performed 10 years ago on 25 patients with <e1>MTX</e1> -induced <e2>liver cirrhosis</e2> indicated that this type of cirrhosis was not of an aggressive nature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1124	 therapy for diabetic coma with insulin (containing the preservative <e1>cresol</e1>) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a <e2>high fever</e2> and respiratory and metabolic acidosis and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1125	 therapy for diabetic coma with <e1>insulin</e1> (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a <e2>high fever</e2> and respiratory and metabolic acidosis and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1126	 therapy for diabetic coma with insulin (containing the preservative <e1>cresol</e1>) and electrolyte solutions was started, the patient complained of <e2>increasing myalgia</e2>, developed a high fever and respiratory and metabolic acidosis and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1127	 therapy for diabetic coma with <e1>insulin</e1> (containing the preservative cresol) and electrolyte solutions was started, the patient complained of <e2>increasing myalgia</e2>, developed a high fever and respiratory and metabolic acidosis and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1128	 therapy for diabetic coma with insulin (containing the preservative <e1>cresol</e1>) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and <e2>lost consciousness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1129	 therapy for diabetic coma with <e1>insulin</e1> (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and <e2>lost consciousness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1130	 therapy for diabetic coma with insulin (containing the preservative <e1>cresol</e1>) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and <e2>respiratory and metabolic acidosis</e2> and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1131	 therapy for diabetic coma with <e1>insulin</e1> (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and <e2>respiratory and metabolic acidosis</e2> and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1132	 other factors or drugs (e.g. <e1>cresol</e1>) are thought to induce <e2>MH</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1133	 case supports the assessment that <e1>MH</e1> and diabetes are associated diseases and that <e2>cresol</e2> could possibly trigger <e1>MH</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1134	 use of <e1>beclomethasone diproprionate</e1> inhaler complicated by the development of an <e2>eosinophilic pneumonia reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1135	 intravascular autoimmune hemolytic anemia</e1> after <e2>fludarabine</e2> treatment for chronic lymphocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1136	 should be aware of the risk of severe <e1>AIHA</e1> in CLL patients with a history of <e1>AIHA</e1> or positivation of the DAT during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1137	 should be aware of the risk of severe <e1>AIHA</e1> in CLL patients with a history of <e1>AIHA</e1> or positivation of the DAT during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1138	 should be aware of the risk of severe <e1>AIHA</e1> in CLL patients with a history of <e1>AIHA</e1> or positivation of the DAT during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1139	 should be aware of the risk of severe <e1>AIHA</e1> in CLL patients with a history of <e1>AIHA</e1> or positivation of the DAT during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1140	 should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or <e1>positivation of the DAT</e1> during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1141	 should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or <e1>positivation of the DAT</e1> during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1142	 occurrence of severe <e1>AIHA</e1> in CLL patients treated with <e2>fludarabine</e2> has been reported by several authors."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1143	 report the case of a patient with chronic lymphocytic leukemia (CLL) who developed fatal intravascular autoimmune hemolytic anemia (<e1>AIHA</e1>) after <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1144	 report the case of a patient with chronic lymphocytic leukemia (CLL) who developed <e1>fatal intravascular autoimmune hemolytic anemia</e1> (AIHA) after <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1145	 the patient was treated again with <e1>fludarabine</e1> nine months later, the <e2>DAT became positive with anti-IgG and anti-C3d antiglobulins</e2> after the second course of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1146	 had just finished a 3-week course of intravenous <e1>tobramycin</e1> for bronchiectasis and had an elevated serum <e1>tobramycin</e1> trough level 1 week before the onset of <e2>tetany</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1147	 in a child with AIDS receiving intravenous <e2>tobramycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1148	 pattern is suggestive of <e1>renal toxicity</e1> due to <e2>tobramycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1149	 In our reported case, a local hyperproduction of TNF-alpha from macrophages that was induced by the injected <e1>insulin</e1> could explain the <e2>dedifferentiation of the adipocytes</e2> of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1150	 In our reported case, a local <e1>hyperproduction of TNF-alpha</e1> from macrophages that was induced by the injected <e2>insulin</e2> could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1151	 -induced <e2>lipoatrophy</e2> in type I diabetes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1152	 To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the <e1>insulin</e1> -induced <e2>lipoatrophies</e2> of a diabetic patient who presented extensive lesions."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1153	 of psoriatic plaques</e1>: an early sign of <e2>methotrexate</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1154	 of psoriatic plaques: an early sign of <e2>methotrexate</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1155	 is an effective but <e2>potentially toxic</e2> treatment for psoriasis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1156	 erosion of psoriatic plaques is a less common sign of <e1>methotrexate</e1> toxicity that may precede evidence of <e2>bone marrow suppression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1157	 erosion of psoriatic plaques is a less common sign of <e2>methotrexate</e2> toxicity that may precede evidence of bone marrow suppression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1158	 erosion of psoriatic plaques</e1> is a less common sign of <e2>methotrexate</e2> toxicity that may precede evidence of bone marrow suppression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1159	 describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of <e2>methotrexate</e2> toxicity and review the literature, emphasizing the risk factors associated with this manifestation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1160	 describe two patients in whom <e1>painful erosions of their psoriasis</e1> developed as the presenting sign of <e2>methotrexate</e2> toxicity and review the literature, emphasizing the risk factors associated with this manifestation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1161	 signs of <e1>methotrexate</e1> toxicity include <e2>bone marrow suppression</e2> and oral and gastrointestinal ulceration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1162	 signs of <e2>methotrexate</e2> toxicity include bone marrow suppression and oral and gastrointestinal ulceration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1163	 signs of <e1>methotrexate</e1> toxicity include bone marrow suppression and <e2>oral and gastrointestinal ulceration</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1164	 treatment with <e1>cimetidine</e1>, there was a rapid deterioration with <e2>decreased oxygen saturation and arterial PO2</e2> values."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1165	 with use of <e1>cimetidine</e1> in tolazoline induced <e2>upper gastrointestinal bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1166	 with use of cimetidine in <e1>tolazoline</e1> induced <e2>upper gastrointestinal bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1167	 given the clinically significant result to the interaction between tolazoline and <e1>cimetidine</e1> we report, the use of <e1>cimetidine</e1> in tolazoline induced <e2>upper gastrointestinal hemorrhage</e2> should deserve more attention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1168	 given the clinically significant result to the interaction between tolazoline and <e1>cimetidine</e1> we report, the use of <e1>cimetidine</e1> in tolazoline induced <e2>upper gastrointestinal hemorrhage</e2> should deserve more attention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1169	 given the clinically significant result to the interaction between <e1>tolazoline</e1> and cimetidine we report, the use of cimetidine in <e1>tolazoline</e1> induced <e2>upper gastrointestinal hemorrhage</e2> should deserve more attention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1170	 given the clinically significant result to the interaction between <e1>tolazoline</e1> and cimetidine we report, the use of cimetidine in <e1>tolazoline</e1> induced <e2>upper gastrointestinal hemorrhage</e2> should deserve more attention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1171	 improved during continuous <e1>tolazoline</e1> infusion, but <e2>gastrointestinal bleeding</e2> occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1172	 (<e1>Ambien</e1>), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the <e2>death</e2> of a 39-year-old obese male who was being treated for depression and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1173	 (Ambien), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the <e2>death</e2> of a 39-year-old obese male who was being treated for depression and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1174	 tissue concentrations in a multiple drug related <e1>death</e1> involving <e2>Ambien</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1175	 tissue concentrations in a multiple drug related <e2>death</e2> involving Ambien."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1176	 <e2>nitrite</e2> toxicity results from industrial exposure, accidental ingestion (e.g., abuse of organic <e2>nitrite</e2>s as an aphrodisiac, especially in the male homosexual population), and suicidal ingestion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1177	 are particularly susceptible to chronic <e1>nitrate</e1> -induced <e2>methemoglobinemia</e2> because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1178	 <e2>esmolol</e2> toxicity may be self-limiting because of its extremely short half-life."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1179	 induction of general anesthesia and administration of a standard dose of intravenous <e1>esmolol hydrochloride</e1>, her cardiac rhythm progressed to <e2>asystole</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1180	 arrest</e1> after <e2>esmolol</e2> administration: a review of acute beta-blocker toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1181	 induced <e2>memory impairment</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1182	 <e1>impaired memory</e1> was found to be due to the <e2>atenolol</e2> he was on and he made a complete recovery on withdrawing the beta-blocker."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1183	 potential role for renal and hepatic impairment in the observed protracted course of <e1>amiodarone</e1> -induced <e2>thyrotoxicosis</e2> is suggested."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1184	 of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted <e1>amiodarone</e1> -induced <e2>thyroiditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1185	 report a case of <e1>amiodarone</e1> -induced <e2>thyrotoxicosis</e2> of protracted duration, unresponsive to conventional thionamide therapy, with therapy limited by severe adverse drug reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1186	 disorder</e1> associated with <e2>isoniazid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1187	 evaluated a patient who developed a <e1>psychotic disorder</e1> after 4 months of <e2>isoniazid</e2> prophylaxis for a positive tuberculosis tine test."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1188	 case report is presented concerning the administration of ketanserin in the treatment of <e1>pulmonary vasoconstriction</e1> and right ventricular failure following the infusion of <e2>protamine</e2> in a patient undergoing coronary artery bypass surgery and mitral valve replacement."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1189	 case report is presented concerning the administration of ketanserin in the treatment of pulmonary vasoconstriction and <e1>right ventricular failure</e1> following the infusion of <e2>protamine</e2> in a patient undergoing coronary artery bypass surgery and mitral valve replacement."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1190	 in the treatment of <e1>protamine</e1> -induced <e2>pulmonary hypertension</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1191	 reversal of heparin by <e1>protamine</e1> may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and <e2>bronchoconstriction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1192	 reversal of heparin by <e1>protamine</e1> may cause severe hemodynamic deterioration, characterized by systemic hypotension, <e2>pulmonary hypertension</e2>, and bronchoconstriction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1193	 reversal of heparin by <e1>protamine</e1> may cause <e2>severe hemodynamic deterioration</e2>, characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1194	 reversal of heparin by <e1>protamine</e1> may cause severe hemodynamic deterioration, characterized by <e2>systemic hypotension</e2>, pulmonary hypertension, and bronchoconstriction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1195	 drug addict with staphylococcal endocarditis treated with <e1>methicillin</e1>, who developed massive proteinuria and <e2>acute nephritic syndrome</e2> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1196	 drug addict with staphylococcal endocarditis treated with <e1>methicillin</e1>, who developed <e2>massive proteinuria</e2> and acute nephritic syndrome is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1197	 glomerulonephritis</e1> and interstitial nephritis in <e2>methicillin</e2> -treated, heroin-related infective endocarditis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1198	 glomerulonephritis and <e1>interstitial nephritis</e1> in <e2>methicillin</e2> -treated, heroin-related infective endocarditis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1199	 This paper presents a new case of <e1>rifabutin</e1> <e2>uveitis</e2> and a review of the various published reports to date."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1200	 the past 3 years there have been several reports of <e1>uveitis</e1> associated with <e2>rifabutin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1201	 associated with <e2>rifabutin</e2> therapy: a clinical alert."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1202	 DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a <e1>large cerebral infarction</e1> during <e2>praziquantel</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-

1203	 cerebral infarction</e1> during <e2>praziquantel</e2> therapy in neurocysticercosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1204	 SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., <e2>diarrhea</e2>, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1205	 SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., <e2>diarrhea</e2>, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1206	 SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, <e2>mucositis</e2>, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1207	 SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, <e2>mucositis</e2>, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1208	 SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, <e2>myelosuppression</e2>, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1209	 SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, <e2>myelosuppression</e2>, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1210	 SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, <e2>neurotoxicity</e2>) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1211	 SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, <e2>neurotoxicity</e2>) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1212	 SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, <e2>stomatitis</e2>, mucositis, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1213	 SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, <e2>stomatitis</e2>, mucositis, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1214	 dehydrogenase deficiency: a pharmacogenetic defect causing <e1>severe adverse reactions</e1> to <e2>5-fluorouracil</e2> -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1215	 To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially <e1>lethal adverse reactions</e1> following <e2>5-fluorouracil</e2> (5-FU)-based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1216	 To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially <e1>lethal adverse reactions</e1> following 5-fluorouracil (<e2>5-FU</e2>)-based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1217	 principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1> -induced neurologic symptoms such as encephalopathy and <e2>coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1218	 principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1> -induced neurologic symptoms such as encephalopathy and <e2>coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1219	 principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1> -induced neurologic symptoms such as <e2>encephalopathy</e2> and coma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1220	 principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1> -induced neurologic symptoms such as <e2>encephalopathy</e2> and coma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1221	 principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1> -induced <e2>neurologic symptoms</e2> such as encephalopathy and coma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1222	 principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1> -induced <e2>neurologic symptoms</e2> such as encephalopathy and coma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1223	 principle treatment for DPD-deficient patients with severe acute <e2>5-FU</e2> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e2>5-FU</e2> -induced neurologic symptoms such as encephalopathy and coma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1224	 principle treatment for DPD-deficient patients with severe acute <e2>5-FU</e2> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e2>5-FU</e2> -induced neurologic symptoms such as encephalopathy and coma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1225	 49-year-old man with Crohn's disease treated with prednisone and mesalamine (<e1>5-ASA</e1>) developed worsening respiratory distress and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1226	 49-year-old man with Crohn's disease treated with prednisone and <e1>mesalamine</e1> (5-ASA) developed worsening respiratory distress and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1227	 49-year-old man with Crohn's disease treated with <e1>prednisone</e1> and mesalamine (5-ASA) developed worsening respiratory distress and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1228	 49-year-old man with Crohn's disease treated with prednisone and mesalamine (<e1>5-ASA</e1>) developed <e2>worsening respiratory distress</e2> and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1229	 49-year-old man with Crohn's disease treated with prednisone and <e1>mesalamine</e1> (5-ASA) developed <e2>worsening respiratory distress</e2> and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1230	 49-year-old man with Crohn's disease treated with <e1>prednisone</e1> and mesalamine (5-ASA) developed <e2>worsening respiratory distress</e2> and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1231	 -induced <e2>hypersensitivity pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1232	 may cause <e2>hypersensitivity pneumonitis</e2> in patients with Crohn's disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1233	 elicited by the extensive administration of <e1>prednisolone</e1> was suspected for the initiation of the generalized <e2>mite infestation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1234	 <e1>Colchicine</e1> has a known <e2>adverse effect on wound healing</e2> through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1235	 <e1>Colchicine</e1> has a known adverse effect on wound healing through its inhibitory effect on tubulin-dependent cell functions and through <e2>collagenase activation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1236	 The findings in these two patients suggest that <e1>colchicine</e1> may <e2>delay corneal wound healing</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1237	 of corneal wound healing</e1> in patients treated with <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1238	 authors report on two patients with <e1>corneal ulcers refractory to conventional treatment</e1> while the patients were undergoing oral <e2>colchicine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1239	 authors suggest that in patients with <e1>corneal ulcers refractory to conventional treatment</e1> who are receiving <e2>colchicine</e2>, cessation of <e2>colchicine</e2> therapy should be considered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1240	 hepatic failure</e1> associated with <e2>bicalutamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1241	 17-year-old female patient who had been taking oral <e1>minocycline</e1> (50 mg twice daily) for 3 weeks for acne developed an <e2>eruption</e2> that progressed to an exfoliative dermatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1242	 17-year-old female patient who had been taking oral <e1>minocycline</e1> (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an <e2>exfoliative dermatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1243	 lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and <e1>dermatitis</e1>: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1244	 lymphadenopathy, <e1>eosinophilia</e1>, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1245	 lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1246	 lymphadenopathy, eosinophilia, lymphocytosis, <e1>hepatitis</e1>, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1247	 <e1>lymphadenopathy</e1>, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1248	 lymphadenopathy, eosinophilia, <e1>lymphocytosis</e1>, hepatitis, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1249	 severe illness was likely caused by <e1>minocycline</e1>, and we speculate that <e1>minocycline</e1> may have acted as a superantigen, causing <e2>lymphocyte over-activation</e2> and massive cytokine release."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1250	 severe illness was likely caused by <e1>minocycline</e1>, and we speculate that <e1>minocycline</e1> may have acted as a superantigen, causing lymphocyte over-activation and <e2>massive cytokine release</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1251	 <e1>severe illness</e1> was likely caused by <e2>minocycline</e2>, and we speculate that <e2>minocycline</e2> may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1252	 hypersensitivity</e1> to <e2>flurbiprofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1253	 movement disorders</e1> in bone marrow transplant patients on <e2>cyclosporin</e2> and ganciclovir."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1254	 movement disorders</e1> in bone marrow transplant patients on cyclosporin and <e2>ganciclovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1255	 patient had <e1>MRI T2 abnormalities</e1> compatible with <e2>cyclosporin</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1256	 patient had MRI T2 abnormalities compatible with <e1>cyclosporin</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1257	 postulate that <e1>cyclosporin</e1>, possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with <e2>eye movement abnormality</e2> in occasional patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1258	 postulate that cyclosporin, possibly together with <e1>ganciclovir</e1>, can produce transient brain stem or neuromuscular dysfunction with <e2>eye movement abnormality</e2> in occasional patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1259	 postulate that <e1>cyclosporin</e1>, possibly together with ganciclovir, can produce <e2>transient brain stem or neuromuscular dysfunction</e2> with eye movement abnormality in occasional patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1260	 postulate that cyclosporin, possibly together with <e1>ganciclovir</e1>, can produce <e2>transient brain stem or neuromuscular dysfunction</e2> with eye movement abnormality in occasional patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1261	 While <e1>thrombosis</e1> has been reported with <e2>GnRH-a</e2> therapy in men with prostate cancer, its association with treatment in this benign case may have been a consequence of the massive tumor size."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1262	 possible effects of <e1>tamoxifen</e1> upon the uterus are discussed in this article, in view of reports of <e1>tamoxifen</e1> associated with <e2>endometrial carcinoma</e2> and endometriosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1263	 possible effects of <e1>tamoxifen</e1> upon the uterus are discussed in this article, in view of reports of <e1>tamoxifen</e1> associated with endometrial carcinoma and <e2>endometriosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1264	 study: <e1>adverse response</e1> to <e2>clonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1265	 cases of <e1>adverse experiences</e1> with <e2>clonidine</e2> are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1266	 one instance a systemic hypoglycemic reaction resulting in head trauma and <e1>confusion</e1> ended in an emegency hospital admission following the substitution of <e2>acetohexamide</e2> for acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1267	 one instance a systemic hypoglycemic reaction resulting in <e1>head trauma</e1> and confusion ended in an emegency hospital admission following the substitution of <e2>acetohexamide</e2> for acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1268	 one instance a <e1>systemic hypoglycemic reaction</e1> resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of <e2>acetohexamide</e2> for acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1269	 of the <e1>itraconazole</e1> caused resolution of the <e2>drug eruption</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1270	 cutaneous coccidioidomycosis and subsequent <e1>drug eruption</e1> to <e2>itraconazole</e2> in a dog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1271	 cutaneous coccidioidomycosis</e1> and subsequent drug eruption to <e2>itraconazole</e2> in a dog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1272	 overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a <e1>potentially fatal symptom</e1> complex referred to as "<e2>retinoic acid</e2> syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1273	 overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as "<e2>retinoic acid</e2> syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1274	 overall <e1>toxicity</e1> is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as "<e2>retinoic acid</e2> syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1275	 days after initiation of therapy with <e1>amiodarone</e1>, the patient experienced syncope and was noted to have recurrent episodes of <e2>polymorphous ventricular tachycardia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1276	 days after initiation of therapy with <e1>amiodarone</e1>, the patient experienced <e2>syncope</e2> and was noted to have recurrent episodes of polymorphous ventricular tachycardia."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1277	 polymorphous ventricular tachycardia</e1> during <e2>amiodarone</e2> therapy for atrial fibrillation complicating cardiomyopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1278	 probable <e1>proarrhythmic</e1> action of <e2>amiodarone</e2>, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1279	 asthma</e1> associated with sustained-release <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1280	 dyspnea associated with <e1>verapamil</e1> administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an <e2>acute asthma</e2> attack following sustained-release <e1>verapamil</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1281	 <e1>dyspnea</e1> associated with <e2>verapamil</e2> administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an acute asthma attack following sustained-release <e2>verapamil</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1282	 Sustained-release <e1>verapamil</e1> is thought to be the cause of the <e2>asthma attack</e2> in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release <e1>verapamil</e1> and were relieved after its discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1283	 Sustained-release <e1>verapamil</e1> is thought to be the cause of the <e2>asthma attack</e2> in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release <e1>verapamil</e1> and were relieved after its discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1284	 To describe a patient with asymptomatic bronchial asthma and hypertension who developed an <e1>acute asthma</e1> attack after receiving sustained-release <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1285	 continued taking <e1>verapamil</e1> for 6 months, then, on her own, stopped all medications including the sustained-release <e1>verapamil</e1>, and her <e2>asthma</e2> symptoms disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1286	 rash in infectious mononucleosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1287	 <e2>ampicillin</e2> rash occurring in cases of infectious mononucleosis is well documented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1288	 case of a patient with infectious mononucleosis treated with <e1>cephalexin</e1> who later showed a <e2>rash</e2> is presented and the previous literature is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1289	 <e1>rash</e1> seen in this patient, who was treated with <e2>cephalexin</e2>, may be similar to the <e1>rash</e1> seen with ampicillin treatment of patients with infectious mononucleosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1290	 <e1>rash</e1> seen in this patient, who was treated with cephalexin, may be similar to the <e1>rash</e1> seen with <e2>ampicillin</e2> treatment of patients with infectious mononucleosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1291	 possible case of <e1>carbamazepine</e1> induced <e2>pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1292	 authors report a case of acute <e1>pancreatitis</e1> (AP) occurring in a patient under treatment with <e2>carbamazepine</e2> (CBZ) for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1293	 authors report a case of acute <e1>pancreatitis</e1> (AP) occurring in a patient under treatment with carbamazepine (<e2>CBZ</e2>) for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1294	 evidence of high plasmatic levels of <e1>CBZ</e1> and the absence of other aetiologic factors lead the authors to conclude that the overdose of <e1>CBZ</e1> could have represented the precipitating of the episode of <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1295	 evidence of high plasmatic levels of <e1>CBZ</e1> and the absence of other aetiologic factors lead the authors to conclude that the overdose of <e1>CBZ</e1> could have represented the precipitating of the episode of <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1296	 risk factors for <e1>MTX</e1> -induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of <e1>MTX</e1> <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1297	 risk factors for <e1>MTX</e1> -induced <e2>pulmonary toxicity</e2> are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of <e1>MTX</e1> pneumonitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1298	 -induced <e2>pneumonitis</e2> in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1299	 the other hand, <e1>MTX</e1> -induced <e2>pneumonitis</e2> seems to be very rare in psoriatic arthritis (PsA)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1300	 review of 194 RA patients and 38 PsA patients receiving <e1>MTX</e1> has identified four RA patients and one PsA patient with <e1>MTX</e1> -induced <e2>pneumonitis</e2>, giving a prevalence of 2.1% and 0.03%, respectively."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1301	 is emerging as one of the most unpredictable and potentially serious, adverse effects of treatment with <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1302	 presence of a lymphocyte alveolitis with a predominance of CD4+ T cells in 3 RA patients and CD8+ T cells with a concomitant increase in neutrophils in another case suggests that immunologically mediated reactions may be one damage mechanism in <e1>MTX</e1> -induced <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1303	 retrospective epidemiological study of deaths from <e1>hepatic angiosarcoma</e1> (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride, 'Thorotrast', and <e2>inorganic arsenic</e2>) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1304	 retrospective epidemiological study of deaths from <e1>hepatic angiosarcoma</e1> (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride, '<e2>Thorotrast</e2>', and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1305	 retrospective epidemiological study of deaths from <e1>hepatic angiosarcoma</e1> (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (<e2>vinyl chloride</e2>, 'Thorotrast', and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1306	 studies have shown that under experimental conditions <e1>ferrous sulfate</e1> may <e2>reduce the gastrointestinal absorption of orally administered levothyroxine sodium</e2> in patients with primary hypothyroidism."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1307	 describe a patient who became <e1>hypothyroid</e1> while taking <e2>ferrous sulfate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1308	 as the use of <e1>hepatitis B vaccination</e1> is growing, adverse side effects, including <e2>mental nerve neuropathy</e2>, should be observed with an increased frequency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1309	 nerve neuropathy</e1> as a result of <e2>hepatitis B vaccination</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1310	 its side effects are few, <e1>tamoxifen</e1> increases the incidence of <e2>proliferative lesions of the endometrium</e2>, which theoretically should be preventable with progestational agents."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1311	 Two postmenopausal women treated with <e1>tamoxifen</e1> and progestational agents for breast carcinoma developed uterine enlargement and <e2>intermittent spotting</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-

1312	 Two postmenopausal women treated with <e1>tamoxifen</e1> and progestational agents for breast carcinoma developed <e2>uterine enlargement</e2> and intermittent spotting."
DRUG-ADE(e1,e2)
Comment: DRUG-

1313	 The value of multihormonal therapy in breast <e1>carcinoma</e1> is not established, and the addition of progestogens to <e2>tamoxifen</e2> may not reduce of developing endometrial lesions, including <e1>carcinoma</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1314	 The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to <e1>tamoxifen</e1> may not reduce of developing <e2>endometrial lesions</e2>, including carcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1315	 and cyclophosphamide toxicity simulating <e2>metastatic nodules</e2> to the lungs in childhood cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1316	 and <e1>cyclophosphamide</e1> toxicity simulating <e2>metastatic nodules</e2> to the lungs in childhood cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1317	 biopsy to confirm metastasis revealed instead <e1>fibrotic lesions</e1> apparently attributable to <e2>bleomycin</e2> or cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1318	 biopsy to confirm metastasis revealed instead <e1>fibrotic lesions</e1> apparently attributable to bleomycin or <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1319	 elderly man with <e1>procainamide hydrochloride</e1> -induced <e2>lupus syndrome</e2> had a circulating anticoagulant against factor XI and a biologic false-positive (BFP) test result for syphilis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1320	 anticoagulant in the <e1>procainamide</e1> -induced <e2>lupus syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1321	 signs of <e1>hypermagnesemia</e1> are an uncommon complication following oral administration of <e2>magnesium sulfate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1322	 of diuresis with fluids and IV administration of calcium may provide successful treatment of <e2>magnesium</e2> toxicosis in horses."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1323	 toxicosis in two horses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1324	 of <e1>magnesium</e1> sulfate in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to <e1>magnesium</e1> toxicosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1325	 of <e1>magnesium sulfate</e1> in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to <e2>magnesium toxicosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1326	 SUMMARIES: In each case, the patients were treated over 5 years with <e1>lovastatin</e1> and developed <e2>rhabdomyolysis</e2> that coincided with the completion of a prescribed regimen of a newer macrolide antibiotic."
DRUG-ADE(e1,e2)
Comment: DRUG-

1327	 The risk of drug-induced <e1>rhabdomyolysis</e1> due to the potential interaction between lovastatin and <e2>azithromycin</e2> or clarithromycin should be considered before the concomitant use of these agents."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1328	 The risk of drug-induced <e1>rhabdomyolysis</e1> due to the potential interaction between lovastatin and azithromycin or <e2>clarithromycin</e2> should be considered before the concomitant use of these agents."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1329	 The risk of drug-induced <e1>rhabdomyolysis</e1> due to the potential interaction between <e2>lovastatin</e2> and azithromycin or clarithromycin should be considered before the concomitant use of these agents."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1330	 Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with <e1>rhabdomyolysis</e1>, including <e2>lovastatin</e2>, a hydroxymethylglutaryl-coenzyme A reductase inhibitor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1331	 is a macrolide antibiotic that may increase the risk of lovastatin-induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1332	 is a macrolide antibiotic that may increase the risk of <e1>lovastatin</e1> -induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1333	 <e1>rhabdomyolysis</e1> possibly associated with clarithromycin and <e2>azithromycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1334	 <e1>rhabdomyolysis</e1> possibly associated with <e2>clarithromycin</e2> and azithromycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1335	 -induced <e2>rhabdomyolysis</e2> possibly associated with clarithromycin and azithromycin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1336	 To describe two cases of <e1>rhabdomyolysis</e1> in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and <e2>azithromycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1337	 To describe two cases of <e1>rhabdomyolysis</e1> in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics <e2>clarithromycin</e2> and azithromycin."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1338	 To describe two cases of <e1>rhabdomyolysis</e1> in patients taking <e2>lovastatin</e2> that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1339	 our knowledge, these cases are the first published reports of lovastatin-induced <e1>rhabdomyolysis</e1> associated with <e2>azithromycin</e2> and clarithromycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1340	 our knowledge, these cases are the first published reports of lovastatin-induced <e1>rhabdomyolysis</e1> associated with azithromycin and <e2>clarithromycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1341	 our knowledge, these cases are the first published reports of <e1>lovastatin</e1> -induced <e2>rhabdomyolysis</e2> associated with azithromycin and clarithromycin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1342	 cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients <e1>died</e1> of PCP occurring during the first month of treatment with <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1343	 report the specifics of 12 cases of <e1>severe hypertension</e1> after the intraoperative use of topical phenylephrine, submucosal <e2>epinephrine</e2>, or both."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1344	 report the specifics of 12 cases of <e1>severe hypertension</e1> after the intraoperative use of topical <e2>phenylephrine</e2>, submucosal epinephrine, or both."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1345	 leukaemia</e1> during <e2>tamoxifen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1346	 is suggested to be <e2>carcinogenic</e2> both through direct genotoxic and epigenetic mechanisms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1347	 report two cases that developed <e1>acute myeloid leukaemia</e1> (AML) during <e2>tamoxifen</e2> therapy for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1348	 report two cases that developed acute myeloid leukaemia (<e1>AML</e1>) during <e2>tamoxifen</e2> therapy for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1349	 in the external auditory canal of acute promyelocytic leukemia</e1> after treatment with <e2>all-trans retinoic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1350	 case suggests the importance of careful observation for <e1>extramedullary relapse</e1> in patients who are treated with <e2>ATRA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1351	 reactions</e1> to propylthiouracil and <e2>methimazole</e2> occur in 3%-5% of adults."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1352	 reactions</e1> to <e2>propylthiouracil</e2> and methimazole occur in 3%-5% of adults."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1353	 maculopapular and papular purpuric eruptions</e1> are perhaps the most common <e2>thionamide</e2> -induced reactions."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1354	 -induced <e2>cutaneous vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1355	 observation of <e1>cutaneous vasculitis</e1> during administration of <e2>propylthiouracil</e2> suggested that clinical awareness of this complication should be of considerable importance."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1356	 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled <e1>heat stroke</e1> during the administration of <e2>zonisamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1357	 receiving <e1>zonisamide</e1> should be monitored for oligohidrosis and the development of <e2>neurological symptoms</e2> associated with an elevation of body temperature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1358	 receiving <e1>zonisamide</e1> should be monitored for <e2>oligohidrosis</e2> and the development of neurological symptoms associated with an elevation of body temperature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1359	 stroke-like episode</e1> in a child caused by <e2>zonisamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1360	 <e1>oligohidrosis</e1> caused by <e2>zonisamide</e2> was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1361	 renal failure</e1> in a patient receiving treatment with <e2>suramin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1362	 <e1>renal failure</e1> should be recognized as a potential complication of <e2>suramin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1363	 potential causes of <e1>renal failure</e1> were not present in our patient and his renal function gradually recovered with the cessation of <e2>suramin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1364	 describe a patient with metastatic prostate cancer who developed <e1>nonoliguric renal failure</e1> during treatment with <e2>suramin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1365	 induced <e2>polyserositis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1366	 report the case of a patient who developed polyserositis (<e1>pericardial effusion</e1>, pleural effusion, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1367	 report the case of a patient who developed polyserositis (<e1>pericardial effusion</e1>, pleural effusion, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1368	 report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and <e1>pericarditis</e1>) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1369	 report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and <e1>pericarditis</e1>) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1370	 report the case of a patient who developed polyserositis (pericardial effusion, <e1>pleural effusion</e1>, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1371	 report the case of a patient who developed polyserositis (pericardial effusion, <e1>pleural effusion</e1>, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1372	 report the case of a patient who developed <e1>polyserositis</e1> (pericardial effusion, pleural effusion, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1373	 report the case of a patient who developed <e1>polyserositis</e1> (pericardial effusion, pleural effusion, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1374	 the disease recurred conventional <e1>amphotericin B</e1> was used again, but had to be stopped because of <e2>severe side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1375	 patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (<e1>ARA-C</e1>); among them, along with myelosuppression, five experienced <e2>fever</e2>, infectious complications, gastrointestinal tract symptoms and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1376	 patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, <e1>cytosine arabinoside</e1> (ARA-C); among them, along with myelosuppression, five experienced <e2>fever</e2>, infectious complications, gastrointestinal tract symptoms and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1377	 patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (<e1>ARA-C</e1>); among them, along with myelosuppression, five experienced fever, infectious complications, <e2>gastrointestinal tract symptoms</e2> and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1378	 patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, <e1>cytosine arabinoside</e1> (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, <e2>gastrointestinal tract symptoms</e2> and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1379	 patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (<e1>ARA-C</e1>); among them, along with myelosuppression, five experienced fever, <e2>infectious complications</e2>, gastrointestinal tract symptoms and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1380	 patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, <e1>cytosine arabinoside</e1> (ARA-C); among them, along with myelosuppression, five experienced fever, <e2>infectious complications</e2>, gastrointestinal tract symptoms and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1381	 patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (<e1>ARA-C</e1>); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and <e2>severe myalgias</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1382	 patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, <e1>cytosine arabinoside</e1> (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and <e2>severe myalgias</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1383	 We believe this to be the first reported case of <e1>rhGH</e1> -induced <e2>hypercalcemia</e2> in an HIV-infected patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1384	 in an AIDS patient treated with <e2>growth hormone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1385	 <e1>hypercalcemia</e1> responded to discontinuation of <e2>rhGH</e2> and a single dose of intravenous pamidronate disodium and has not recurred in 8 months of follow-up."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1386	 report a male patient with advanced AIDS who developed <e1>hypercalcemia</e1> 2 weeks after institution of <e2>rhGH</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1387	 reactions</e1> to <e2>cisplatin</e2> following multiple uncomplicated courses: a report on two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1388	 patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested <e2>abdominal pain</e2>, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1389	 patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested <e2>abdominal pain</e2>, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1390	 patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, <e2>dyspnea</e2>, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1391	 patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, <e2>dyspnea</e2>, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1392	 patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1393	 patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1394	 patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested <e2>general erythema</e2>, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, <e2>general erythema</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1395	 patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested <e2>general erythema</e2>, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, <e2>general erythema</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1396	 patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested <e2>general erythema</e2>, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, <e2>general erythema</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1397	 patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested <e2>general erythema</e2>, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, <e2>general erythema</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1398	 patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced <e2>hypersensitivity reactions</e2> to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1399	 patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced <e2>hypersensitivity reactions</e2> to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1400	 patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and <e2>hypotension</e2>; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1401	 patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and <e2>hypotension</e2>; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1402	 report an unusually short lived and asymptomatic episode of severe <e1>cisplatin</e1> -induced <e2>renal tubular salt wasting</e2> in a fit 41-year-old patient with malignant teratoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1403	 should include <e1>phenolphthalein</e1> in their list of possible causes of drug-induced <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1404	 <e1>Phenolphthalein</e1> is the active ingredient in several over-the-counter laxative preparations and has only rarely been reported to cause <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1405	 To report a case of <e1>phenolphthalein</e1> -induced toxic epidermal necrolysis (<e2>TEN</e2>) in a patient maintained on several other medications more commonly known to be associated with <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1406	 To report a case of <e1>phenolphthalein</e1> -induced toxic epidermal necrolysis (<e2>TEN</e2>) in a patient maintained on several other medications more commonly known to be associated with <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1407	 To report a case of <e1>phenolphthalein</e1> -induced <e2>toxic epidermal necrolysis</e2> (TEN) in a patient maintained on several other medications more commonly known to be associated with TEN."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1408	 -induced <e2>toxic epidermal necrolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1409	 patient's previous <e1>rash</e1> and the temporal relation of this event and the ingestion of <e2>phenolphthalein</e2>, as well as the similarity of this case to other reports, point to <e2>phenolphthalein</e2> as the cause of TEN in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1410	 patient's previous rash and the temporal relation of this event and the ingestion of <e1>phenolphthalein</e1>, as well as the similarity of this case to other reports, point to <e1>phenolphthalein</e1> as the cause of <e2>TEN</e2> in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1411	 toxicity induced by clarithromycin coadministration in psychiatric patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1412	 toxicity</e1> induced by <e2>clarithromycin</e2> coadministration in psychiatric patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1413	 clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of <e1>carbamazepine</e1>, such as drowsiness, dizziness, and <e2>ataxia</e2>, which resolved within 5 days after clarithromycin discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1414	 <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and <e2>ataxia</e2>, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1415	 <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and <e2>ataxia</e2>, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1416	 clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of <e1>carbamazepine</e1>, such as drowsiness, <e2>dizziness</e2>, and ataxia, which resolved within 5 days after clarithromycin discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1417	 <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, <e2>dizziness</e2>, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1418	 <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, <e2>dizziness</e2>, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1419	 clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of <e1>carbamazepine</e1>, such as <e2>drowsiness</e2>, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1420	 <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as <e2>drowsiness</e2>, dizziness, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1421	 <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as <e2>drowsiness</e2>, dizziness, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1422	 clarithromycin coadministration, four out of the seven patients developed moderate-to-severe <e1>toxic symptoms</e1> of <e2>carbamazepine</e2>, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1423	 <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe <e2>toxic symptoms</e2> of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1424	 <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe <e2>toxic symptoms</e2> of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1425	 present report suggests that clarithromycin coadministration induces increased plasma <e1>carbamazepine</e1> concentrations, which may result in <e1>carbamazepine</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1426	 present report suggests that clarithromycin coadministration induces increased plasma <e1>carbamazepine</e1> concentrations, which may result in <e1>carbamazepine</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1427	 present report suggests that <e1>clarithromycin</e1> coadministration induces increased plasma carbamazepine concentrations, which may result in <e2>carbamazepine toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1428	 present report suggests that clarithromycin coadministration induces increased plasma <e2>carbamazepine</e2> concentrations, which may result in <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1429	 present report suggests that clarithromycin coadministration induces increased plasma <e2>carbamazepine</e2> concentrations, which may result in <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1430	 present report suggests that <e1>clarithromycin</e1> coadministration induces <e2>increased plasma carbamazepine</e2> concentrations, which may result in carbamazepine toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1431	 hemorrhagic gastritis associated with <e2>acetazolamide</e2> intoxication in a patient with chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1432	 hemorrhagic gastritis</e1> associated with <e2>acetazolamide</e2> intoxication in a patient with chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1433	 far as we know, this is the first case report of <e1>acute hemorrhagic gastritis</e1> associated with <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1434	 far as we know, this is the first case report of acute hemorrhagic gastritis associated with <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1435	 was thus diagnosed as having <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1436	 experienced a case of chronic renal failure in a patient suffering from <e1>acute hemorrhagic gastritis</e1> associated with <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1437	 experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1438	 thus concluded that an excessive dose of <e1>AZ</e1> had probably <e2>destroyed the gastric mucosal barrier</e2> or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1439	 thus concluded that an excessive dose of <e1>AZ</e1> had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of <e2>hemorrhagic gastritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1440	 thus concluded that an excessive dose of <e1>AZ</e1> had probably destroyed the gastric mucosal barrier or <e2>thrombocytopenia due to bone marrow disorder</e2> and thus eventually led to the development of hemorrhagic gastritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1441	 association with this tocolysis, <e1>urinary calculus</e1> of <e2>magnesium ammonium phosphate</e2> occurred at 34 weeks gestation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1442	 tocolysis as the cause of <e2>urinary calculus</e2> during pregnancy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1443	 induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1444	 the next day, after a total dose of only 600 mg of <e1>danazol</e1>, <e2>gingival bleeding</e2> and purpura occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1445	 the next day, after a total dose of only 600 mg of <e1>danazol</e1>, gingival bleeding and <e2>purpura</e2> occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1446	 diagnosed this case as <e1>danazol</e1> induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1447	 occasionally accompanies the <e1>heparin</e1> -associated <e2>thrombocytopenia</e2> and thrombosis syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1448	 occasionally accompanies the <e1>heparin</e1> -associated thrombocytopenia and <e2>thrombosis syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1449	 necrosis</e1> is a rare complication of subcutaneous <e2>heparin</e2> therapy that usually occurs at injection sites."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1450	 necrosis</e1> secondary to <e2>low-molecular weight heparin</e2> in a patient with antiphospholipid antibody syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1451	 describe a patient with the antiphospholipid syndrome who had <e1>skin necrosis</e1> develop from <e2>low-molecular weight heparin</e2> therapy at sites distant from injection sites."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1452	 <e2>reserpine</e2> toxicity, in particular central nervous system (CNS) disturbances, was reported more frequently in patients also receiving barbiturates, suggesting additive CNS effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1453	 case of <e1>contact dermatitis</e1> due to <e2>sodium bisulfite</e2> in an ophthalmic solution."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1454	 we diagnosed her eruption as <e1>contact dermatitis</e1> due to <e2>sodium bisulfite</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1455	 we diagnosed her <e1>eruption</e1> as contact dermatitis due to <e2>sodium bisulfite</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1456	 report a case of <e1>contact dermatitis</e1> due to <e2>sodium bisulfite</e2> in Tathion eye drops."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1457	 pancreatitis</e1> after long-term <e2>5-aminosalicylic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1458	 pancreatitis</e1> is a known, although rare, complication of <e2>mesalamine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1459	 rechallenge, performed in both patients, confirmed the diagnosis of <e1>mesalamine</e1> -induced <e2>pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1460	 case reports provide evidence that <e1>5-aminosalicylic acid</e1> may induce <e2>acute pancreatitis</e2> after long term treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1461	 describe two cases of <e1>acute pancreatitis</e1> that occurred after long term <e2>mesalamine</e2> therapy for ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1462	 35-year-old nephrotic man developed <e1>acute renal failure</e1> with serum creatinine to 1543 micromol/l after a month of therapy with <e2>enalapril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1463	 renal failure</e1> with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with <e2>enalapril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1464	 renal failure with <e1>severe tubulointerstitial changes</e1> in a patient with minimal change nephrotic syndrome treated with <e2>enalapril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1465	 <e1>ritonavir</e1> -induced <e2>maculopapular eruption</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1466	 should be added to the list of drugs that can induce <e2>adverse cutaneous reactions</e2> in HIV patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1467	 report 2 cases of maculopapular eruption and <e1>fever</e1> in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of <e2>ritonavir</e2>, a protease inhibitor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1468	 report 2 cases of <e1>maculopapular eruption</e1> and fever in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of <e2>ritonavir</e2>, a protease inhibitor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1469	 caused by <e2>methicillin</e2> therapy for staphylococcal septicemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1470	 of the literature relating to <e1>methicillin</e1> -induced <e2>nephropathy</e2> suggests a hypersensitivity origin for this disorder, but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1471	 25-year-old woman sought medical attention because of iliocaval manifestations of <e1>retroperitoneal fibrosis</e1> while she was taking <e2>methysergide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1472	 -induced <e2>retroperitoneal fibrosis</e2>: successful outcome and two new laboratory features."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1473	 associated with <e2>alpha-interferon</e2> in a patient with chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1474	 report a case of <e1>vitiligo</e1> that occurred during the second month of <e2>interferon alpha 2a</e2> therapy for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1475	 case is reported of an elderly woman who developed <e1>febrile agranulocytosis</e1> several weeks after commencing <e2>ticlopidine</e2> but who had a favorable outcome after cessation of that drug and treatment with filgastrim."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1476	 associated with <e2>ticlopidine</e2>: a possible benefit with filgastim."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1477	 is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression, typically <e2>aplastic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1478	 is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with <e2>severe bone marrow suppression</e2>, typically aplastic anemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1479	 was also shown to reverse <e1>ifosfamide</e1> -related <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1480	 -associated <e2>neurotoxicity</e2> was noted within hours of drug administration and improved rapidly following hemodialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1481	 We evaluated the in vitro hemodialysis ratio and subsequent <e1>toxicity</e1> and pharmacokinetics of <e2>ifosfamide</e2> in an anephric patient with Wilms' tumor."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1482	 <e1>toxicity</e1> and plasma concentrations of ifosfamide, chloroacetaldehyde, and <e2>4-hydroxyifosfamide</e2> were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1483	 <e1>toxicity</e1> and plasma concentrations of ifosfamide, <e2>chloroacetaldehyde</e2>, and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1484	 <e1>toxicity</e1> and plasma concentrations of <e2>ifosfamide</e2>, chloroacetaldehyde, and 4-hydroxy<e2>ifosfamide</e2> were then determined over 24 h after a single 1.6 g/m2 dose of <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1485	 <e1>toxicity</e1> and plasma concentrations of <e2>ifosfamide</e2>, chloroacetaldehyde, and 4-hydroxy<e2>ifosfamide</e2> were then determined over 24 h after a single 1.6 g/m2 dose of <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1486	 pharmacokinetics, and in vitro hemodialysis clearance of <e2>ifosfamide</e2> and metabolites in an anephric pediatric patient with Wilms' tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1487	 55-year-old woman developed symptoms suggestive of <e1>hepatitis</e1> 12 weeks after first receiving <e2>methyldopa</e2> for hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1488	 -induced <e2>liver injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1489	 a rapid and relentless progression of <e1>methyldopa</e1> -induced <e2>liver injury</e2> is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1490	 respiratory depression</e1> as a complication of nebulised <e2>morphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1491	 15 min after the first administration of nebulised <e1>morphine</e1> the patient became markedly <e2>bradypneic</e2> (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1492	 15 min after the first administration of nebulised <e1>morphine</e1> the patient became markedly bradypneic (respiratory rate: 4-5 bpm), <e2>hypotensive</e2> (BP 70/40 mmHg), and responded only partially to command."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1493	 To present a case of <e1>respiratory depression</e1> following the administration of nebulised <e2>morphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1494	 dystonia</e1> with thalamic and brainstem lesions after initial <e2>penicillamine</e2> treatment in Wilson's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1495	 dystonia with <e1>thalamic and brainstem lesions</e1> after initial <e2>penicillamine</e2> treatment in Wilson's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1496	 these data, <e1>acute generalized dystonia</e1> with brainstem and thalamic lesions may occur in WD patients after an initial <e2>d-penicillamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1497	 these data, acute generalized dystonia with <e1>brainstem and thalamic lesions</e1> may occur in WD patients after an initial <e2>d-penicillamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1498	 reported 3 patients who developed <e1>acute generalized dystonia</e1> and akinetic rigid syndrome following an initial therapy with <e2>d-penicillamine</e2> 125-500 mg daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1499	 reported 3 patients who developed acute generalized dystonia and <e1>akinetic rigid syndrome</e1> following an initial therapy with <e2>d-penicillamine</e2> 125-500 mg daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1500	 movements</e1> due to ischemic infarcts after intravenous <e2>heroin</e2> overdose: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1501	 movements due to <e1>ischemic infarcts</e1> after intravenous <e2>heroin</e2> overdose: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1502	 1 presented <e1>bilateral ballism</e1> 1 week after intravenous <e2>heroin</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1503	 is an infrequent but recognized complication of <e2>heroin</e2> addiction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1504	 <e1>heroin</e1> addicts, aged 34 and 19 years, developed <e2>ballistic movements</e2> after intravenous <e1>heroin</e1> overdose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1505	 MEDLINE search identified all the reported cases of <e1>hypersensitivity reactions</e1> to <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1506	 to intravenous <e2>cyclosporine</e2> and tolerance to oral <e2>cyclosporine</e2>: case report and review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1507	 <e1>Hypersensitivity reactions</e1> to <e2>cyclosporine</e2> are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1508	 <e1>Hypersensitivity reactions</e1> to cyclosporine are due to <e2>Cremophor EL</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1509	 <e1>Hypersensitivity reactions</e1> to <e2>cyclosporine</e2> are due to Cremophor EL."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1510	 a <e1>hypersensitivity reaction</e1> to one formulation of <e2>cyclosporine</e2> does not preclude use of a different formulation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1511	 We report a patient who had an <e1>anaphylactic reaction</e1> during the intravenous infusion of <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1512	 To investigate the mechanisms involved in <e1>hypersensitivity reactions</e1> to <e2>cyclosporine</e2> and determine the feasibility of future <e2>cyclosporine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1513	 To investigate the mechanisms involved in <e1>hypersensitivity reactions</e1> to <e2>cyclosporine</e2> and determine the feasibility of future <e2>cyclosporine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1514	 literature search revealed 22 cases of <e1>hypersensitivity reaction</e1> to <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1515	 -induced <e2>priapism</e2>: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1516	 present the first case of a patient with <e1>priapism</e1> after oral intake of the phenothiazine <e2>prothipendylhydrochloride</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1517	 chemotherapeutics, including vincristine, <e1>actinomycin D</e1>, and epirubicin in case 1 and vincristine and <e1>actinomycin D</e1> in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1518	 chemotherapeutics, including vincristine, <e1>actinomycin D</e1>, and epirubicin in case 1 and vincristine and <e1>actinomycin D</e1> in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1519	 chemotherapeutics, including vincristine, actinomycin D, and <e1>epirubicin</e1> in case 1 and vincristine and actinomycin D in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1520	 chemotherapeutics, including <e1>vincristine</e1>, actinomycin D, and epirubicin in case 1 and <e1>vincristine</e1> and actinomycin D in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1521	 chemotherapeutics, including <e1>vincristine</e1>, actinomycin D, and epirubicin in case 1 and <e1>vincristine</e1> and actinomycin D in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1522	 conclude that vincristine and <e1>actinomycin D</e1> were the cause of this rare from of <e2>hepatotoxicity</e2> and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1523	 conclude that <e1>vincristine</e1> and actinomycin D were the cause of this rare from of <e2>hepatotoxicity</e2> and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1524	 the combination of <e1>bleomycin</e1> and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking <e2>acral necrosis</e2> in patients who develop Raynaud's phenomenon under chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1525	 the combination of <e1>bleomycin</e1> and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop <e2>Raynaud's phenomenon</e2> under chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1526	 this report, one patient who developed <e1>gangrene</e1> after <e2>bleomycin</e2> and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1527	 this report, one patient who developed <e1>gangrene</e1> after bleomycin and vincristine/<e2>vinblastine</e2> chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1528	 this report, one patient who developed <e1>gangrene</e1> after bleomycin and <e2>vincristine</e2>/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1529	 this report, one patient who developed gangrene after <e1>bleomycin</e1> and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of <e2>severe Raynaud's phenomenon</e2> related to the same regimen are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1530	 this report, one patient who developed gangrene after bleomycin and vincristine/<e1>vinblastine</e1> chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of <e2>severe Raynaud's phenomenon</e2> related to the same regimen are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1531	 this report, one patient who developed gangrene after bleomycin and <e1>vincristine</e1>/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of <e2>severe Raynaud's phenomenon</e2> related to the same regimen are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1532	 of essential <e1>thrombocythemia</e1> in a patient treated with <e2>interferon alfa</e2> and pentostatin for hairy cell leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1533	 of essential <e1>thrombocythemia</e1> in a patient treated with interferon alfa and <e2>pentostatin</e2> for hairy cell leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1534	 cancers including various types of <e1>hematological malignancy</e1> have been reported in patients with hairy cell leukemia treated with chemotherapy or <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1535	 cancers</e1> including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1536	 of beta-blockade on symptomatic <e1>dexamethasone</e1> -induced <e2>hypertrophic obstructive cardiomyopathy</e2> in premature infants: three case reports and literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1537	 patient had a <e1>lower average heart rate</e1> and two patients had lower average mean blood pressure values during <e2>propranolol</e2> treatment, none of which was clinically significant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1538	 patient had a lower average heart rate and two patients had <e1>lower average mean blood pressure</e1> values during <e2>propranolol</e2> treatment, none of which was clinically significant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1539	 DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and <e1>left ventricular outflow tract obstruction</e1> developed during <e2>dexamethasone</e2> treatment for bronchopulmonary dysplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1540	 DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant <e1>septal hypertrophy</e1> and left ventricular outflow tract obstruction developed during <e2>dexamethasone</e2> treatment for bronchopulmonary dysplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1541	 SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and <e1>abdominal cramping</e1> on day 6 of therapy with <e2>clindamycin</e2> vaginal cream for bacterial vaginosis."
DRUG-ADE(e2,e1)
Comment: DRUG-

1542	 SUMMARY: A 25-year-old postpartum white woman developed <e1>multiple watery stools</e1> and abdominal cramping on day 6 of therapy with <e2>clindamycin</e2> vaginal cream for bacterial vaginosis."
DRUG-ADE(e2,e1)
Comment: DRUG-

1543	 difficile toxin-induced colitis</e1> after use of <e2>clindamycin phosphate</e2> vaginal cream."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1544	 This report indicates <e1>clindamycin</e1> phosphate vaginal cream as the most probable cause of <e2>CDIC</e2> due to the temporal relationship between the occurrence of diarrhea and <e1>clindamycin</e1> administration, lack of concomitant medications, and documentation of C. difficile toxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1545	 This report indicates <e1>clindamycin phosphate</e1> vaginal cream as the most probable cause of <e2>CDIC</e2> due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1546	 This report indicates <e1>clindamycin</e1> phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and <e1>clindamycin</e1> administration, lack of concomitant medications, and documentation of <e2>C. difficile toxin</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1547	 This report indicates <e1>clindamycin phosphate</e1> vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of <e2>C. difficile toxin</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1548	 This report indicates <e1>clindamycin</e1> phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of <e2>diarrhea</e2> and <e1>clindamycin</e1> administration, lack of concomitant medications, and documentation of C. difficile toxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1549	 This report indicates <e1>clindamycin phosphate</e1> vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of <e2>diarrhea</e2> and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1550	 No published clinical studies in patients receiving <e1>clindamycin</e1> vaginal cream for bacterial vaginosis have documented <e2>C. difficile toxin in stool</e2> samples of patients with diarrhea."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1551	 No published clinical studies in patients receiving <e1>clindamycin</e1> vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with <e2>diarrhea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1552	 To report a case of <e1>toxin-positive Clostridium difficile-induced colitis</e1> (CDIC) after use of <e2>clindamycin phosphate</e2> vaginal cream."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1553	 54-year-old man developed <e1>TEN</e1> 4 weeks after beginning <e2>lamotrigine</e2> for complex partial seizures related to a glioblastoma multiforme brain tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1554	 of <e1>lamotrigine</e1>, especially in combination with valproic acid, may lead to the development of <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1555	 of lamotrigine, especially in combination with <e1>valproic acid</e1>, may lead to the development of <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1556	 toxic epidermal necrolysis</e1> related to <e2>lamotrigine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1557	 was hypothesized that valproic acid may interfere with glucuronidation of <e1>lamotrigine</e1>, leading to increased serum <e1>lamotrigine</e1> levels, or perhaps alter the drug's metabolism, resulting in <e2>accumulation of a toxic intermediate metabolite</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1558	 was hypothesized that <e1>valproic acid</e1> may interfere with glucuronidation of lamotrigine, leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in <e2>accumulation of a toxic intermediate metabolite</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1559	 was hypothesized that valproic acid may interfere with glucuronidation of <e1>lamotrigine</e1>, leading to increased serum <e1>lamotrigine</e1> levels, or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1560	 was hypothesized that <e1>valproic acid</e1> may interfere with glucuronidation of lamotrigine, leading to <e2>increased serum lamotrigine levels</e2>, or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1561	 date, eight cases of TEN and one of <e1>SJS</e1> related to <e2>lamotrigine</e2> administration have been reported in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1562	 date, eight cases of <e1>TEN</e1> and one of SJS related to <e2>lamotrigine</e2> administration have been reported in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1563	 <e1>syndrome of increased affect</e1> in response to <e2>risperidone</e2> among patients with schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1564	 of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and <e2>depression</e2> and periods of crying and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1565	 of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of intolerable affect, including <e2>feelings of agitation</e2> and depression and periods of crying and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1566	 of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1567	 of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of <e2>intolerable affect</e2>, including feelings of agitation and depression and periods of crying and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1568	 of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and <e2>periods of crying</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1569	 authors suggest that <e1>risperidone</e1> may <e2>increase affect</e2> in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1570	 toxicity can cause severe central nervous system insult in which a characteristic pattern of <e2>bilateral putaminal injury</e2> is noted on brain imaging studies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1571	 toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1572	 toxicity can cause <e2>severe central nervous system insult</e2> in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1573	 infarct in <e2>methanol</e2> intoxication: case report and role of brain imaging studies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1574	 infarct</e1> in <e2>methanol</e2> intoxication: case report and role of brain imaging studies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1575	 basal ganglia toxicologic mechanisms of <e2>methanol</e2> poisoning are reviewed, and the role of brain imaging studies will regard to diagnosis, prognosis and impact on management is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1576	 present a fatal case of subacute <e1>methanol</e1> toxicity with associated diffuse brain involvement, including <e2>bilateral putaminal necrosis</e2> and cerebral edema with ventricular compression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1577	 present a fatal case of subacute <e1>methanol</e1> toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and <e2>cerebral edema</e2> with ventricular compression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1578	 present a fatal case of subacute <e1>methanol</e1> toxicity with associated <e2>diffuse brain involvement</e2>, including bilateral putaminal necrosis and cerebral edema with ventricular compression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1579	 present a <e1>fatal</e1> case of subacute <e2>methanol</e2> toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1580	 present a fatal case of subacute <e2>methanol</e2> toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1581	 present a fatal case of subacute <e1>methanol</e1> toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with <e2>ventricular compression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1582	 28 year old white schizophrenic male has been under <e1>risperidone</e1> monotherapy for about one year when he developed <e2>dyskinetic movements</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1583	 -induced <e2>tardive dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1584	 report presents a potential case of <e1>risperidone</e1> -induced <e2>tardive dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1585	 ocular pressure</e1> in two patients with narrow angle glaucoma treated with <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1586	 61-year-old man developed <e1>clinical lupus syndrome</e1> with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1587	 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and <e1>diffuse proliferative glomerulonephritis</e1> following 26 months of <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1588	 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive <e1>lupus erythematosus</e1> (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1589	 in <e2>procainamide</e2> induced lupus erythematosus: report of a case and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1590	 in <e1>procainamide</e1> induced <e2>lupus erythematosus</e2>: report of a case and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1591	 report a 76-year-old man who developed an <e1>acute blistering eruption</e1> following high-dose <e2>penicillin</e2> treatment for pneumococcal septicaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1592	 case of prolonged <e1>suxamethonium</e1> <e2>apnoea</e2> successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1593	 <e2>apnoea</e2> terminated with commercial serumcholinesterase."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1594	 arrest</e1> associated with <e2>sulprostone</e2> use during caesarean section."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1595	 postulate that the bolus of <e1>sulprostone</e1> resulted in possible coronary spasm that resulted in <e2>cardiac arrest</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1596	 postulate that the bolus of <e1>sulprostone</e1> resulted in possible <e2>coronary spasm</e2> that resulted in cardiac arrest."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1597	 case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and <e1>desmethylsertraline</e1> blood levels, resulted in a <e2>doubling of the lamotrigine blood level</e2> with symptoms of toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1598	 case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the <e2>lamotrigine</e2> blood level with symptoms of toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1599	 case 1, a total daily dose of 25 mg <e1>sertraline</e1>, with nondetectable <e1>sertraline</e1> and desmethyl<e1>sertraline</e1> blood levels, resulted in a <e2>doubling of the lamotrigine blood level</e2> with symptoms of toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1600	 case 1, a total daily dose of 25 mg <e1>sertraline</e1>, with nondetectable <e1>sertraline</e1> and desmethyl<e1>sertraline</e1> blood levels, resulted in a <e2>doubling of the lamotrigine blood level</e2> with symptoms of toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1601	 case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and <e1>desmethylsertraline</e1> blood levels, resulted in a doubling of the lamotrigine blood level with <e2>symptoms of toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1602	 case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the <e1>lamotrigine</e1> blood level with <e2>symptoms of toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1603	 case 1, a total daily dose of 25 mg <e1>sertraline</e1>, with nondetectable <e1>sertraline</e1> and desmethyl<e1>sertraline</e1> blood levels, resulted in a doubling of the lamotrigine blood level with <e2>symptoms of toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1604	 case 1, a total daily dose of 25 mg <e1>sertraline</e1>, with nondetectable <e1>sertraline</e1> and desmethyl<e1>sertraline</e1> blood levels, resulted in a doubling of the lamotrigine blood level with <e2>symptoms of toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1605	 toxicity secondary to sertraline."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1606	 toxicity</e1> secondary to <e2>sertraline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1607	 withdrawal syndrome is characterized by a <e2>decrease in prostate-specific antigen</e2> (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1608	 withdrawal syndrome is characterized by a <e1>decrease in prostate-specific antigen</e1> (PSA) after <e2>flutamide</e2> withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1609	 withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1610	 withdrawal syndrome</e1> is characterized by a decrease in prostate-specific antigen (PSA) after <e2>flutamide</e2> withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1611	 prostate-specific antigen response in <e2>flutamide</e2> withdrawal syndrome despite disease progression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1612	 prostate-specific antigen response</e1> in <e2>flutamide</e2> withdrawal syndrome despite disease progression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1613	 case illustrates the potential <e1>decoupling of PSA response</e1> from disease status in <e2>flutamide</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1614	 describe a patient with androgen-independent prostate cancer in whom <e1>PSA continued to decrease</e1> for a period of 15 months after <e2>flutamide</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1615	 reaction</e1> to oral <e2>prednisone</e2>: a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1616	 describe the case of a nonatopic 17-year-old girl with bronchial asthma and aspirin intolerance who developed a dramatic <e1>anaphylactic reaction</e1> to oral <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1617	 treated with <e1>HAL</e1> showed a highly <e2>significant 32%-46% loss of tyrosine hydroxylase (TH) immunoreactive neurons</e2> in the substantia nigra, and 20% contraction of the TH stained dendritic arbour."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1618	 Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite <e1>vomiting</e1> within 1 to 1.5 hours after challenges with Viokase and <e2>Pancrease MT 16</e2>, but not with placebo."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1619	 Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite <e1>vomiting</e1> within 1 to 1.5 hours after challenges with <e2>Viokase</e2> and Pancrease MT 16, but not with placebo."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1620	 was treated with <e1>Pancrease MT 16</e1>, but had consistent <e2>vomiting</e2> 1 to 2 hours after administration of enzymes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1621	 <e1>vomiting</e1> occurred on switching to different pancreatic enzymes preparations, ie, <e2>Creon 10</e2>, Viokase, and Pancrease MT 16."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1622	 <e1>vomiting</e1> occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and <e2>Pancrease MT 16</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1623	 <e1>vomiting</e1> occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, <e2>Viokase</e2>, and Pancrease MT 16."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1624	 <e1>valproate</e1> ingestion induces <e2>symptomatic methemoglobinemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1625	 report for the first time the development of <e1>symptomatic methemoglobinemia</e1> after an acute ingestion of divalproex sodium (<e2>Depakote</e2>), resulting in serum concentrations 10 times greater than the therapeutic range."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1626	 report for the first time the development of <e1>symptomatic methemoglobinemia</e1> after an acute ingestion of <e2>divalproex sodium</e2> (Depakote), resulting in serum concentrations 10 times greater than the therapeutic range."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1627	 rare cases <e1>mitomycin C</e1> (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by <e2>hemolytic anemia</e2>, thrombocytopenia and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1628	 rare cases mitomycin C (<e1>MMC</e1>) may induce cancer-associated hemolytic uremic syndrome, which is characterized by <e2>hemolytic anemia</e2>, thrombocytopenia and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1629	 rare cases <e1>mitomycin C</e1> (MMC) may induce cancer-associated <e2>hemolytic uremic syndrome</e2>, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1630	 rare cases mitomycin C (<e1>MMC</e1>) may induce cancer-associated <e2>hemolytic uremic syndrome</e2>, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1631	 rare cases <e1>mitomycin C</e1> (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and <e2>progressive renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1632	 rare cases mitomycin C (<e1>MMC</e1>) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and <e2>progressive renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1633	 rare cases <e1>mitomycin C</e1> (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, <e2>thrombocytopenia</e2> and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1634	 rare cases mitomycin C (<e1>MMC</e1>) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, <e2>thrombocytopenia</e2> and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1635	 C</e1> -related <e2>hemolytic uremic syndrome</e2> in cancer patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1636	 report a case of <e1>MMC</e1> -related <e2>hemolytic uremic syndrome</e2>, and discuss the etiologic parameters, clinical aspects, prognosis and treatment modalities of this severe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1637	 T-lymphocyte depletion</e1>, myelosuppression, and subsequent severe infections are the major side effects of <e2>fludarabine phosphate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1638	 T-lymphocyte depletion, <e1>myelosuppression</e1>, and subsequent severe infections are the major side effects of <e2>fludarabine phosphate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1639	 T-lymphocyte depletion, myelosuppression, and subsequent <e1>severe infections</e1> are the major side effects of <e2>fludarabine phosphate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1640	 respiratory syncytial virus pulmonary infection</e1> in a patient treated with <e2>fludarabine</e2> for chronic lymphocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1641	 report here on a heretofore undescribed <e1>respiratory syncytial virus (RSV) infection</e1> in a patient with a long-standing history of refractory CLL that was treated with <e2>fludarabine phosphate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1642	 syndrome</e1> induced by transitioning from <e2>phenelzine</e2> to venlafaxine: four patient reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1643	 syndrome</e1> induced by transitioning from phenelzine to <e2>venlafaxine</e2>: four patient reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1644	 this <e1>G-CSF</e1> -driven <e2>leucocytosis</e2> was alarming it did not appear to have adversely affected the patient's prognosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1645	 monocytosis</e1> in M4 AML following chemotherapy and <e2>G-CSF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1646	 describe a patient with M4 AML treated with standard chemotherapy followed by <e1>G-CSF</e1> who developed marked <e2>monocytosis</e2> on day 8 of <e1>G-CSF</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1647	 describe a patient with M4 AML treated with standard chemotherapy followed by <e1>G-CSF</e1> who developed marked <e2>monocytosis</e2> on day 8 of <e1>G-CSF</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1648	 2 demonstrated after 40 months on <e1>chlorambucil</e1> the presence of a <e2>balanced translocation</e2>, t (1;5) (p36;q31) in 90% of the cells."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1649	 abnormalities</e1> after <e2>chlorambucil</e2> therapy of polycythaemia vera."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1650	 of steroid and decreasing the dose of <e1>PTU</e1> produced a good clinical response and the <e2>ANCA</e2> disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1651	 cytoplasmic antibody-positive crescentic glomerulonephritis</e1> associated with <e2>propylthiouracil</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1652	 teenage girl with crescentic glomerulonephritis had <e1>antineutrophil cytoplasmic antibody</e1> (ANCA) detected after she had received <e2>propylthiouracil</e2> (PTU) for hyperthyroidism without cutaneous vasculitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1653	 teenage girl with crescentic glomerulonephritis had <e1>antineutrophil cytoplasmic antibody</e1> (ANCA) detected after she had received propylthiouracil (<e2>PTU</e2>) for hyperthyroidism without cutaneous vasculitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1654	 was concluded that <e1>ANCA</e1> is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with <e2>PTU</e2> appeared to induce <e1>ANCA</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1655	 was concluded that <e1>ANCA</e1> is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with <e2>PTU</e2> appeared to induce <e1>ANCA</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1656	 <e1>drug interaction</e1> between zafirlukast and <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1657	 <e1>drug interaction</e1> between <e2>zafirlukast</e2> and theophylline."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1658	 were made to stop and then restart the <e1>theophylline</e1> therapy at progressively lower doses; however, with each attempt, the patient's <e2>reaction to the drug became more toxic</e2>, with serum <e1>theophylline</e1> levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1659	 were made to stop and then restart the <e1>theophylline</e1> therapy at progressively lower doses; however, with each attempt, the patient's <e2>reaction to the drug became more toxic</e2>, with serum <e1>theophylline</e1> levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1660	 explanation for the noted increase in the <e2>theophylline</e2> level is that metabolism occurs mainly by cytochrome P450 (CYP 1A2), an enzyme that is known to be inhibited with high concentrations of zafirlukast."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1661	 explanation for the noted <e1>increase in the theophylline level</e1> is that metabolism occurs mainly by cytochrome P450 (CYP 1A2), an enzyme that is known to be inhibited with high concentrations of <e2>zafirlukast</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1662	 her serum <e1>theophylline levels had increased to the toxic range</e1> (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (<e2>Accolate</e2>, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1663	 her serum <e2>theophylline</e2> levels had increased to the toxic range (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1664	 her serum <e1>theophylline levels had increased to the toxic range</e1> (133.2 micromol/L [24 microg/mL]) shortly after the addition of <e2>zafirlukast</e2> (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1665	 noted increase in the <e2>theophylline</e2> level after zafirlukast administration is in contrast to the original reports by the manufacturer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1666	 noted <e1>increase in the theophylline level</e1> after <e2>zafirlukast</e2> administration is in contrast to the original reports by the manufacturer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1667	 present the first case (to our knowledge) of a potentially serious <e1>drug-drug interaction</e1> between zafirlukast and <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1668	 present the first case (to our knowledge) of a potentially serious <e1>drug-drug interaction</e1> between <e2>zafirlukast</e2> and theophylline."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1669	 21-year-old patient developed <e1>rhabdomyolysis</e1> during his nineteenth week of treatment with <e2>clozapine</e2> for drug-resistant schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1670	 is speculated to cause <e2>rhabdomyolysis</e2> in patients with defective calcium-activated K+ channels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1671	 associated with <e2>clozapine</e2> treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1672	 describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or <e1>anticholinergic symptoms</e1> with the use of <e2>diphenhydramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1673	 describe children and adolescents with chronic hematologic and oncologic diseases who exhibited <e1>drug-seeking behavior</e1> or anticholinergic symptoms with the use of <e2>diphenhydramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1674	 other causes, <e1>Pentasa</e1> -associated <e2>pancytopenia</e2> was considered."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1675	 developed fever, nausea, <e1>diarrhea</e1>, and malaise and stopped taking on the third day after commencing <e2>Pentasa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1676	 developed <e1>fever</e1>, nausea, diarrhea, and malaise and stopped taking on the third day after commencing <e2>Pentasa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1677	 developed fever, nausea, diarrhea, and <e1>malaise</e1> and stopped taking on the third day after commencing <e2>Pentasa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1678	 developed fever, <e1>nausea</e1>, diarrhea, and malaise and stopped taking on the third day after commencing <e2>Pentasa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1679	 associated with <e2>5-aminosalicylic acid</e2> use in a patient with Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1680	 report a case of <e1>pancytopenia</e1> in a 23-year-old man with Crohn's disease who was treated with <e2>5-aminosalicylic acid</e2> (Pentasa; Nisshin, Tokyo, Japan) 3.0 g/day."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1681	 report a case of <e1>pancytopenia</e1> in a 23-year-old man with Crohn's disease who was treated with 5-aminosalicylic acid (<e2>Pentasa</e2>; Nisshin, Tokyo, Japan) 3.0 g/day."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1682	 <e1>Changes in the plasma cortisol level</e1> were reported in a male patient with panic disorder during the period of low-dose <e2>alprazolam</e2> treatment (mean 0.62 +/- 0.15 mg/day) compared with during the period of high-dose period (mean 1.08 +/- 0.28 mg/day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1683	 Thus, the <e1>decreased plasma cortisol level</e1> during <e2>alprazolam</e2> treatment of panic disorder was suggested to be caused not by symptom alleviation due to <e2>alprazolam</e2> but by <e2>alprazolam</e2> administration itself."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1684	 plasma cortisol level</e1> during <e2>alprazolam</e2> treatment of panic disorder: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1685	 describe a renal transplant recipient maintained on <e1>cyclosporine</e1> and prednisone developing <e2>Nocardia Asteroides brain abscess</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1686	 describe a renal transplant recipient maintained on cyclosporine and <e1>prednisone</e1> developing <e2>Nocardia Asteroides brain abscess</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1687	 children undergoing <e1>cisplatin</e1> chemotherapy are known to be at risk for <e2>progressive sensorineural hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1688	 47 year-old woman who had a 4-year history of intramuscular <e1>pentazocine</e1> injections in the lower extremities, developed <e2>gradual stiffness</e2> and weakness of the lower extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1689	 47 year-old woman who had a 4-year history of intramuscular <e1>pentazocine</e1> injections in the lower extremities, developed gradual stiffness and <e2>weakness of the lower extremities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1690	 in longterm usage and early recognition of <e1>pentazocine</e1> toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced <e2>fibrous myopathy</e2> and localized neuropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1691	 in longterm usage and early recognition of <e1>pentazocine</e1> toxicity as a <e2>neuromuscular complication</e2> are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1692	 in longterm usage and early recognition of <e1>pentazocine</e1> toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized <e2>neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1693	 in longterm usage and early recognition of <e2>pentazocine</e2> toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1694	 -induced <e2>fibrous myopathy</e2> and localized neuropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1695	 -induced fibrous myopathy and localized <e2>neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1696	 two of these cases <e1>akathisia</e1> resolved after withdrawal of <e2>olanzapine</e2> and substitution by a classical or an atypical neuroleptic agent, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1697	 other atypical neuroleptics <e1>olanzapine</e1> is considered to show a reduced prevalence of <e2>extrapyramidal side effects</e2> when compared to classical neuroleptic drugs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1698	 should therefore be aware of possible <e1>extrapyramidal side effects</e1> with <e2>olanzapine</e2> that are reduced compared to classical neuroleptic drugs but not completely eliminated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1699	 akathisia</e1> during <e2>olanzapine</e2> treatment of acute schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1700	 report on three patients with acute schizophrenia, who developed <e1>severe akathisia</e1> during treatment with <e2>olanzapine</e2> (20-25 mg/d)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1701	 occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with <e2>metrifonate</e2>, an irreversible acetylcholinesterase inhibitor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1702	 1 eye had <e1>vitreous hemorrhage</e1> after repeated injections of <e2>tPA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1703	 repeated intracameral <e1>tPA</e1> injections may cause unwanted complications such as <e2>vitreous hemorrhage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1704	 <e1>praziquantel</e1> administration may have been effective in killing the parasite in both patients, we are concerned about the production of marked <e2>inflammation</e2> as a result of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1705	 is a drug-related response to various medications, such as <e2>Haloperidol</e2>, which the patient was receiving."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1706	 -induced <e2>aplastic anemia</e2> in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1707	 present a case of a 58-year-old female patient with Graves' disease who developed <e1>AA</e1> in the third exposure to <e2>methimazole</e2> (MMI)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1708	 induced by <e2>Adriamycin</e2> (Pharmacia & Upjohn, Columbus, OH) has been observed experimentally in rats."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1709	 case demonstrates that hypersensitivity reaction to <e1>pranlukast</e1> and resultant <e2>ATIN</e2> is possible, and that periodic urine testing in patients receiving <e1>pranlukast</e1> should be considered."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1710	 case demonstrates that hypersensitivity reaction to <e1>pranlukast</e1> and resultant <e2>ATIN</e2> is possible, and that periodic urine testing in patients receiving <e1>pranlukast</e1> should be considered."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1711	 case demonstrates that <e1>hypersensitivity reaction</e1> to <e2>pranlukast</e2> and resultant ATIN is possible, and that periodic urine testing in patients receiving <e2>pranlukast</e2> should be considered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1712	 case demonstrates that <e1>hypersensitivity reaction</e1> to <e2>pranlukast</e2> and resultant ATIN is possible, and that periodic urine testing in patients receiving <e2>pranlukast</e2> should be considered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1713	 nephritis</e1> induced by the leukotriene receptor antagonist <e2>pranlukast</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1714	 6 months of <e1>pranlukast</e1> withdrawal, <e2>anemia</e2> resolved and urinary sediment and renal function normalized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1715	 65-year-old woman with angina pectoris presented with <e1>syncope</e1> after sublingual ingestion of <e2>isosorbide dinitrate</e2> (5 mg)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1716	 patients for whom <e1>nitrate</e1> has been prescribed should be warned of the occurrence of <e2>hypotension</e2>, leading to unconsciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1717	 patients for whom <e1>nitrate</e1> has been prescribed should be warned of the occurrence of hypotension, leading to <e2>unconsciousness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-A

1718	 a postural challenge test after administration of <e1>isosorbide dinitrate</e1> (5 mg), <e2>blood pressure decreased</e2> from 120/67 to 65/35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats/min."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1719	 a postural challenge test after administration of <e1>isosorbide dinitrate</e1> (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by syncope with a <e2>sudden decrease in pulse rate</e2> from 85 to 60 beats/min."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1720	 a postural challenge test after administration of <e1>isosorbide dinitrate</e1> (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by <e2>syncope</e2> with a sudden decrease in pulse rate from 85 to 60 beats/min."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1721	 in a 65-year-old woman after <e2>nitrate</e2> ingestion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1722	 diabetic cases of <e1>acute dizziness</e1> due to initial administration of <e2>voglibose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1723	 observed 3 diabetic patients with <e1>intolerable dizziness</e1> followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, <e2>voglibose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1724	 observed 3 diabetic patients with intolerable dizziness followed by <e1>nausea</e1> and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, <e2>voglibose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1725	 observed 3 diabetic patients with intolerable dizziness followed by nausea and <e1>vomiting</e1> immediately after an initial administration of the alpha-glucosidase inhibitor, <e2>voglibose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1726	 -associated <e2>sudden sensorineural hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1727	 is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include <e2>tinnitus</e2> and transient hearing loss."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1728	 is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and <e2>transient hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1729	 article reports the case of an otherwise healthy patient who experienced permanent <e1>sensorineural hearing loss</e1> after a brief course of <e2>naproxen</e2> and reviews the literature on NSAID-related permanent <e1>sensorineural hearing loss</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1730	 and gingival pain</e1> as side effects of <e2>niacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1731	 cause of these previously unreported side effects of <e1>niacin</e1> therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, <e2>hyperalgesia of sensory nerve receptors</e2>, and potentiation of inflammation in the gingiva with referral of pain to the teeth."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1732	 cause of these previously unreported side effects of <e1>niacin</e1> therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of <e2>pain to the teeth</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1733	 cause of these previously unreported side effects of <e1>niacin</e1> therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and <e2>potentiation of inflammation in the gingiva</e2> with referral of pain to the teeth."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1734	 cause of these previously unreported side effects of <e1>niacin</e1> therapy is uncertain but may be related to <e2>prostaglandin-mediated vasodilatation</e2>, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1735	 65-year-old white men with coronary heart disease, given <e1>niacin</e1> therapy for dyslipidemia for 5 months, developed <e2>intense dental and gingival pain</e2> that was associated with increases in dose and that was relieved with discontinuance of <e1>niacin</e1> treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1736	 65-year-old white men with coronary heart disease, given <e1>niacin</e1> therapy for dyslipidemia for 5 months, developed <e2>intense dental and gingival pain</e2> that was associated with increases in dose and that was relieved with discontinuance of <e1>niacin</e1> treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1737	 major hazards of treatment of hypophosphatemic osteomalacia with phosphate and <e1>calcitriol</e1> are secondary hyperparathyroidism and vitamin D intoxication, <e2>potassium loss</e2> also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1738	 major hazards of treatment of hypo<e1>phosphate</e1>mic osteomalacia with <e1>phosphate</e1> and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, <e2>potassium loss</e2> also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1739	 major hazards of treatment of hypophosphatemic osteomalacia with phosphate and <e1>calcitriol</e1> are <e2>secondary hyperparathyroidism</e2> and vitamin D intoxication, potassium loss also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1740	 major hazards of treatment of hypo<e1>phosphate</e1>mic osteomalacia with <e1>phosphate</e1> and calcitriol are <e2>secondary hyperparathyroidism</e2> and vitamin D intoxication, potassium loss also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1741	 major hazards of treatment of hypophosphatemic osteomalacia with phosphate and <e1>calcitriol</e1> are secondary hyperparathyroidism and <e2>vitamin D intoxication</e2>, potassium loss also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1742	 major hazards of treatment of hypo<e1>phosphate</e1>mic osteomalacia with <e1>phosphate</e1> and calcitriol are secondary hyperparathyroidism and <e2>vitamin D intoxication</e2>, potassium loss also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1743	 <e1>phosphate</e1> treatment leads to <e2>hypokalemia</e2> in hypo<e1>phosphate</e1>mic osteomalacia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1744	 was concluded that potassium loss occurred by a non-renal (intestinal) route in <e1>phosphate</e1> -induced <e2>hypokalemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1745	 was concluded that <e1>potassium loss</e1> occurred by a non-renal (intestinal) route in <e2>phosphate</e2> -induced hypokalemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1746	 hypokalemia</e1> developed during <e2>phosphate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1747	 mechanism of the <e1>decrease in plasma potassium</e1> induced by <e2>phosphate</e2> treatment was investigated in a 24-year-old hypertensive patient with hypo<e2>phosphate</e2>mic osteomalacia, who was the youngest of four patients, belonging to a 23 number kindred of five generations."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1748	 potassium gradient (TTKG) also decreased</e1> and an inverse correlation was found between TTKG and doses of <e2>phosphate</e2> (r = -0.37; p < 0.02; N = 38)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1749	 pneumopathy</e1> after <e2>gold</e2> -salts compounds administration, requiring mechanical ventilation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1750	 <e1>pulmonary toxicity</e1> of <e2>gold</e2> salts is an uncommon cause of life-threatening respiratory failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1751	 pulmonary toxicity of <e1>gold</e1> salts is an uncommon cause of life-threatening <e2>respiratory failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1752	 report a case of severe <e1>respiratory failure</e1> due to <e2>gold</e2> salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1753	 this relapse coincided with development of a strong delayed-type <e1>hypersensitivity response</e1> to <e2>tuberculin</e2> and improved after treatment with the anti-inflammatory agent oxpentifylline, it was probably caused by restoration of pathogen-specific cellular immunity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1754	 patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and <e1>glycosuria</e1> during a period of topical administration of a corticosteroid cream, <e2>halcinonide</e2> cream 0.1%, under occlusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1755	 patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed <e1>postprandial hyperglycemia</e1> and glycosuria during a period of topical administration of a corticosteroid cream, <e2>halcinonide</e2> cream 0.1%, under occlusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1756	 second patient with a similar glucose tolerance test result showed <e1>postprandial hyperglycemia</e1> when treated similarly with <e2>betamethasone valerate</e2> cream 0.1%."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1757	 1 week of <e1>nefazodone</e1> therapy the patient experienced headache, <e2>confusion</e2>, and "gray areas" in her vision, without abnormal ophthalmologic findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1758	 1 week of <e1>nefazodone</e1> therapy the patient experienced headache, confusion, and "<e2>gray areas</e2>" in her vision, without abnormal ophthalmologic findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1759	 1 week of <e1>nefazodone</e1> therapy the patient experienced <e2>headache</e2>, confusion, and "gray areas" in her vision, without abnormal ophthalmologic findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1760	 of antidepressant agents such as <e1>nefazodone</e1>, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to <e2>interfere with tacrolimus metabolism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1761	 of antidepressant agents such as nefazodone, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to interfere with <e2>tacrolimus</e2> metabolism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1762	 between tacrolimus and <e2>nefazodone</e2> in a stable renal transplant recipient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1763	 between <e2>tacrolimus</e2> and nefazodone in a stable renal transplant recipient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1764	 suspect that <e1>nefazodone</e1> <e2>inhibits metabolism of tacrolimus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1765	 suspect that nefazodone inhibits metabolism of <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1766	 report the case of <e1>intoxication</e1> of a 41-year-old female patient suffering from major depression with <e2>mirtazapine</e2> complicated by severe hypothermia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1767	 We report a case of the use of pamidronate for significant hypercalcemia secondary to acute <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1768	 We report a case of the use of pamidronate for significant <e1>hypercalcemia</e1> secondary to acute <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1769	 therapy should be considered in patients with hypercalcemia secondary to acute <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1770	 therapy should be considered in patients with <e1>hypercalcemia</e1> secondary to acute <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1771	 patient was initially treated with hydration and <e1>furosemide</e1> but developed <e2>congestive heart failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1772	 use of pamidronate for hypercalcemia secondary to acute <e2>vitamin D</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1773	 report the use of pamidronate for acute, <e1>severe hypercalcemia</e1> secondary to iatrogenic <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1774	 report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1775	 40-year-old man with a long standing history of rheumatoid arthritis was treated with <e1>MTX</e1> over a 6 month period and developed an <e2>overwhelming hepatic necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1776	 -induced <e2>hepatic necrosis</e2> requiring liver transplantation in a patient with rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1777	 -induced <e2>hepatic injury</e2> and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1778	 -induced hepatic injury and <e2>liver enzyme elevations</e2> have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1779	 should be aware of the possibility that <e1>vinorelbine</e1> may cause SIADH and possibly <e2>hypokalemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1780	 should be aware of the possibility that <e1>vinorelbine</e1> may cause <e2>SIADH</e2> and possibly hypokalemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1781	 Because of its structural similarity to the other vinca alkaloids, <e1>vinorelbine</e1> is believed to be responsible for <e2>SIADH</e2> in our patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1782	 To describe onset of syndrome of inappropriate antidiuretic hormone (<e1>SIADH</e1>) associated with <e2>vinorelbine</e2> therapy for advanced breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1783	 To describe onset of <e1>syndrome of inappropriate antidiuretic hormone</e1> (SIADH) associated with <e2>vinorelbine</e2> therapy for advanced breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1784	 of inappropriate antidiuretic hormone</e1> associated with <e2>vinorelbine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1785	 hydrochloride</e1> -induced <e2>QT prolongation</e2> and T wave inversion on electrocardiogram during treatment for symptomatic atrial fibrillation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1786	 hydrochloride</e1> -induced QT prolongation and <e2>T wave inversion</e2> on electrocardiogram during treatment for symptomatic atrial fibrillation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1787	 an immunological mechanism might be involved in the mechanism of <e1>pirmenol</e1> -induced <e2>QT prolongation</e2> and T wave inversion on the electrocardiogram."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1788	 an immunological mechanism might be involved in the mechanism of <e1>pirmenol</e1> -induced QT prolongation and <e2>T wave inversion</e2> on the electrocardiogram."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1789	 report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked <e1>prolongation of the QT interval</e1> and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral <e2>pirmenol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1790	 report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and <e1>T wave inversion</e1> on electrocardiogram was demonstrated reproducibly shortly after the administration of oral <e2>pirmenol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1791	 muscular cysticercosis with <e1>myositis</e1> induced by <e2>praziquantel</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1792	 describe a case of disseminated muscular cysticercosis followed by myositis (fever, <e1>diffuse myalgia</e1>, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1793	 describe a case of disseminated muscular cysticercosis followed by myositis (<e1>fever</e1>, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1794	 describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and <e1>inflammatory reaction around dying cysticerci</e1>) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1795	 describe a case of disseminated muscular cysticercosis followed by <e1>myositis</e1> (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1796	 describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, <e1>weakness of the lower limbs</e1>, and inflammatory reaction around dying cysticerci) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1797	 subfascial hematoma</e1> after <e2>alteplase</e2> therapy for acute myocardial infarction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1798	 should be aware of the possible association between the use of <e1>alteplase</e1> and the development of <e2>subfascial hemorrhage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1799	 authors report a case of a patient who received <e1>alteplase</e1> for acute myocardial infarction and developed spontaneous <e2>subfascial hematoma</e2> without any evidence of direct trauma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1800	 development of <e1>cutaneous ecchymosis</e1> associated with a sudden fall in hemoglobin after the administration of <e2>alteplase</e2> should strongly suggest the possibility of diffuse subfascial hematoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1801	 development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of <e1>alteplase</e1> should strongly suggest the possibility of <e2>diffuse subfascial hematoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1802	 development of cutaneous ecchymosis associated with a <e1>sudden fall in hemoglobin</e1> after the administration of <e2>alteplase</e2> should strongly suggest the possibility of diffuse subfascial hematoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1803	 <e1>fatal case of pancytopenia</e1> due to <e2>levomepromazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1804	 <e1>fatal pancytopenia</e1> occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, <e2>diazepam</e2> and lithium carbonate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1805	 <e1>fatal pancytopenia</e1> occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with <e2>levomepromazine</e2>, diazepam and lithium carbonate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1806	 <e1>fatal pancytopenia</e1> occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, diazepam and <e2>lithium carbonate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1807	 -induced <e2>thyrotoxicosis</e2> associated with thyrotropin receptor antibody."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1808	 -induced thyrotoxicosis associated with <e2>thyrotropin receptor antibody</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1809	 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking <e1>amiodarone</e1> for 4 years, developed <e2>thyrotoxicosis</e2> with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1810	 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking <e1>amiodarone</e1> for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or <e2>thyrotropin-binding inhibiting immunoglobulin</e2> (TBII)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1811	 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking <e1>amiodarone</e1> for 4 years, developed thyrotoxicosis with subacute onset, accompanied by <e2>transiently positive thyrotropin (TSH) receptor antibody</e2> (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1812	 <e1>amiodarone</e1> was first marketed in 1992 in Japan, the incidence of <e1>amiodarone</e1> -induced thyrotoxicosis (<e2>AIT</e2>) has been increasing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1813	 <e1>amiodarone</e1> was first marketed in 1992 in Japan, the incidence of <e1>amiodarone</e1> -induced <e2>thyrotoxicosis</e2> (AIT) has been increasing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1814	 in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with <e1>amiodarone</e1> -induced <e2>destructive thyroiditis</e2>, as reported in patients with <e2>destructive thyroiditis</e2>, such as subacute and silent thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1815	 in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with <e1>amiodarone</e1> -induced <e2>destructive thyroiditis</e2>, as reported in patients with <e2>destructive thyroiditis</e2>, such as subacute and silent thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1816	 in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with <e1>amiodarone</e1> -induced destructive <e2>thyroiditis</e2>, as reported in patients with destructive <e2>thyroiditis</e2>, such as subacute and silent <e2>thyroiditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1817	 in vitro findings and clinical course suggest that <e1>TRAb/TBII without thyroid-stimulating activity</e1> may develop in patients with <e2>amiodarone</e2> -induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1818	 <e1>Lipoid pneumonia</e1> as a result of <e2>mineral oil</e2> aspiration still occurs in the pediatric population."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1819	 patients with swallowing dysfunction and pneumonia, a history of <e1>mineral oil</e1> use should be obtained and a diagnosis of <e2>ELP</e2> should be considered in the differential diagnoses if <e1>mineral oil</e1> use has occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1820	 patients with swallowing dysfunction and pneumonia, a history of <e1>mineral oil</e1> use should be obtained and a diagnosis of <e2>ELP</e2> should be considered in the differential diagnoses if <e1>mineral oil</e1> use has occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1821	 patients with swallowing dysfunction and <e1>pneumonia</e1>, a history of <e2>mineral oil</e2> use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if <e2>mineral oil</e2> use has occurred."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1822	 patients with swallowing dysfunction and <e1>pneumonia</e1>, a history of <e2>mineral oil</e2> use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if <e2>mineral oil</e2> use has occurred."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1823	 patients with <e1>swallowing dysfunction</e1> and pneumonia, a history of <e2>mineral oil</e2> use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if <e2>mineral oil</e2> use has occurred."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1824	 patients with <e1>swallowing dysfunction</e1> and pneumonia, a history of <e2>mineral oil</e2> use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if <e2>mineral oil</e2> use has occurred."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1825	 pneumonia</e1>: a silent complication of <e2>mineral oil</e2> aspiration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1826	 oil</e1>, a hydrocarbon, may not elicit a normal protective cough reflex and may <e2>impair mucociliary transport</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1827	 case points to the need for increased awareness by the general pediatricians of the <e1>potential hazards</e1> of <e2>mineral oil</e2> use for chronic constipation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1828	 of <e1>ELP</e1> in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of <e2>mineral oil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1829	 of ELP in children is generally supportive, with the symptoms and <e1>roentgenographic abnormalities</e1> resolving within months after stopping the use of <e2>mineral oil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1830	 report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic <e1>mineral oil</e1> ingestion presenting as asymptomatic exogenous lipoid pneumonia (<e2>ELP</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1831	 report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic <e1>mineral oil</e1> ingestion presenting as asymptomatic <e2>exogenous lipoid pneumonia</e2> (ELP)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1832	 unusual cause of <e1>burn injury</e1>: unsupervised use of drugs that contain <e2>psoralens</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1833	 <e1>psoralens</e1> sensitize skin to ultraviolet A light, <e2>phototoxic reactions</e2> are the most frequent adverse effect of this treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1834	 this article, we present the case of a vitiligo patient who was admitted to our facility with an <e1>intense burn</e1> after the topical use of <e2>8-methoxypsoralen</e2> solution as a suntanning agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1835	 may sometimes be a major injury in <e1>psoralen</e1> users because high doses or inappropriate use of the drug may render the <e2>skin extremely sensitive</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1836	 may sometimes be a major injury in <e2>psoralen</e2> users because high doses or inappropriate use of the drug may render the skin extremely sensitive."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1837	 <e1>Metoclopramide</e1> may cause reversible <e2>nonthrombocytopenic vascular-type palpable purpura</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1838	 To report a case of reversible <e1>nonthrombocytopenic palpable purpura</e1> associated with <e2>metoclopramide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1839	 <e1>nonthrombocytopenic palpable purpura</e1> associated with <e2>metoclopramide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1840	 treatment was terminated in 1975 because of lithium intoxication with a <e2>diabetes insipidus-like syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1841	 treatment was terminated in 1975 because of <e1>lithium</e1> intoxication with a <e2>diabetes insipidus-like syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1842	 treatment was terminated in 1975 because of <e2>lithium intoxication</e2> with a diabetes insipidus-like syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1843	 treatment was terminated in 1975 because of <e2>lithium</e2> intoxication with a diabetes insipidus-like syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1844	 caused by <e2>clozapine</e2> was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01)."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1845	 has been encountered from 0.2 to 61.7% in <e2>clozapine</e2> -treated patients, mostly with a transient course and spontaneous remission."
DRUG-ADE(e2,e1)
Comment: DRUG-A

1846	 challenge with <e1>clozapine</e1> in a history of <e2>eosinophilia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

